cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	beta	r	Traits	SNP_position	Gene_position
PRAD	cis	rs75358501	0.636	rs2241347	MIMAT0014995	hsa-miR-3130-5p	-22.15	3.25e-74	-0.94	-0.72	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206783257	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs2241347	MIMAT0014995_1	hsa-miR-3130-5p	-22.15	3.25e-74	-0.94	-0.72	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206783257	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs11895370	MIMAT0014995	hsa-miR-3130-5p	-21.68	5.13e-72	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206789990	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs11895370	MIMAT0014995_1	hsa-miR-3130-5p	-21.68	5.13e-72	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206789990	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs12471008	MIMAT0014995	hsa-miR-3130-5p	-21.48	4.17e-71	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206775059	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs12471008	MIMAT0014995_1	hsa-miR-3130-5p	-21.48	4.17e-71	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206775059	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs768533	MIMAT0014995	hsa-miR-3130-5p	-21.48	4.17e-71	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776113	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs768533	MIMAT0014995_1	hsa-miR-3130-5p	-21.48	4.17e-71	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776113	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.688	rs2287629	MIMAT0014995	hsa-miR-3130-5p	21.44	6.74e-71	0.94	0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785690	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.688	rs2287629	MIMAT0014995_1	hsa-miR-3130-5p	21.44	6.74e-71	0.94	0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785690	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs7576591	MIMAT0014995	hsa-miR-3130-5p	-21.38	1.3e-70	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784502	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs7576591	MIMAT0014995_1	hsa-miR-3130-5p	-21.38	1.3e-70	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784502	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs2287628	MIMAT0014995	hsa-miR-3130-5p	-21.38	1.3e-70	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785809	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs2287628	MIMAT0014995_1	hsa-miR-3130-5p	-21.38	1.3e-70	-0.93	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206785809	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs13427002	MIMAT0014995	hsa-miR-3130-5p	-21.25	4.72e-70	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206778949	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs13427002	MIMAT0014995_1	hsa-miR-3130-5p	-21.25	4.72e-70	-0.94	-0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206778949	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs888621	MIMAT0014995	hsa-miR-3130-5p	21.22	6.77e-70	0.93	0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784626	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs888621	MIMAT0014995_1	hsa-miR-3130-5p	21.22	6.77e-70	0.93	0.71	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206784626	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs10199766	MIMAT0014995	hsa-miR-3130-5p	-20.75	1.01e-67	-0.94	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206777144	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs10199766	MIMAT0014995_1	hsa-miR-3130-5p	-20.75	1.01e-67	-0.94	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206777144	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs725980	MIMAT0014995	hsa-miR-3130-5p	-20.74	1.15e-67	-0.93	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206773856	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs725980	MIMAT0014995_1	hsa-miR-3130-5p	-20.74	1.15e-67	-0.93	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206773856	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs957414	MIMAT0014995	hsa-miR-3130-5p	-20.59	5.71e-67	-0.93	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206800861	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs957414	MIMAT0014995_1	hsa-miR-3130-5p	-20.59	5.71e-67	-0.93	-0.7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206800861	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs3815686	MIMAT0014995	hsa-miR-3130-5p	-20.55	8.72e-67	-0.93	-0.69	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206768278	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs3815686	MIMAT0014995_1	hsa-miR-3130-5p	-20.55	8.72e-67	-0.93	-0.69	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206768278	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.688	rs28365797	MIMAT0014995	hsa-miR-3130-5p	-19.9	8.44e-64	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765122	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.688	rs28365797	MIMAT0014995_1	hsa-miR-3130-5p	-19.9	8.44e-64	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765122	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs4673363	MIMAT0014995	hsa-miR-3130-5p	-19.74	4.72e-63	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206804687	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs4673363	MIMAT0014995_1	hsa-miR-3130-5p	-19.74	4.72e-63	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206804687	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs57600974	MIMAT0014995	hsa-miR-3130-5p	-19.74	4.72e-63	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206805471	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs57600974	MIMAT0014995_1	hsa-miR-3130-5p	-19.74	4.72e-63	-0.92	-0.68	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206805471	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs12478466	MIMAT0014995	hsa-miR-3130-5p	-19.41	1.61e-61	-0.91	-0.67	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206806288	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs12478466	MIMAT0014995_1	hsa-miR-3130-5p	-19.41	1.61e-61	-0.91	-0.67	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206806288	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs16838834	MIMAT0014995	hsa-miR-3130-5p	-19.35	3.16e-61	-0.92	-0.67	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765071	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs16838834	MIMAT0014995_1	hsa-miR-3130-5p	-19.35	3.16e-61	-0.92	-0.67	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206765071	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.584	rs11894165	MIMAT0014995	hsa-miR-3130-5p	-18.93	2.58e-59	-0.93	-0.66	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206759688	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.584	rs11894165	MIMAT0014995_1	hsa-miR-3130-5p	-18.93	2.58e-59	-0.93	-0.66	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206759688	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.688	rs1862087	MIMAT0014995	hsa-miR-3130-5p	-18.93	2.58e-59	-0.93	-0.66	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206760843	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.688	rs1862087	MIMAT0014995_1	hsa-miR-3130-5p	-18.93	2.58e-59	-0.93	-0.66	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206760843	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs1862089	MIMAT0014995	hsa-miR-3130-5p	-17.04	1.08e-50	-0.88	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206755794	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs1862089	MIMAT0014995_1	hsa-miR-3130-5p	-17.04	1.08e-50	-0.88	-0.63	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206755794	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs7580138	MIMAT0014995	hsa-miR-3130-5p	-16.95	3.01e-50	-0.86	-0.62	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206750560	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs7580138	MIMAT0014995_1	hsa-miR-3130-5p	-16.95	3.01e-50	-0.86	-0.62	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206750560	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.636	rs10932164	MIMAT0014995	hsa-miR-3130-5p	-16.9	5.14e-50	-0.89	-0.62	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206751601	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs10932164	MIMAT0014995_1	hsa-miR-3130-5p	-16.9	5.14e-50	-0.89	-0.62	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206751601	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.748	rs12470963	MIMAT0014995	hsa-miR-3130-5p	-15.49	9.63e-44	-0.91	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206774869	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.748	rs12470963	MIMAT0014995_1	hsa-miR-3130-5p	-15.49	9.63e-44	-0.91	-0.59	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206774869	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.901	rs79499040	MIMAT0014995	hsa-miR-3130-5p	-11.01	3.85e-25	-0.85	-0.46	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776206	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.901	rs79499040	MIMAT0014995_1	hsa-miR-3130-5p	-11.01	3.85e-25	-0.85	-0.46	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206776206	chr2:206783246~206783266:+
PRAD	cis	rs1712517	0.566	rs1163073	MIMAT0005951	hsa-miR-1307-3p	10.84	1.72e-24	0.36	0.45	Migraine;	chr10:103263177	chr10:103394301~103394322:-
PRAD	cis	rs75358501	0.901	rs76270461	MIMAT0014995	hsa-miR-3130-5p	-10.72	4.69e-24	-0.84	-0.45	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206788929	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.901	rs76270461	MIMAT0014995_1	hsa-miR-3130-5p	-10.72	4.69e-24	-0.84	-0.45	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206788929	chr2:206783246~206783266:+
PRAD	cis	rs1712517	0.566	rs7917388	MIMAT0005951	hsa-miR-1307-3p	-10.67	7.63e-24	-0.36	-0.45	Migraine;	chr10:103295206	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.525	rs11191642	MIMAT0005951	hsa-miR-1307-3p	-10.67	7.63e-24	-0.36	-0.45	Migraine;	chr10:103296155	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.588	rs12220267	MIMAT0005951	hsa-miR-1307-3p	-10.66	8.15e-24	-0.36	-0.45	Migraine;	chr10:103315955	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.526	rs113528138	MIMAT0005951	hsa-miR-1307-3p	-10.64	9.51e-24	-0.35	-0.45	Migraine;	chr10:103365694	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.525	rs2271751	MIMAT0005951	hsa-miR-1307-3p	-10.62	1.14e-23	-0.35	-0.45	Migraine;	chr10:103415374	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.503	rs72846198	MIMAT0005951	hsa-miR-1307-3p	-10.62	1.16e-23	-0.36	-0.45	Migraine;	chr10:103338267	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.566	rs7076274	MIMAT0005951	hsa-miR-1307-3p	-10.58	1.56e-23	-0.36	-0.45	Migraine;	chr10:103286250	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.545	rs3740381	MIMAT0005951	hsa-miR-1307-3p	-10.58	1.56e-23	-0.36	-0.45	Migraine;	chr10:103286932	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.525	rs11191667	MIMAT0005951	hsa-miR-1307-3p	-10.54	2.31e-23	-0.35	-0.44	Migraine;	chr10:103369141	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.525	rs7911488	MIMAT0005951	hsa-miR-1307-3p	-10.54	2.31e-23	-0.35	-0.44	Migraine;	chr10:103394332	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.524	rs1712509	MIMAT0005951	hsa-miR-1307-3p	-10.41	6.53e-23	-0.35	-0.44	Migraine;	chr10:103254113	chr10:103394301~103394322:-
PRAD	cis	rs4917385	1	rs4917385	MIMAT0005951	hsa-miR-1307-3p	10.22	3.35e-22	0.34	0.43	Systemic lupus erythematosus;	chr10:103243964	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.524	rs4917384	MIMAT0005951	hsa-miR-1307-3p	10.1	8.96e-22	0.34	0.43	Migraine;	chr10:103236031	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.787	rs1163089	MIMAT0005951	hsa-miR-1307-3p	-9.86	6.56e-21	-0.31	-0.42	Migraine;	chr10:103284207	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs7916056	MIMAT0005951	hsa-miR-1307-3p	9.72	2.15e-20	0.3	0.42	Migraine;	chr10:103238157	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs2008530	MIMAT0005951	hsa-miR-1307-3p	-9.69	2.75e-20	-0.3	-0.41	Migraine;	chr10:103299082	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs7913461	MIMAT0005951	hsa-miR-1307-3p	-9.64	4.05e-20	-0.3	-0.41	Migraine;	chr10:103241568	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs1163086	MIMAT0005951	hsa-miR-1307-3p	-9.61	5.16e-20	-0.3	-0.41	Migraine;	chr10:103279822	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs1712516	MIMAT0005951	hsa-miR-1307-3p	-9.6	5.52e-20	-0.3	-0.41	Migraine;	chr10:103273871	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.773	rs1063461	MIMAT0005951	hsa-miR-1307-3p	-9.58	6.27e-20	-0.3	-0.41	Migraine;	chr10:103289348	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.74	rs4293062	MIMAT0005951	hsa-miR-1307-3p	-9.58	6.27e-20	-0.3	-0.41	Migraine;	chr10:103292867	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.744	rs11191641	MIMAT0005951	hsa-miR-1307-3p	-9.58	6.27e-20	-0.3	-0.41	Migraine;	chr10:103293183	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.744	rs4293063	MIMAT0005951	hsa-miR-1307-3p	-9.58	6.27e-20	-0.3	-0.41	Migraine;	chr10:103293219	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.844	rs1163087	MIMAT0005951	hsa-miR-1307-3p	-9.56	7.26e-20	-0.3	-0.41	Migraine;	chr10:103283532	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.74	rs4917387	MIMAT0005951	hsa-miR-1307-3p	-9.51	1.11e-19	-0.3	-0.41	Migraine;	chr10:103348698	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191672	MIMAT0005951	hsa-miR-1307-3p	-9.51	1.14e-19	-0.3	-0.41	Migraine;	chr10:103379204	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191666	MIMAT0005951	hsa-miR-1307-3p	-9.46	1.69e-19	-0.29	-0.41	Migraine;	chr10:103367521	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs10883858	MIMAT0005951	hsa-miR-1307-3p	-9.46	1.69e-19	-0.29	-0.41	Migraine;	chr10:103367951	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191676	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.11e-19	-0.29	-0.4	Migraine;	chr10:103395309	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs2292807	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.11e-19	-0.29	-0.4	Migraine;	chr10:103395888	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs7921655	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.13e-19	-0.29	-0.4	Migraine;	chr10:103353944	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs7074749	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.13e-19	-0.29	-0.4	Migraine;	chr10:103356299	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.74	rs11191663	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.13e-19	-0.29	-0.4	Migraine;	chr10:103358705	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191664	MIMAT0005951	hsa-miR-1307-3p	-9.38	3.13e-19	-0.29	-0.4	Migraine;	chr10:103358719	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs59744322	MIMAT0005951	hsa-miR-1307-3p	-9.32	5.13e-19	-0.29	-0.4	Migraine;	chr10:103386935	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs10883857	MIMAT0005951	hsa-miR-1307-3p	9.23	1.01e-18	0.29	0.4	Migraine;	chr10:103367830	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs61871160	MIMAT0005951	hsa-miR-1307-3p	-9.23	1.05e-18	-0.29	-0.4	Migraine;	chr10:103384531	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.687	rs1422581	MIMAT0003249	hsa-miR-584-5p	-9.21	1.2e-18	-0.52	-0.4	Breast cancer;	chr5:149057823	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs40523	MIMAT0003249	hsa-miR-584-5p	-9.14	2.16e-18	-0.52	-0.39	Breast cancer;	chr5:149064623	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250674	MIMAT0003249	hsa-miR-584-5p	-9.1	2.83e-18	-0.52	-0.39	Breast cancer;	chr5:149059034	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250667	MIMAT0003249	hsa-miR-584-5p	-9.1	2.83e-18	-0.52	-0.39	Breast cancer;	chr5:149075571	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.844	rs4918003	MIMAT0005951	hsa-miR-1307-3p	-9.1	2.98e-18	-0.28	-0.39	Migraine;	chr10:103284400	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.844	rs1163075	MIMAT0005951	hsa-miR-1307-3p	9.05	4.09e-18	0.28	0.39	Migraine;	chr10:103261506	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs61350103	MIMAT0005951	hsa-miR-1307-3p	-9.05	4.24e-18	-0.28	-0.39	Migraine;	chr10:103309363	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191654	MIMAT0005951	hsa-miR-1307-3p	-9.05	4.24e-18	-0.28	-0.39	Migraine;	chr10:103317367	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs61869827	MIMAT0005951	hsa-miR-1307-3p	-9.05	4.24e-18	-0.28	-0.39	Migraine;	chr10:103319682	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.771	rs11191645	MIMAT0005951	hsa-miR-1307-3p	-9.05	4.24e-18	-0.28	-0.39	Migraine;	chr10:103299551	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.687	rs250678	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149055267	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.652	rs250680	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149056461	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs3095947	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149057165	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs10040624	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149058016	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs42364	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149059295	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs36044	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149061565	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs36046	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149061694	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs36048	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149062150	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs40522	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149062732	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250664	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149074260	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250666	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149075059	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs185155	MIMAT0003249	hsa-miR-584-5p	9.05	4.28e-18	0.52	0.39	Breast cancer;	chr5:149076330	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs384979	MIMAT0003249	hsa-miR-584-5p	-9.05	4.28e-18	-0.52	-0.39	Breast cancer;	chr5:149079704	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs2915809	MIMAT0003249	hsa-miR-584-5p	9.03	5.15e-18	0.52	0.39	Breast cancer;	chr5:149072548	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs36043	MIMAT0003249	hsa-miR-584-5p	9.02	5.19e-18	0.51	0.39	Breast cancer;	chr5:149061420	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250673	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149066235	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250672	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149066547	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250671	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149066960	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.652	rs250670	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149067083	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs168750	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149067193	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs2963484	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149071564	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs250663	MIMAT0003249	hsa-miR-584-5p	8.97	7.74e-18	0.51	0.39	Breast cancer;	chr5:149073554	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.844	rs1163081	MIMAT0005951	hsa-miR-1307-3p	-8.95	9.4e-18	-0.28	-0.39	Migraine;	chr10:103270083	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.844	rs1163074	MIMAT0005951	hsa-miR-1307-3p	-8.94	9.79e-18	-0.28	-0.39	Migraine;	chr10:103262005	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.687	rs41181	MIMAT0003249	hsa-miR-584-5p	-8.9	1.33e-17	-0.51	-0.39	Breast cancer;	chr5:149064694	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.873	rs7903004	MIMAT0005951	hsa-miR-1307-3p	8.9	1.35e-17	0.28	0.39	Migraine;	chr10:103244344	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs1891292	MIMAT0005951	hsa-miR-1307-3p	8.89	1.49e-17	0.27	0.39	Migraine;	chr10:103241753	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.904	rs7905968	MIMAT0005951	hsa-miR-1307-3p	-8.86	1.77e-17	-0.28	-0.38	Migraine;	chr10:103375562	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.74	rs11191643	MIMAT0005951	hsa-miR-1307-3p	-8.85	1.91e-17	-0.28	-0.38	Migraine;	chr10:103297804	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.836	rs7093039	MIMAT0005951	hsa-miR-1307-3p	-8.84	2.15e-17	-0.28	-0.38	Migraine;	chr10:103389790	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.838	rs6584543	MIMAT0005951	hsa-miR-1307-3p	8.81	2.66e-17	0.27	0.38	Migraine;	chr10:103237257	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs7894240	MIMAT0005951	hsa-miR-1307-3p	8.81	2.71e-17	0.27	0.38	Migraine;	chr10:103240612	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.687	rs250679	MIMAT0003249	hsa-miR-584-5p	-8.81	2.78e-17	-0.51	-0.38	Breast cancer;	chr5:149055389	chr5:149062373~149062394:-
PRAD	cis	rs75358501	0.901	rs16838691	MIMAT0014995	hsa-miR-3130-5p	-8.8	2.89e-17	-0.74	-0.38	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206718128	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.901	rs16838691	MIMAT0014995_1	hsa-miR-3130-5p	-8.8	2.89e-17	-0.74	-0.38	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206718128	chr2:206783246~206783266:+
PRAD	cis	rs250677	0.687	rs40149	MIMAT0003249	hsa-miR-584-5p	8.8	2.96e-17	0.51	0.38	Breast cancer;	chr5:149064712	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.904	rs10883863	MIMAT0005951	hsa-miR-1307-3p	8.74	4.48e-17	0.27	0.38	Migraine;	chr10:103402122	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs1163083	MIMAT0005951	hsa-miR-1307-3p	-8.72	5.4e-17	-0.27	-0.38	Migraine;	chr10:103278698	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.835	rs2506961	MIMAT0005951	hsa-miR-1307-3p	8.69	6.81e-17	0.27	0.38	Migraine;	chr10:103248169	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.873	rs1712510	MIMAT0005951	hsa-miR-1307-3p	8.69	6.81e-17	0.27	0.38	Migraine;	chr10:103249329	chr10:103394301~103394322:-
PRAD	cis	rs1712517	0.836	rs11191649	MIMAT0005951	hsa-miR-1307-3p	-8.57	1.69e-16	-0.27	-0.37	Migraine;	chr10:103307280	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.652	rs36045	MIMAT0003249	hsa-miR-584-5p	-8.51	2.54e-16	-0.52	-0.37	Breast cancer;	chr5:149061621	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.904	rs6584547	MIMAT0005951	hsa-miR-1307-3p	-8.5	2.74e-16	-0.27	-0.37	Migraine;	chr10:103305652	chr10:103394301~103394322:-
PRAD	cis	rs6543140	0.964	rs4851578	MIMAT0019927	hsa-miR-4772-3p	-8.48	3.14e-16	-0.42	-0.37	Blood protein levels;	chr2:102412491	chr2:102432336~102432357:+
PRAD	cis	rs250677	0.652	rs168751	MIMAT0003249	hsa-miR-584-5p	8.48	3.22e-16	0.51	0.37	Breast cancer;	chr5:149058701	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs2963485	MIMAT0003249	hsa-miR-584-5p	-8.45	3.87e-16	-0.49	-0.37	Breast cancer;	chr5:149072480	chr5:149062373~149062394:-
PRAD	cis	rs6543140	0.964	rs2080288	MIMAT0019927	hsa-miR-4772-3p	-8.45	3.9e-16	-0.41	-0.37	Blood protein levels;	chr2:102405706	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6761350	MIMAT0019927	hsa-miR-4772-3p	-8.44	4.4e-16	-0.41	-0.37	Blood protein levels;	chr2:102414316	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.929	rs7602207	MIMAT0019927	hsa-miR-4772-3p	-8.44	4.4e-16	-0.41	-0.37	Blood protein levels;	chr2:102415906	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs2160200	MIMAT0019927	hsa-miR-4772-3p	-8.44	4.4e-16	-0.41	-0.37	Blood protein levels;	chr2:102417503	chr2:102432336~102432357:+
PRAD	cis	rs250677	0.652	rs1422582	MIMAT0003249	hsa-miR-584-5p	8.43	4.57e-16	0.52	0.37	Breast cancer;	chr5:149057362	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.652	rs36042	MIMAT0003249	hsa-miR-584-5p	8.43	4.57e-16	0.52	0.37	Breast cancer;	chr5:149060219	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.687	rs171636	MIMAT0003249	hsa-miR-584-5p	8.43	4.76e-16	0.52	0.37	Breast cancer;	chr5:149054982	chr5:149062373~149062394:-
PRAD	cis	rs75358501	1	rs75358501	MIMAT0014995	hsa-miR-3130-5p	-8.43	4.79e-16	-0.73	-0.37	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206713131	chr2:206783276~206783296:-
PRAD	cis	rs75358501	1	rs75358501	MIMAT0014995_1	hsa-miR-3130-5p	-8.43	4.79e-16	-0.73	-0.37	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206713131	chr2:206783246~206783266:+
PRAD	cis	rs250677	0.524	rs250665	MIMAT0003249	hsa-miR-584-5p	8.38	6.61e-16	0.43	0.37	Breast cancer;	chr5:149074831	chr5:149062373~149062394:-
PRAD	cis	rs6543140	0.964	rs1035126	MIMAT0019927	hsa-miR-4772-3p	-8.35	8.18e-16	-0.41	-0.37	Blood protein levels;	chr2:102403521	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.601	rs7558013	MIMAT0019927	hsa-miR-4772-3p	-8.32	1.02e-15	-0.44	-0.36	Blood protein levels;	chr2:102376346	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs62154972	MIMAT0019927	hsa-miR-4772-3p	-8.31	1.13e-15	-0.41	-0.36	Blood protein levels;	chr2:102432278	chr2:102432336~102432357:+
PRAD	cis	rs1712517	0.566	rs7917388	MIMAT0022727	hsa-miR-1307-5p	-8.31	1.15e-15	-0.32	-0.36	Migraine;	chr10:103295206	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.525	rs11191642	MIMAT0022727	hsa-miR-1307-5p	-8.31	1.15e-15	-0.32	-0.36	Migraine;	chr10:103296155	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.566	rs7076274	MIMAT0022727	hsa-miR-1307-5p	-8.3	1.22e-15	-0.32	-0.36	Migraine;	chr10:103286250	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.545	rs3740381	MIMAT0022727	hsa-miR-1307-5p	-8.3	1.22e-15	-0.32	-0.36	Migraine;	chr10:103286932	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.588	rs12220267	MIMAT0022727	hsa-miR-1307-5p	-8.29	1.3e-15	-0.31	-0.36	Migraine;	chr10:103315955	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.503	rs72846198	MIMAT0022727	hsa-miR-1307-5p	-8.29	1.32e-15	-0.32	-0.36	Migraine;	chr10:103338267	chr10:103394341~103394361:-
PRAD	cis	rs250677	0.524	rs40521	MIMAT0003249	hsa-miR-584-5p	-8.28	1.37e-15	-0.43	-0.36	Breast cancer;	chr5:149060076	chr5:149062373~149062394:-
PRAD	cis	rs6543140	0.601	rs78178597	MIMAT0019927	hsa-miR-4772-3p	-8.28	1.42e-15	-0.44	-0.36	Blood protein levels;	chr2:102407136	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.89	rs61122764	MIMAT0019927	hsa-miR-4772-3p	-8.26	1.57e-15	-0.41	-0.36	Blood protein levels;	chr2:102383060	chr2:102432336~102432357:+
PRAD	cis	rs1712517	1	rs3123794	MIMAT0005951	hsa-miR-1307-3p	-8.24	1.87e-15	-0.26	-0.36	Migraine;	chr10:103273985	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.524	rs417413	MIMAT0003249	hsa-miR-584-5p	8.23	2e-15	0.42	0.36	Breast cancer;	chr5:149073163	chr5:149062373~149062394:-
PRAD	cis	rs7255436	0.965	rs11666233	MIMAT0021017	hsa-miR-4999-5p	8.22	2.21e-15	0.44	0.36	HDL cholesterol;	chr19:8387161	chr19:8389340~8389360:-
PRAD	cis	rs6543140	0.929	rs11465700	MIMAT0019927	hsa-miR-4772-3p	-8.21	2.25e-15	-0.4	-0.36	Blood protein levels;	chr2:102441208	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs4851010	MIMAT0019927	hsa-miR-4772-3p	8.21	2.37e-15	0.4	0.36	Blood protein levels;	chr2:102439667	chr2:102432336~102432357:+
PRAD	cis	rs7255436	0.965	rs62117510	MIMAT0021017	hsa-miR-4999-5p	8.19	2.73e-15	0.44	0.36	HDL cholesterol;	chr19:8387729	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs28729307	MIMAT0021017	hsa-miR-4999-5p	8.19	2.73e-15	0.44	0.36	HDL cholesterol;	chr19:8387858	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.894	rs10413136	MIMAT0021017	hsa-miR-4999-5p	8.19	2.73e-15	0.44	0.36	HDL cholesterol;	chr19:8387995	chr19:8389340~8389360:-
PRAD	cis	rs1712517	1	rs1163084	MIMAT0005951	hsa-miR-1307-3p	-8.19	2.73e-15	-0.26	-0.36	Migraine;	chr10:103279291	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.617	rs166106	MIMAT0003249	hsa-miR-584-5p	8.16	3.4e-15	0.5	0.36	Breast cancer;	chr5:149067498	chr5:149062373~149062394:-
PRAD	cis	rs1712517	1	rs1712517	MIMAT0005951	hsa-miR-1307-3p	-8.16	3.41e-15	-0.25	-0.36	Migraine;	chr10:103273258	chr10:103394301~103394322:-
PRAD	cis	rs250677	0.641	rs2915807	MIMAT0003249	hsa-miR-584-5p	8.15	3.59e-15	0.5	0.36	Breast cancer;	chr5:149071387	chr5:149062373~149062394:-
PRAD	cis	rs7255436	0.965	rs7254882	MIMAT0021017	hsa-miR-4999-5p	8.15	3.67e-15	0.44	0.36	HDL cholesterol;	chr19:8388938	chr19:8389340~8389360:-
PRAD	cis	rs250677	0.652	rs250675	MIMAT0003249	hsa-miR-584-5p	-8.14	3.74e-15	-0.5	-0.36	Breast cancer;	chr5:149059002	chr5:149062373~149062394:-
PRAD	cis	rs6543140	0.964	rs6748390	MIMAT0019927	hsa-miR-4772-3p	-8.14	3.89e-15	-0.4	-0.36	Blood protein levels;	chr2:102445715	chr2:102432336~102432357:+
PRAD	cis	rs7255436	0.83	rs4350678	MIMAT0021017	hsa-miR-4999-5p	8.13	4.16e-15	0.45	0.36	HDL cholesterol;	chr19:8382482	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.931	rs7249520	MIMAT0021017	hsa-miR-4999-5p	8.13	4.22e-15	0.45	0.36	HDL cholesterol;	chr19:8381172	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs7249624	MIMAT0021017	hsa-miR-4999-5p	8.13	4.22e-15	0.45	0.36	HDL cholesterol;	chr19:8381251	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs11668346	MIMAT0021017	hsa-miR-4999-5p	8.12	4.31e-15	0.44	0.36	HDL cholesterol;	chr19:8385970	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs12981318	MIMAT0021017	hsa-miR-4999-5p	8.12	4.31e-15	0.44	0.36	HDL cholesterol;	chr19:8386546	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs7351098	MIMAT0021017	hsa-miR-4999-5p	8.12	4.31e-15	0.44	0.36	HDL cholesterol;	chr19:8386787	chr19:8389340~8389360:-
PRAD	cis	rs7255436	0.965	rs11666003	MIMAT0021017	hsa-miR-4999-5p	8.12	4.31e-15	0.44	0.36	HDL cholesterol;	chr19:8387218	chr19:8389340~8389360:-
PRAD	cis	rs1712517	0.904	rs4918007	MIMAT0005951	hsa-miR-1307-3p	8.12	4.34e-15	0.26	0.36	Migraine;	chr10:103347713	chr10:103394301~103394322:-
PRAD	cis	rs7255436	0.928	rs7250870	MIMAT0021017	hsa-miR-4999-5p	8.11	4.69e-15	0.44	0.36	HDL cholesterol;	chr19:8388798	chr19:8389340~8389360:-
PRAD	cis	rs6543140	0.572	rs17027173	MIMAT0019927	hsa-miR-4772-3p	-8.11	4.92e-15	-0.43	-0.36	Blood protein levels;	chr2:102440583	chr2:102432336~102432357:+
PRAD	cis	rs1712517	0.526	rs113528138	MIMAT0022727	hsa-miR-1307-5p	-8.1	5.09e-15	-0.31	-0.36	Migraine;	chr10:103365694	chr10:103394341~103394361:-
PRAD	cis	rs6543140	0.964	rs6736135	MIMAT0019927	hsa-miR-4772-3p	-8.09	5.52e-15	-0.4	-0.36	Blood protein levels;	chr2:102448464	chr2:102432336~102432357:+
PRAD	cis	rs7255436	0.965	rs4044435	MIMAT0021017	hsa-miR-4999-5p	8.08	5.74e-15	0.45	0.36	HDL cholesterol;	chr19:8383293	chr19:8389340~8389360:-
PRAD	cis	rs1712517	0.525	rs11191667	MIMAT0022727	hsa-miR-1307-5p	-8.07	6.17e-15	-0.31	-0.35	Migraine;	chr10:103369141	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.525	rs7911488	MIMAT0022727	hsa-miR-1307-5p	-8.07	6.17e-15	-0.31	-0.35	Migraine;	chr10:103394332	chr10:103394341~103394361:-
PRAD	cis	rs6543140	0.601	rs6543135	MIMAT0019927	hsa-miR-4772-3p	-8.06	6.87e-15	-0.43	-0.35	Blood protein levels;	chr2:102445946	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs10200081	MIMAT0019927	hsa-miR-4772-3p	-8.04	8.13e-15	-0.4	-0.35	Blood protein levels;	chr2:102475097	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6543136	MIMAT0019927	hsa-miR-4772-3p	-8	1.02e-14	-0.39	-0.35	Blood protein levels;	chr2:102449087	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6543138	MIMAT0019927	hsa-miR-4772-3p	-8	1.02e-14	-0.39	-0.35	Blood protein levels;	chr2:102449672	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs918000	MIMAT0019927	hsa-miR-4772-3p	-8	1.02e-14	-0.39	-0.35	Blood protein levels;	chr2:102451402	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.927	rs917999	MIMAT0019927	hsa-miR-4772-3p	-8	1.02e-14	-0.39	-0.35	Blood protein levels;	chr2:102451409	chr2:102432336~102432357:+
PRAD	cis	rs7255436	1	rs7255436	MIMAT0021017	hsa-miR-4999-5p	8	1.06e-14	0.44	0.35	HDL cholesterol;	chr19:8368312	chr19:8389340~8389360:-
PRAD	cis	rs250677	0.524	rs183140	MIMAT0003249	hsa-miR-584-5p	7.99	1.09e-14	0.42	0.35	Breast cancer;	chr5:149059240	chr5:149062373~149062394:-
PRAD	cis	rs1712517	0.566	rs1163073	MIMAT0022727	hsa-miR-1307-5p	7.99	1.12e-14	0.3	0.35	Migraine;	chr10:103263177	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.525	rs2271751	MIMAT0022727	hsa-miR-1307-5p	-7.99	1.13e-14	-0.3	-0.35	Migraine;	chr10:103415374	chr10:103394341~103394361:-
PRAD	cis	rs950880	0.71	rs1474309	MIMAT0019927	hsa-miR-4772-3p	-7.96	1.36e-14	-0.66	-0.35	Serum protein levels (sST2);	chr2:102474542	chr2:102432336~102432357:+
PRAD	cis	rs1712517	0.838	rs1891293	MIMAT0005951	hsa-miR-1307-3p	7.96	1.41e-14	0.25	0.35	Migraine;	chr10:103242040	chr10:103394301~103394322:-
PRAD	cis	rs6543140	0.964	rs11903551	MIMAT0019927	hsa-miR-4772-3p	-7.96	1.45e-14	-0.39	-0.35	Blood protein levels;	chr2:102467721	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6543143	MIMAT0019927	hsa-miR-4772-3p	-7.96	1.45e-14	-0.39	-0.35	Blood protein levels;	chr2:102468960	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs13383602	MIMAT0019927	hsa-miR-4772-3p	-7.96	1.45e-14	-0.39	-0.35	Blood protein levels;	chr2:102469502	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs4851592	MIMAT0019927	hsa-miR-4772-3p	-7.96	1.45e-14	-0.39	-0.35	Blood protein levels;	chr2:102471181	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs10193485	MIMAT0019927	hsa-miR-4772-3p	-7.95	1.49e-14	-0.39	-0.35	Blood protein levels;	chr2:102473114	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs10196334	MIMAT0019927	hsa-miR-4772-3p	-7.95	1.49e-14	-0.39	-0.35	Blood protein levels;	chr2:102473582	chr2:102432336~102432357:+
PRAD	cis	rs4917385	1	rs4917385	MIMAT0022727	hsa-miR-1307-5p	7.94	1.6e-14	0.3	0.35	Systemic lupus erythematosus;	chr10:103243964	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.524	rs1712509	MIMAT0022727	hsa-miR-1307-5p	-7.93	1.67e-14	-0.3	-0.35	Migraine;	chr10:103254113	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.524	rs4917384	MIMAT0022727	hsa-miR-1307-5p	7.83	3.48e-14	0.3	0.35	Migraine;	chr10:103236031	chr10:103394341~103394361:-
PRAD	cis	rs6543140	0.964	rs4851593	MIMAT0019927	hsa-miR-4772-3p	7.82	3.81e-14	0.39	0.34	Blood protein levels;	chr2:102472767	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs10169192	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102455751	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs11886793	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102455760	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs2310301	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102456475	chr2:102432336~102432357:+
PRAD	cis	rs6543140	1	rs6543140	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102457814	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs13390895	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102459039	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.855	rs4851591	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102460963	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs7561351	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102461320	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs13393175	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102462389	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.865	rs6760275	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102463147	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6734203	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102463606	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6543142	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102465546	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.929	rs6742530	MIMAT0019927	hsa-miR-4772-3p	-7.79	4.48e-14	-0.39	-0.34	Blood protein levels;	chr2:102465820	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs4851589	MIMAT0019927	hsa-miR-4772-3p	-7.72	7.39e-14	-0.38	-0.34	Blood protein levels;	chr2:102460685	chr2:102432336~102432357:+
PRAD	cis	rs75358501	0.901	rs17212861	MIMAT0014995	hsa-miR-3130-5p	-7.68	1.01e-13	-0.73	-0.34	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206725849	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.901	rs17212861	MIMAT0014995_1	hsa-miR-3130-5p	-7.68	1.01e-13	-0.73	-0.34	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206725849	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.901	rs115783504	MIMAT0014995	hsa-miR-3130-5p	-7.68	1.01e-13	-0.73	-0.34	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206725950	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.901	rs115783504	MIMAT0014995_1	hsa-miR-3130-5p	-7.68	1.01e-13	-0.73	-0.34	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206725950	chr2:206783246~206783266:+
PRAD	cis	rs6543140	0.964	rs2141781	MIMAT0019927	hsa-miR-4772-3p	-7.64	1.34e-13	-0.38	-0.34	Blood protein levels;	chr2:102466446	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs6543144	MIMAT0019927	hsa-miR-4772-3p	-7.62	1.53e-13	-0.38	-0.34	Blood protein levels;	chr2:102476116	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs1523206	MIMAT0019927	hsa-miR-4772-3p	-7.58	1.97e-13	-0.38	-0.34	Blood protein levels;	chr2:102453715	chr2:102432336~102432357:+
PRAD	cis	rs6543140	0.964	rs1523205	MIMAT0019927	hsa-miR-4772-3p	-7.58	1.97e-13	-0.38	-0.34	Blood protein levels;	chr2:102453716	chr2:102432336~102432357:+
PRAD	cis	rs1867631	0.958	rs7536188	MIMAT0014979	hsa-miR-3117-3p	7.45	4.61e-13	0.39	0.33	Menopause (age at onset);	chr1:66622243	chr1:66628485~66628505:+
PRAD	cis	rs1867631	1	rs11208928	MIMAT0014979	hsa-miR-3117-3p	-7.29	1.4e-12	-0.4	-0.32	Menopause (age at onset);	chr1:66623879	chr1:66628485~66628505:+
PRAD	cis	rs1867631	1	rs11208927	MIMAT0014979	hsa-miR-3117-3p	-7.28	1.48e-12	-0.39	-0.32	Menopause (age at onset);	chr1:66623878	chr1:66628485~66628505:+
PRAD	cis	rs950880	0.71	rs1474309	MIMAT0019926	hsa-miR-4772-5p	7.18	2.91e-12	0.61	0.32	Serum protein levels (sST2);	chr2:102474542	chr2:102432300~102432321:+
PRAD	cis	rs1867631	1	rs10889636	MIMAT0014979	hsa-miR-3117-3p	7.15	3.47e-12	0.38	0.32	Menopause (age at onset);	chr1:66624241	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs1432798	MIMAT0003249	hsa-miR-584-5p	7.09	5.06e-12	0.41	0.32	Breast cancer;	chr5:149003782	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.674	rs7543607	MIMAT0014979	hsa-miR-3117-3p	-7.08	5.43e-12	-0.35	-0.32	Presence of antiphospholipid antibodies;	chr1:66546909	chr1:66628485~66628505:+
PRAD	cis	rs6543140	0.693	rs7579737	MIMAT0019927	hsa-miR-4772-3p	-7.08	5.46e-12	-0.36	-0.32	Blood protein levels;	chr2:102370901	chr2:102432336~102432357:+
PRAD	cis	rs250677	1	rs190378	MIMAT0003249	hsa-miR-584-5p	7.07	6.09e-12	0.4	0.32	Breast cancer;	chr5:149054712	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.674	rs2121051	MIMAT0014979	hsa-miR-3117-3p	-7.02	8.32e-12	-0.36	-0.31	Presence of antiphospholipid antibodies;	chr1:66551494	chr1:66628485~66628505:+
PRAD	cis	rs250677	1	rs28173	MIMAT0003249	hsa-miR-584-5p	6.99	9.85e-12	0.39	0.31	Breast cancer;	chr5:149044010	chr5:149062373~149062394:-
PRAD	cis	rs250677	1	rs36069	MIMAT0003249	hsa-miR-584-5p	6.96	1.18e-11	0.39	0.31	Breast cancer;	chr5:149037690	chr5:149062373~149062394:-
PRAD	cis	rs1867631	1	rs6665859	MIMAT0014979	hsa-miR-3117-3p	-6.95	1.3e-11	-0.37	-0.31	Menopause (age at onset);	chr1:66611872	chr1:66628485~66628505:+
PRAD	cis	rs1867631	1	rs7546090	MIMAT0014979	hsa-miR-3117-3p	-6.94	1.38e-11	-0.37	-0.31	Menopause (age at onset);	chr1:66618298	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.958	rs7520226	MIMAT0014979	hsa-miR-3117-3p	-6.93	1.42e-11	-0.37	-0.31	Menopause (age at onset);	chr1:66615312	chr1:66628485~66628505:+
PRAD	cis	rs250677	1	rs36080	MIMAT0003249	hsa-miR-584-5p	6.93	1.45e-11	0.39	0.31	Breast cancer;	chr5:149050888	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs3763022	MIMAT0003249	hsa-miR-584-5p	6.93	1.46e-11	0.39	0.31	Breast cancer;	chr5:149001515	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.634	rs994396	MIMAT0014979	hsa-miR-3117-3p	-6.91	1.63e-11	-0.36	-0.31	Presence of antiphospholipid antibodies;	chr1:66546553	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.674	rs4134135	MIMAT0014979	hsa-miR-3117-3p	-6.91	1.63e-11	-0.36	-0.31	Presence of antiphospholipid antibodies;	chr1:66547045	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.876	rs10889637	MIMAT0014979	hsa-miR-3117-3p	-6.91	1.68e-11	-0.37	-0.31	Menopause (age at onset);	chr1:66631782	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.634	rs4142763	MIMAT0014979	hsa-miR-3117-3p	-6.89	1.94e-11	-0.35	-0.31	Presence of antiphospholipid antibodies;	chr1:66532353	chr1:66628485~66628505:+
PRAD	cis	rs250677	1	rs250677	MIMAT0003249	hsa-miR-584-5p	6.86	2.23e-11	0.39	0.31	Breast cancer;	chr5:149053986	chr5:149062373~149062394:-
PRAD	cis	rs250677	1	rs250676	MIMAT0003249	hsa-miR-584-5p	6.85	2.47e-11	0.39	0.31	Breast cancer;	chr5:149045955	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.649	rs967325	MIMAT0014979	hsa-miR-3117-3p	-6.83	2.81e-11	-0.35	-0.31	Presence of antiphospholipid antibodies;	chr1:66538039	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.655	rs3830025	MIMAT0005878	hsa-miR-1287-5p	6.8	3.32e-11	0.35	0.3	Metabolite levels;	chr10:98416347	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.655	rs3830024	MIMAT0005878	hsa-miR-1287-5p	6.8	3.32e-11	0.35	0.3	Metabolite levels;	chr10:98416349	chr10:98395271~98395292:-
PRAD	cis	rs250677	1	rs36079	MIMAT0003249	hsa-miR-584-5p	6.78	3.66e-11	0.38	0.3	Breast cancer;	chr5:149050941	chr5:149062373~149062394:-
PRAD	cis	rs1867631	0.585	rs6694782	MIMAT0014979	hsa-miR-3117-3p	6.75	4.42e-11	0.33	0.3	Menopause (age at onset);	chr1:66661079	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs17109208	MIMAT0003249	hsa-miR-584-5p	6.75	4.44e-11	0.41	0.3	Breast cancer;	chr5:148998912	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.649	rs1415984	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.73e-11	-0.34	-0.3	Presence of antiphospholipid antibodies;	chr1:66536434	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.649	rs6691033	MIMAT0014979	hsa-miR-3117-3p	-6.74	4.79e-11	-0.34	-0.3	Presence of antiphospholipid antibodies;	chr1:66541746	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs4431331	MIMAT0003249	hsa-miR-584-5p	6.72	5.39e-11	0.4	0.3	Breast cancer;	chr5:148974011	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.576	rs7354983	MIMAT0014979	hsa-miR-3117-3p	-6.7	6.28e-11	-0.35	-0.3	Presence of antiphospholipid antibodies;	chr1:66522466	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.576	rs7354930	MIMAT0014979	hsa-miR-3117-3p	-6.66	7.99e-11	-0.35	-0.3	Presence of antiphospholipid antibodies;	chr1:66520694	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.576	rs1338194	MIMAT0014979	hsa-miR-3117-3p	-6.66	7.99e-11	-0.35	-0.3	Presence of antiphospholipid antibodies;	chr1:66520793	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.634	rs12143964	MIMAT0014979	hsa-miR-3117-3p	-6.66	8.19e-11	-0.33	-0.3	Presence of antiphospholipid antibodies;	chr1:66544583	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.585	rs6670827	MIMAT0014979	hsa-miR-3117-3p	-6.63	9.83e-11	-0.33	-0.3	Menopause (age at onset);	chr1:66661323	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.546	rs1998716	MIMAT0014979	hsa-miR-3117-3p	-6.62	1.02e-10	-0.32	-0.3	Presence of antiphospholipid antibodies;	chr1:66651423	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.798	rs11168080	MIMAT0003249	hsa-miR-584-5p	6.6	1.13e-10	0.4	0.3	Breast cancer;	chr5:149030258	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs1007400	MIMAT0003249	hsa-miR-584-5p	-6.59	1.24e-10	-0.4	-0.3	Breast cancer;	chr5:149003072	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs891920	MIMAT0003249	hsa-miR-584-5p	6.58	1.29e-10	0.4	0.3	Breast cancer;	chr5:148989855	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.559	rs17109198	MIMAT0003249	hsa-miR-584-5p	6.58	1.29e-10	0.4	0.3	Breast cancer;	chr5:148990149	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs56309414	MIMAT0003249	hsa-miR-584-5p	6.58	1.29e-10	0.4	0.3	Breast cancer;	chr5:148996463	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs4562031	MIMAT0003249	hsa-miR-584-5p	-6.58	1.34e-10	-0.4	-0.3	Breast cancer;	chr5:148988888	chr5:149062373~149062394:-
PRAD	cis	rs1867631	0.585	rs12062570	MIMAT0014979	hsa-miR-3117-3p	-6.57	1.37e-10	-0.32	-0.3	Menopause (age at onset);	chr1:66620602	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.565	rs1536112	MIMAT0014979	hsa-miR-3117-3p	6.57	1.38e-10	0.31	0.29	Presence of antiphospholipid antibodies;	chr1:66641542	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.585	rs5008753	MIMAT0014979	hsa-miR-3117-3p	-6.57	1.41e-10	-0.32	-0.29	Menopause (age at onset);	chr1:66626565	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs6872172	MIMAT0003249	hsa-miR-584-5p	-6.57	1.42e-10	-0.4	-0.29	Breast cancer;	chr5:148979966	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs6580589	MIMAT0003249	hsa-miR-584-5p	-6.57	1.42e-10	-0.4	-0.29	Breast cancer;	chr5:148980772	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs6580590	MIMAT0003249	hsa-miR-584-5p	-6.57	1.42e-10	-0.4	-0.29	Breast cancer;	chr5:148980811	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs10040598	MIMAT0003249	hsa-miR-584-5p	-6.57	1.42e-10	-0.4	-0.29	Breast cancer;	chr5:148986157	chr5:149062373~149062394:-
PRAD	cis	rs1867631	0.585	rs12094526	MIMAT0014979	hsa-miR-3117-3p	-6.57	1.42e-10	-0.33	-0.29	Menopause (age at onset);	chr1:66660431	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.585	rs4655639	MIMAT0014979	hsa-miR-3117-3p	-6.56	1.44e-10	-0.32	-0.29	Menopause (age at onset);	chr1:66623407	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.585	rs4655642	MIMAT0014979	hsa-miR-3117-3p	-6.56	1.44e-10	-0.32	-0.29	Menopause (age at onset);	chr1:66624400	chr1:66628485~66628505:+
PRAD	cis	rs250677	1	rs40525	MIMAT0003249	hsa-miR-584-5p	-6.56	1.46e-10	-0.37	-0.29	Breast cancer;	chr5:149053369	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs8181292	MIMAT0005878	hsa-miR-1287-5p	6.56	1.5e-10	0.33	0.29	Metabolite levels;	chr10:98415720	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs6872701	MIMAT0003249	hsa-miR-584-5p	-6.56	1.51e-10	-0.4	-0.29	Breast cancer;	chr5:148979523	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs7909822	MIMAT0005878	hsa-miR-1287-5p	6.55	1.53e-10	0.33	0.29	Metabolite levels;	chr10:98412278	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.576	rs1338200	MIMAT0014979	hsa-miR-3117-3p	-6.55	1.59e-10	-0.34	-0.29	Presence of antiphospholipid antibodies;	chr1:66526514	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs998304	MIMAT0003249	hsa-miR-584-5p	6.54	1.69e-10	0.4	0.29	Breast cancer;	chr5:149002802	chr5:149062373~149062394:-
PRAD	cis	rs1867631	0.585	rs9787219	MIMAT0014979	hsa-miR-3117-3p	-6.53	1.72e-10	-0.32	-0.29	Menopause (age at onset);	chr1:66614476	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.585	rs11208922	MIMAT0014979	hsa-miR-3117-3p	-6.53	1.72e-10	-0.32	-0.29	Menopause (age at onset);	chr1:66614543	chr1:66628485~66628505:+
PRAD	cis	rs1867631	1	rs10889640	MIMAT0014979	hsa-miR-3117-3p	-6.53	1.74e-10	-0.35	-0.29	Menopause (age at onset);	chr1:66662168	chr1:66628485~66628505:+
PRAD	cis	rs1867631	1	rs10789213	MIMAT0014979	hsa-miR-3117-3p	-6.53	1.74e-10	-0.35	-0.29	Menopause (age at onset);	chr1:66662518	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs10040798	MIMAT0003249	hsa-miR-584-5p	-6.52	1.82e-10	-0.39	-0.29	Breast cancer;	chr5:148987761	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.565	rs6689755	MIMAT0014979	hsa-miR-3117-3p	-6.52	1.86e-10	-0.31	-0.29	Presence of antiphospholipid antibodies;	chr1:66647367	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs6584202	MIMAT0005878	hsa-miR-1287-5p	6.52	1.87e-10	0.33	0.29	Metabolite levels;	chr10:98410626	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.576	rs7355221	MIMAT0014979	hsa-miR-3117-3p	-6.52	1.89e-10	-0.34	-0.29	Presence of antiphospholipid antibodies;	chr1:66520618	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs2895837	MIMAT0003249	hsa-miR-584-5p	-6.5	2.07e-10	-0.39	-0.29	Breast cancer;	chr5:148977972	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs2217638	MIMAT0003249	hsa-miR-584-5p	-6.49	2.25e-10	-0.39	-0.29	Breast cancer;	chr5:148984792	chr5:149062373~149062394:-
PRAD	cis	rs1867631	0.585	rs11208940	MIMAT0014979	hsa-miR-3117-3p	6.49	2.27e-10	0.32	0.29	Menopause (age at onset);	chr1:66661559	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs4705302	MIMAT0003249	hsa-miR-584-5p	-6.47	2.51e-10	-0.39	-0.29	Breast cancer;	chr5:148975399	chr5:149062373~149062394:-
PRAD	cis	rs1867631	1	rs10789212	MIMAT0014979	hsa-miR-3117-3p	-6.46	2.63e-10	-0.34	-0.29	Menopause (age at onset);	chr1:66662472	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs1432801	MIMAT0003249	hsa-miR-584-5p	6.46	2.64e-10	0.39	0.29	Breast cancer;	chr5:149011416	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.565	rs2147776	MIMAT0014979	hsa-miR-3117-3p	-6.46	2.78e-10	-0.31	-0.29	Presence of antiphospholipid antibodies;	chr1:66641720	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs62378210	MIMAT0003249	hsa-miR-584-5p	6.45	2.82e-10	0.39	0.29	Breast cancer;	chr5:149005322	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.576	rs1547737	MIMAT0014979	hsa-miR-3117-3p	-6.44	2.99e-10	-0.35	-0.29	Presence of antiphospholipid antibodies;	chr1:66518237	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs10477400	MIMAT0003249	hsa-miR-584-5p	-6.43	3.29e-10	-0.39	-0.29	Breast cancer;	chr5:148980035	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.69	rs113195335	MIMAT0005878	hsa-miR-1287-5p	6.42	3.39e-10	0.32	0.29	Metabolite levels;	chr10:98415775	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs3750603	MIMAT0005878	hsa-miR-1287-5p	6.42	3.39e-10	0.32	0.29	Metabolite levels;	chr10:98415779	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs3750601	MIMAT0005878	hsa-miR-1287-5p	6.42	3.4e-10	0.32	0.29	Metabolite levels;	chr10:98414804	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs2147900	MIMAT0005878	hsa-miR-1287-5p	6.42	3.4e-10	0.32	0.29	Metabolite levels;	chr10:98414964	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.576	rs2859914	MIMAT0014979	hsa-miR-3117-3p	-6.42	3.44e-10	-0.34	-0.29	Presence of antiphospholipid antibodies;	chr1:66524157	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs11954893	MIMAT0003249	hsa-miR-584-5p	6.42	3.46e-10	0.39	0.29	Breast cancer;	chr5:149012799	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs3814140	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411005	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs3814142	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411347	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.691	rs3829853	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411417	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs10748728	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411441	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs10748729	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411614	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs10748730	MIMAT0005878	hsa-miR-1287-5p	6.42	3.52e-10	0.32	0.29	Metabolite levels;	chr10:98411683	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs4705301	MIMAT0003249	hsa-miR-584-5p	6.42	3.53e-10	0.38	0.29	Breast cancer;	chr5:148975339	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs7910014	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98412353	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs7910247	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98412495	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs7913541	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98412722	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs2274246	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98415303	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs2274245	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98415325	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs2274244	MIMAT0005878	hsa-miR-1287-5p	6.4	3.83e-10	0.32	0.29	Metabolite levels;	chr10:98415461	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs7702695	MIMAT0003249	hsa-miR-584-5p	6.39	4e-10	0.39	0.29	Breast cancer;	chr5:149022987	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs6875902	MIMAT0003249	hsa-miR-584-5p	6.39	4.18e-10	0.4	0.29	Breast cancer;	chr5:149028330	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs6584204	MIMAT0005878	hsa-miR-1287-5p	6.39	4.21e-10	0.32	0.29	Metabolite levels;	chr10:98413823	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.917	rs36066	MIMAT0003249	hsa-miR-584-5p	6.38	4.28e-10	0.37	0.29	Breast cancer;	chr5:149040208	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs6584205	MIMAT0005878	hsa-miR-1287-5p	6.38	4.3e-10	0.32	0.29	Metabolite levels;	chr10:98414049	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.806	rs9804285	MIMAT0005878	hsa-miR-1287-5p	6.38	4.34e-10	0.32	0.29	Metabolite levels;	chr10:98409715	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs2274243	MIMAT0005878	hsa-miR-1287-5p	6.38	4.46e-10	0.32	0.29	Metabolite levels;	chr10:98415510	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs7923729	MIMAT0005878	hsa-miR-1287-5p	6.37	4.65e-10	0.32	0.29	Metabolite levels;	chr10:98409708	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs6584198	MIMAT0005878	hsa-miR-1287-5p	6.37	4.65e-10	0.32	0.29	Metabolite levels;	chr10:98410149	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs6584201	MIMAT0005878	hsa-miR-1287-5p	6.37	4.65e-10	0.32	0.29	Metabolite levels;	chr10:98410452	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs12259939	MIMAT0005878	hsa-miR-1287-5p	6.37	4.7e-10	0.32	0.29	Metabolite levels;	chr10:98409264	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs10038913	MIMAT0003249	hsa-miR-584-5p	-6.36	4.9e-10	-0.38	-0.29	Breast cancer;	chr5:148974661	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs1061437	MIMAT0005878	hsa-miR-1287-5p	6.36	4.96e-10	0.32	0.29	Metabolite levels;	chr10:98416397	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.958	rs17109282	MIMAT0003249	hsa-miR-584-5p	-6.36	5.01e-10	-0.37	-0.29	Breast cancer;	chr5:149037114	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.958	rs43147	MIMAT0003249	hsa-miR-584-5p	-6.35	5.14e-10	-0.38	-0.29	Breast cancer;	chr5:149037540	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.727	rs6584199	MIMAT0005878	hsa-miR-1287-5p	6.35	5.19e-10	0.32	0.29	Metabolite levels;	chr10:98410226	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs55732303	MIMAT0003249	hsa-miR-584-5p	6.35	5.32e-10	0.39	0.29	Breast cancer;	chr5:149012975	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.587	rs3814141	MIMAT0005878	hsa-miR-1287-5p	6.34	5.54e-10	0.34	0.29	Metabolite levels;	chr10:98411271	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs10042466	MIMAT0003249	hsa-miR-584-5p	6.33	5.73e-10	0.38	0.29	Breast cancer;	chr5:149014071	chr5:149062373~149062394:-
PRAD	cis	rs250677	1	rs36082	MIMAT0003249	hsa-miR-584-5p	6.33	6.02e-10	0.37	0.28	Breast cancer;	chr5:149049281	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs10883091	MIMAT0005878	hsa-miR-1287-5p	6.33	6.03e-10	0.32	0.28	Metabolite levels;	chr10:98407482	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs10883092	MIMAT0005878	hsa-miR-1287-5p	6.33	6.03e-10	0.32	0.28	Metabolite levels;	chr10:98407519	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.958	rs10056942	MIMAT0003249	hsa-miR-584-5p	6.32	6.25e-10	0.37	0.28	Breast cancer;	chr5:149036551	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.916	rs17109279	MIMAT0003249	hsa-miR-584-5p	6.32	6.25e-10	0.37	0.28	Breast cancer;	chr5:149037018	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs12523526	MIMAT0003249	hsa-miR-584-5p	-6.32	6.34e-10	-0.39	-0.28	Breast cancer;	chr5:148969544	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs6584200	MIMAT0005878	hsa-miR-1287-5p	6.32	6.45e-10	0.32	0.28	Metabolite levels;	chr10:98410280	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs9787550	MIMAT0005878	hsa-miR-1287-5p	6.31	6.59e-10	0.32	0.28	Metabolite levels;	chr10:98409294	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs919731	MIMAT0003249	hsa-miR-584-5p	-6.31	6.84e-10	-0.38	-0.28	Breast cancer;	chr5:148972587	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.522	rs10045726	MIMAT0003249	hsa-miR-584-5p	-6.31	6.84e-10	-0.38	-0.28	Breast cancer;	chr5:148973427	chr5:149062373~149062394:-
PRAD	cis	rs7072216	0.763	rs10736129	MIMAT0005878	hsa-miR-1287-5p	-6.3	7.03e-10	-0.32	-0.28	Metabolite levels;	chr10:98411814	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs10050928	MIMAT0003249	hsa-miR-584-5p	-6.3	7.04e-10	-0.38	-0.28	Breast cancer;	chr5:148973900	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.958	rs36070	MIMAT0003249	hsa-miR-584-5p	6.29	7.37e-10	0.37	0.28	Breast cancer;	chr5:149037677	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.958	rs36068	MIMAT0003249	hsa-miR-584-5p	6.29	7.37e-10	0.37	0.28	Breast cancer;	chr5:149037949	chr5:149062373~149062394:-
PRAD	cis	rs250677	0.958	rs36067	MIMAT0003249	hsa-miR-584-5p	6.29	7.37e-10	0.37	0.28	Breast cancer;	chr5:149037990	chr5:149062373~149062394:-
PRAD	cis	rs8064299	0.967	rs880827	MIMAT0017994	hsa-miR-3615	6.26	8.82e-10	0.33	0.28	Monocyte count;	chr17:74771296	chr17:74748663~74748683:+
PRAD	cis	rs6681460	0.576	rs6588203	MIMAT0014979	hsa-miR-3117-3p	-6.26	8.82e-10	-0.32	-0.28	Presence of antiphospholipid antibodies;	chr1:66525168	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.535	rs6588204	MIMAT0014979	hsa-miR-3117-3p	-6.26	8.82e-10	-0.32	-0.28	Presence of antiphospholipid antibodies;	chr1:66525325	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.74	rs11191643	MIMAT0022727	hsa-miR-1307-5p	-6.26	8.87e-10	-0.22	-0.28	Migraine;	chr10:103297804	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.763	rs942803	MIMAT0005878	hsa-miR-1287-5p	6.26	9.14e-10	0.32	0.28	Metabolite levels;	chr10:98408874	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.649	rs1415974	MIMAT0014979	hsa-miR-3117-3p	6.25	9.47e-10	0.31	0.28	Presence of antiphospholipid antibodies;	chr1:66539820	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs942805	MIMAT0005878	hsa-miR-1287-5p	6.25	9.62e-10	0.32	0.28	Metabolite levels;	chr10:98408615	chr10:98395271~98395292:-
PRAD	cis	rs250677	0.522	rs919730	MIMAT0003249	hsa-miR-584-5p	-6.24	9.87e-10	-0.38	-0.28	Breast cancer;	chr5:148972838	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.966	rs4655650	MIMAT0014979	hsa-miR-3117-3p	-6.24	1.01e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66676603	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.522	rs12520924	MIMAT0003249	hsa-miR-584-5p	-6.23	1.09e-09	-0.38	-0.28	Breast cancer;	chr5:148969586	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.966	rs10889643	MIMAT0014979	hsa-miR-3117-3p	-6.22	1.11e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66677685	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.649	rs967322	MIMAT0014979	hsa-miR-3117-3p	-6.2	1.24e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66537763	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs10732782	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98406749	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.691	rs7910973	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98406975	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs7911036	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98407258	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs10883090	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98407479	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs45523432	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98407679	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs12763044	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98407694	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs942808	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98408345	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs942807	MIMAT0005878	hsa-miR-1287-5p	6.19	1.31e-09	0.32	0.28	Metabolite levels;	chr10:98408462	chr10:98395271~98395292:-
PRAD	cis	rs2284932	0.556	rs6727168	MIMAT0016895	hsa-miR-2355-5p	-6.19	1.31e-09	-0.3	-0.28	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207124746	chr2:207110043~207110063:-
PRAD	cis	rs6681460	0.649	rs4655494	MIMAT0014979	hsa-miR-3117-3p	-6.19	1.34e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66537193	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs942804	MIMAT0005878	hsa-miR-1287-5p	6.19	1.36e-09	0.32	0.28	Metabolite levels;	chr10:98408742	chr10:98395271~98395292:-
PRAD	cis	rs6681460	1	rs1325263	MIMAT0014979	hsa-miR-3117-3p	-6.18	1.4e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66664108	chr1:66628485~66628505:+
PRAD	cis	rs7894407	0.856	rs7093667	MIMAT0005951	hsa-miR-1307-3p	-6.18	1.42e-09	-0.21	-0.28	White matter hyperintensity burden;	chr10:103320818	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.966	rs10789214	MIMAT0014979	hsa-miR-3117-3p	-6.18	1.44e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66681134	chr1:66628485~66628505:+
PRAD	cis	rs250677	0.958	rs36078	MIMAT0003249	hsa-miR-584-5p	6.17	1.53e-09	0.37	0.28	Breast cancer;	chr5:149051004	chr5:149062373~149062394:-
PRAD	cis	rs6681460	0.966	rs6588215	MIMAT0014979	hsa-miR-3117-3p	-6.17	1.55e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66676266	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.866	rs1856318	MIMAT0014979	hsa-miR-3117-3p	-6.15	1.68e-09	-0.32	-0.28	Presence of antiphospholipid antibodies;	chr1:66558532	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.608	rs10889624	MIMAT0014979	hsa-miR-3117-3p	-6.15	1.73e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66540124	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs2872078	MIMAT0014979	hsa-miR-3117-3p	-6.14	1.79e-09	-0.31	-0.28	Presence of antiphospholipid antibodies;	chr1:66661684	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs733345	MIMAT0005878	hsa-miR-1287-5p	6.14	1.82e-09	0.31	0.28	Metabolite levels;	chr10:98404458	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.763	rs733346	MIMAT0005878	hsa-miR-1287-5p	6.14	1.82e-09	0.31	0.28	Metabolite levels;	chr10:98404568	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.726	rs4474372	MIMAT0005878	hsa-miR-1287-5p	6.14	1.82e-09	0.31	0.28	Metabolite levels;	chr10:98404814	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.649	rs7540195	MIMAT0014979	hsa-miR-3117-3p	6.13	1.86e-09	0.31	0.28	Presence of antiphospholipid antibodies;	chr1:66536723	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.649	rs1947083	MIMAT0014979	hsa-miR-3117-3p	-6.13	1.94e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66539118	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.649	rs1856315	MIMAT0014979	hsa-miR-3117-3p	-6.13	1.94e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66539546	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.621	rs3750605	MIMAT0005878	hsa-miR-1287-5p	6.13	1.95e-09	0.33	0.28	Metabolite levels;	chr10:98415897	chr10:98395271~98395292:-
PRAD	cis	rs1712517	0.787	rs1163089	MIMAT0022727	hsa-miR-1307-5p	-6.12	1.98e-09	-0.22	-0.28	Migraine;	chr10:103284207	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs11191672	MIMAT0022727	hsa-miR-1307-5p	-6.12	2.05e-09	-0.22	-0.28	Migraine;	chr10:103379204	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.966	rs10889642	MIMAT0014979	hsa-miR-3117-3p	-6.11	2.14e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66677651	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.649	rs10889625	MIMAT0014979	hsa-miR-3117-3p	-6.11	2.15e-09	-0.3	-0.28	Presence of antiphospholipid antibodies;	chr1:66541552	chr1:66628485~66628505:+
PRAD	cis	rs8064299	0.967	rs3744208	MIMAT0017994	hsa-miR-3615	-6.11	2.15e-09	-0.32	-0.28	Monocyte count;	chr17:74771426	chr17:74748663~74748683:+
PRAD	cis	rs7072216	0.763	rs7091709	MIMAT0005878	hsa-miR-1287-5p	6.1	2.28e-09	0.31	0.28	Metabolite levels;	chr10:98407848	chr10:98395271~98395292:-
PRAD	cis	rs1712517	0.74	rs4917387	MIMAT0022727	hsa-miR-1307-5p	-6.1	2.33e-09	-0.22	-0.28	Migraine;	chr10:103348698	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.649	rs1338184	MIMAT0014979	hsa-miR-3117-3p	6.08	2.54e-09	0.3	0.27	Presence of antiphospholipid antibodies;	chr1:66539389	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs10889634	MIMAT0014979	hsa-miR-3117-3p	6.08	2.6e-09	0.29	0.27	Presence of antiphospholipid antibodies;	chr1:66600228	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6681460	MIMAT0014979	hsa-miR-3117-3p	6.07	2.64e-09	0.3	0.27	Presence of antiphospholipid antibodies;	chr1:66657374	chr1:66628485~66628505:+
PRAD	cis	rs8064299	0.967	rs878905	MIMAT0017994	hsa-miR-3615	-6.07	2.65e-09	-0.32	-0.27	Monocyte count;	chr17:74773272	chr17:74748663~74748683:+
PRAD	cis	rs8064299	0.967	rs878907	MIMAT0017994	hsa-miR-3615	-6.07	2.65e-09	-0.32	-0.27	Monocyte count;	chr17:74773555	chr17:74748663~74748683:+
PRAD	cis	rs7072216	0.763	rs2147901	MIMAT0005878	hsa-miR-1287-5p	-6.06	2.79e-09	-0.31	-0.27	Metabolite levels;	chr10:98405739	chr10:98395271~98395292:-
PRAD	cis	rs1712517	0.844	rs1163074	MIMAT0022727	hsa-miR-1307-5p	-6.06	2.81e-09	-0.21	-0.27	Migraine;	chr10:103262005	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.873	rs7903004	MIMAT0022727	hsa-miR-1307-5p	6.06	2.93e-09	0.21	0.27	Migraine;	chr10:103244344	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.866	rs996123	MIMAT0014979	hsa-miR-3117-3p	-6.05	2.96e-09	-0.31	-0.27	Presence of antiphospholipid antibodies;	chr1:66559660	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.727	rs942809	MIMAT0005878	hsa-miR-1287-5p	6.05	2.96e-09	0.31	0.27	Metabolite levels;	chr10:98408244	chr10:98395271~98395292:-
PRAD	cis	rs1712517	0.844	rs1163081	MIMAT0022727	hsa-miR-1307-5p	-6.05	2.97e-09	-0.21	-0.27	Migraine;	chr10:103270083	chr10:103394341~103394361:-
PRAD	cis	rs8064299	0.967	rs7420	MIMAT0017994	hsa-miR-3615	6.05	3.04e-09	0.32	0.27	Monocyte count;	chr17:74769076	chr17:74748663~74748683:+
PRAD	cis	rs1712517	0.873	rs1712516	MIMAT0022727	hsa-miR-1307-5p	-6.05	3.1e-09	-0.21	-0.27	Migraine;	chr10:103273871	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs2147777	MIMAT0014979	hsa-miR-3117-3p	-6.05	3.12e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66663571	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6680876	MIMAT0014979	hsa-miR-3117-3p	-6.05	3.12e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66663799	chr1:66628485~66628505:+
PRAD	cis	rs8064299	0.967	rs878906	MIMAT0017994	hsa-miR-3615	-6.04	3.13e-09	-0.32	-0.27	Monocyte count;	chr17:74773195	chr17:74748663~74748683:+
PRAD	cis	rs77637988	0.723	rs7587917	MIMAT0031175	hsa-miR-548ba	-6.04	3.15e-09	-0.35	-0.27	Joint mobility (Beighton score);	chr2:48538939	chr2:49059603~49059624:+
PRAD	cis	rs6681460	1	rs6670378	MIMAT0014979	hsa-miR-3117-3p	-6.04	3.17e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66660902	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.771	rs11191645	MIMAT0022727	hsa-miR-1307-5p	-6.04	3.19e-09	-0.22	-0.27	Migraine;	chr10:103299551	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.901	rs1570815	MIMAT0014979	hsa-miR-3117-3p	-6.04	3.21e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66673984	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.844	rs1163075	MIMAT0022727	hsa-miR-1307-5p	6.04	3.24e-09	0.21	0.27	Migraine;	chr10:103261506	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs61350103	MIMAT0022727	hsa-miR-1307-5p	-6.04	3.3e-09	-0.22	-0.27	Migraine;	chr10:103309363	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs11191654	MIMAT0022727	hsa-miR-1307-5p	-6.04	3.3e-09	-0.22	-0.27	Migraine;	chr10:103317367	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs61869827	MIMAT0022727	hsa-miR-1307-5p	-6.04	3.3e-09	-0.22	-0.27	Migraine;	chr10:103319682	chr10:103394341~103394361:-
PRAD	cis	rs7894407	0.856	rs10883855	MIMAT0005951	hsa-miR-1307-3p	-6.03	3.38e-09	-0.2	-0.27	White matter hyperintensity burden;	chr10:103332690	chr10:103394301~103394322:-
PRAD	cis	rs1867631	1	rs1867631	MIMAT0014979	hsa-miR-3117-3p	-6.03	3.47e-09	-0.33	-0.27	Menopause (age at onset);	chr1:66580443	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs4655647	MIMAT0014979	hsa-miR-3117-3p	-6.02	3.64e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66640394	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.771	rs2008530	MIMAT0022727	hsa-miR-1307-5p	-6.02	3.66e-09	-0.22	-0.27	Migraine;	chr10:103299082	chr10:103394341~103394361:-
PRAD	cis	rs77637988	0.533	rs13398791	MIMAT0031175	hsa-miR-548ba	-6.02	3.67e-09	-0.35	-0.27	Joint mobility (Beighton score);	chr2:48395181	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.578	rs4953572	MIMAT0031175	hsa-miR-548ba	6.01	3.88e-09	0.34	0.27	Joint mobility (Beighton score);	chr2:48396868	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.771	rs61871160	MIMAT0022727	hsa-miR-1307-5p	-6.01	3.9e-09	-0.22	-0.27	Migraine;	chr10:103384531	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs10889641	MIMAT0014979	hsa-miR-3117-3p	-6	4.1e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66672684	chr1:66628485~66628505:+
PRAD	cis	rs7894407	0.76	rs1163085	MIMAT0005951	hsa-miR-1307-3p	-5.99	4.2e-09	-0.2	-0.27	White matter hyperintensity burden;	chr10:103279484	chr10:103394301~103394322:-
PRAD	cis	rs6681460	1	rs6689864	MIMAT0014979	hsa-miR-3117-3p	-5.99	4.21e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66602429	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6696927	MIMAT0014979	hsa-miR-3117-3p	-5.98	4.44e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66604698	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.771	rs59744322	MIMAT0022727	hsa-miR-1307-5p	-5.98	4.44e-09	-0.21	-0.27	Migraine;	chr10:103386935	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs11191676	MIMAT0022727	hsa-miR-1307-5p	-5.98	4.62e-09	-0.21	-0.27	Migraine;	chr10:103395309	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs2292807	MIMAT0022727	hsa-miR-1307-5p	-5.98	4.62e-09	-0.21	-0.27	Migraine;	chr10:103395888	chr10:103394341~103394361:-
PRAD	cis	rs2284932	0.591	rs2269076	MIMAT0016895	hsa-miR-2355-5p	5.97	4.68e-09	0.31	0.27	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207123015	chr2:207110043~207110063:-
PRAD	cis	rs1712517	0.771	rs11191666	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.79e-09	-0.21	-0.27	Migraine;	chr10:103367521	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs10883858	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.79e-09	-0.21	-0.27	Migraine;	chr10:103367951	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs7921655	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.87e-09	-0.21	-0.27	Migraine;	chr10:103353944	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs7074749	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.87e-09	-0.21	-0.27	Migraine;	chr10:103356299	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.74	rs11191663	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.87e-09	-0.21	-0.27	Migraine;	chr10:103358705	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs11191664	MIMAT0022727	hsa-miR-1307-5p	-5.97	4.87e-09	-0.21	-0.27	Migraine;	chr10:103358719	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.966	rs7524851	MIMAT0014979	hsa-miR-3117-3p	-5.96	5e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66627335	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs4655646	MIMAT0014979	hsa-miR-3117-3p	-5.96	5e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66628653	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs4655640	MIMAT0014979	hsa-miR-3117-3p	-5.96	5.05e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66623537	chr1:66628485~66628505:+
PRAD	cis	rs7894407	0.892	rs10883859	MIMAT0005951	hsa-miR-1307-3p	5.96	5.12e-09	0.2	0.27	White matter hyperintensity burden;	chr10:103368377	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.625	rs12138066	MIMAT0014979	hsa-miR-3117-3p	-5.96	5.2e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66638133	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.625	rs6696812	MIMAT0014979	hsa-miR-3117-3p	-5.95	5.23e-09	-0.3	-0.27	Presence of antiphospholipid antibodies;	chr1:66634626	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.959	rs11208914	MIMAT0014979	hsa-miR-3117-3p	-5.94	5.71e-09	-0.33	-0.27	Menopause (age at onset);	chr1:66584045	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs7519747	MIMAT0014979	hsa-miR-3117-3p	-5.93	5.86e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66675040	chr1:66628485~66628505:+
PRAD	cis	rs34198350	0.636	rs10495950	MIMAT0031175	hsa-miR-548ba	-5.93	5.89e-09	-0.51	-0.27	QT interval in Tripanosoma cruzi seropositivity;	chr2:48207625	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.844	rs1163087	MIMAT0022727	hsa-miR-1307-5p	-5.93	5.92e-09	-0.21	-0.27	Migraine;	chr10:103283532	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.844	rs4918003	MIMAT0022727	hsa-miR-1307-5p	-5.93	5.97e-09	-0.21	-0.27	Migraine;	chr10:103284400	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs1329978	MIMAT0014979	hsa-miR-3117-3p	-5.93	5.99e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66650548	chr1:66628485~66628505:+
PRAD	cis	rs77637988	0.578	rs12328506	MIMAT0031175	hsa-miR-548ba	-5.93	6.11e-09	-0.34	-0.27	Joint mobility (Beighton score);	chr2:48396045	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.773	rs1063461	MIMAT0022727	hsa-miR-1307-5p	-5.92	6.45e-09	-0.21	-0.27	Migraine;	chr10:103289348	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.74	rs4293062	MIMAT0022727	hsa-miR-1307-5p	-5.92	6.45e-09	-0.21	-0.27	Migraine;	chr10:103292867	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.744	rs11191641	MIMAT0022727	hsa-miR-1307-5p	-5.92	6.45e-09	-0.21	-0.27	Migraine;	chr10:103293183	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.744	rs4293063	MIMAT0022727	hsa-miR-1307-5p	-5.92	6.45e-09	-0.21	-0.27	Migraine;	chr10:103293219	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs10789210	MIMAT0014979	hsa-miR-3117-3p	-5.91	6.73e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66600347	chr1:66628485~66628505:+
PRAD	cis	rs77637988	0.631	rs7587385	MIMAT0031175	hsa-miR-548ba	-5.9	7.02e-09	-0.33	-0.27	Joint mobility (Beighton score);	chr2:48373552	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.631	rs7573316	MIMAT0031175	hsa-miR-548ba	-5.9	7.02e-09	-0.33	-0.27	Joint mobility (Beighton score);	chr2:48373553	chr2:49059603~49059624:+
PRAD	cis	rs6681460	1	rs6588207	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.22e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66600872	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs4655636	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.22e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66602854	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs9662962	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.23e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66655681	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs9659879	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.23e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66655751	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs7521111	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.23e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66655951	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs7521123	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.23e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66655980	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6697088	MIMAT0014979	hsa-miR-3117-3p	5.9	7.23e-09	0.29	0.27	Presence of antiphospholipid antibodies;	chr1:66579041	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6656550	MIMAT0014979	hsa-miR-3117-3p	-5.9	7.25e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66656869	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs1536115	MIMAT0014979	hsa-miR-3117-3p	-5.89	7.36e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66655318	chr1:66628485~66628505:+
PRAD	cis	rs77637988	0.578	rs11683099	MIMAT0031175	hsa-miR-548ba	-5.89	7.49e-09	-0.34	-0.27	Joint mobility (Beighton score);	chr2:48384380	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.873	rs7916056	MIMAT0022727	hsa-miR-1307-5p	5.89	7.49e-09	0.21	0.27	Migraine;	chr10:103238157	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.836	rs11191649	MIMAT0022727	hsa-miR-1307-5p	-5.89	7.52e-09	-0.21	-0.27	Migraine;	chr10:103307280	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs7524818	MIMAT0014979	hsa-miR-3117-3p	-5.89	7.68e-09	-0.28	-0.27	Presence of antiphospholipid antibodies;	chr1:66606348	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6659968	MIMAT0014979	hsa-miR-3117-3p	-5.89	7.7e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66657776	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs2031478	MIMAT0014979	hsa-miR-3117-3p	-5.89	7.7e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66658059	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs6680944	MIMAT0014979	hsa-miR-3117-3p	-5.88	8.13e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66656882	chr1:66628485~66628505:+
PRAD	cis	rs10454142	0.731	rs11680719	MIMAT0031175	hsa-miR-548ba	-5.87	8.35e-09	-0.35	-0.27	Sex hormone-binding globulin levels;	chr2:48430704	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.966	rs11208932	MIMAT0014979	hsa-miR-3117-3p	-5.87	8.4e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66632170	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs4475861	MIMAT0005878	hsa-miR-1287-5p	5.87	8.58e-09	0.31	0.27	Metabolite levels;	chr10:98405232	chr10:98395271~98395292:-
PRAD	cis	rs34020101	1	rs34020101	MIMAT0019927	hsa-miR-4772-3p	-5.86	8.73e-09	-0.28	-0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil counts;Sum eosinophil basophil counts;	chr2:102435015	chr2:102432336~102432357:+
PRAD	cis	rs77637988	0.604	rs7566239	MIMAT0031175	hsa-miR-548ba	-5.86	8.82e-09	-0.33	-0.27	Joint mobility (Beighton score);	chr2:48371743	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.553	rs10169629	MIMAT0031175	hsa-miR-548ba	-5.86	8.95e-09	-0.34	-0.27	Joint mobility (Beighton score);	chr2:48397905	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.934	rs10889635	MIMAT0014979	hsa-miR-3117-3p	-5.86	9.15e-09	-0.29	-0.27	Presence of antiphospholipid antibodies;	chr1:66609892	chr1:66628485~66628505:+
PRAD	cis	rs1163656	0.502	rs7310000	MIMAT0003287	hsa-miR-618	-5.85	9.3e-09	-0.39	-0.27	Dental caries;	chr12:80933498	chr12:80935796~80935818:-
PRAD	cis	rs1712517	0.904	rs6584547	MIMAT0022727	hsa-miR-1307-5p	-5.85	9.34e-09	-0.21	-0.27	Migraine;	chr10:103305652	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.873	rs1163086	MIMAT0022727	hsa-miR-1307-5p	-5.85	9.54e-09	-0.21	-0.26	Migraine;	chr10:103279822	chr10:103394341~103394361:-
PRAD	cis	rs77637988	0.603	rs72820445	MIMAT0031175	hsa-miR-548ba	-5.85	9.68e-09	-0.33	-0.26	Joint mobility (Beighton score);	chr2:48380717	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.625	rs12127199	MIMAT0014979	hsa-miR-3117-3p	-5.84	9.74e-09	-0.3	-0.26	Presence of antiphospholipid antibodies;	chr1:66638059	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.873	rs7913461	MIMAT0022727	hsa-miR-1307-5p	-5.84	9.77e-09	-0.21	-0.26	Migraine;	chr10:103241568	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs7532173	MIMAT0014979	hsa-miR-3117-3p	-5.84	9.86e-09	-0.28	-0.26	Presence of antiphospholipid antibodies;	chr1:66620428	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.604	rs7546825	MIMAT0014979	hsa-miR-3117-3p	-5.84	9.91e-09	-0.3	-0.26	Presence of antiphospholipid antibodies;	chr1:66636119	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs1325261	MIMAT0014979	hsa-miR-3117-3p	-5.84	9.99e-09	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66644833	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs2044399	MIMAT0014979	hsa-miR-3117-3p	-5.84	1e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66588397	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs2044400	MIMAT0014979	hsa-miR-3117-3p	-5.84	1e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66588398	chr1:66628485~66628505:+
PRAD	cis	rs2284932	0.533	rs918282	MIMAT0016895	hsa-miR-2355-5p	5.84	1e-08	0.3	0.26	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207127274	chr2:207110043~207110063:-
PRAD	cis	rs2284932	0.533	rs16839275	MIMAT0016895	hsa-miR-2355-5p	5.84	1e-08	0.3	0.26	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207127431	chr2:207110043~207110063:-
PRAD	cis	rs6681460	1	rs1562217	MIMAT0014979	hsa-miR-3117-3p	5.81	1.16e-08	0.28	0.26	Presence of antiphospholipid antibodies;	chr1:66607883	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.901	rs1373911	MIMAT0014979	hsa-miR-3117-3p	-5.81	1.16e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66575382	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.835	rs2506961	MIMAT0022727	hsa-miR-1307-5p	5.81	1.17e-08	0.2	0.26	Migraine;	chr10:103248169	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.873	rs1712510	MIMAT0022727	hsa-miR-1307-5p	5.81	1.17e-08	0.2	0.26	Migraine;	chr10:103249329	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.771	rs10883857	MIMAT0022727	hsa-miR-1307-5p	5.81	1.21e-08	0.21	0.26	Migraine;	chr10:103367830	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.873	rs7894240	MIMAT0022727	hsa-miR-1307-5p	5.81	1.21e-08	0.2	0.26	Migraine;	chr10:103240612	chr10:103394341~103394361:-
PRAD	cis	rs7894407	0.76	rs1163072	MIMAT0005951	hsa-miR-1307-3p	5.8	1.23e-08	0.19	0.26	White matter hyperintensity burden;	chr10:103264621	chr10:103394301~103394322:-
PRAD	cis	rs2284932	0.556	rs2014766	MIMAT0016895	hsa-miR-2355-5p	5.8	1.23e-08	0.3	0.26	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207126660	chr2:207110043~207110063:-
PRAD	cis	rs1163656	0.502	rs10862209	MIMAT0003287	hsa-miR-618	-5.8	1.24e-08	-0.39	-0.26	Dental caries;	chr12:80933176	chr12:80935796~80935818:-
PRAD	cis	rs1163656	0.502	rs11114658	MIMAT0003287	hsa-miR-618	-5.8	1.24e-08	-0.39	-0.26	Dental caries;	chr12:80933378	chr12:80935796~80935818:-
PRAD	cis	rs77637988	0.578	rs7576964	MIMAT0031175	hsa-miR-548ba	-5.8	1.25e-08	-0.33	-0.26	Joint mobility (Beighton score);	chr2:48374309	chr2:49059603~49059624:+
PRAD	cis	rs2284932	0.591	rs2269078	MIMAT0016895	hsa-miR-2355-5p	5.8	1.27e-08	0.3	0.26	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207121339	chr2:207110043~207110063:-
PRAD	cis	rs1163656	0.502	rs17007704	MIMAT0003287	hsa-miR-618	-5.79	1.3e-08	-0.4	-0.26	Dental caries;	chr12:80932218	chr12:80935796~80935818:-
PRAD	cis	rs6681460	0.966	rs10749763	MIMAT0014979	hsa-miR-3117-3p	-5.78	1.37e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66596443	chr1:66628485~66628505:+
PRAD	cis	rs1163656	0.502	rs17007711	MIMAT0003287	hsa-miR-618	5.78	1.38e-08	0.39	0.26	Dental caries;	chr12:80934305	chr12:80935796~80935818:-
PRAD	cis	rs1712517	0.873	rs1163083	MIMAT0022727	hsa-miR-1307-5p	-5.77	1.49e-08	-0.2	-0.26	Migraine;	chr10:103278698	chr10:103394341~103394361:-
PRAD	cis	rs6681460	1	rs4655648	MIMAT0014979	hsa-miR-3117-3p	-5.76	1.52e-08	-0.28	-0.26	Presence of antiphospholipid antibodies;	chr1:66648626	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs10749765	MIMAT0014979	hsa-miR-3117-3p	-5.76	1.59e-08	-0.28	-0.26	Presence of antiphospholipid antibodies;	chr1:66684597	chr1:66628485~66628505:+
PRAD	cis	rs8064299	1	rs8064299	MIMAT0017994	hsa-miR-3615	-5.76	1.59e-08	-0.3	-0.26	Monocyte count;	chr17:74766507	chr17:74748663~74748683:+
PRAD	cis	rs6681460	1	rs1445575	MIMAT0014979	hsa-miR-3117-3p	-5.75	1.61e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66586481	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.934	rs4655628	MIMAT0014979	hsa-miR-3117-3p	-5.75	1.61e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66586926	chr1:66628485~66628505:+
PRAD	cis	rs6681460	1	rs964574	MIMAT0014979	hsa-miR-3117-3p	-5.75	1.65e-08	-0.28	-0.26	Presence of antiphospholipid antibodies;	chr1:66597202	chr1:66628485~66628505:+
PRAD	cis	rs77637988	0.516	rs55744465	MIMAT0031175	hsa-miR-548ba	-5.74	1.74e-08	-0.34	-0.26	Joint mobility (Beighton score);	chr2:48405316	chr2:49059603~49059624:+
PRAD	cis	rs6681460	1	rs9662943	MIMAT0014979	hsa-miR-3117-3p	5.73	1.87e-08	0.29	0.26	Presence of antiphospholipid antibodies;	chr1:66655449	chr1:66628485~66628505:+
PRAD	cis	rs1867631	0.565	rs10749764	MIMAT0014979	hsa-miR-3117-3p	-5.72	1.92e-08	-0.29	-0.26	Menopause (age at onset);	chr1:66684023	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.873	rs1891292	MIMAT0022727	hsa-miR-1307-5p	5.71	1.99e-08	0.2	0.26	Migraine;	chr10:103241753	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.625	rs6680364	MIMAT0014979	hsa-miR-3117-3p	-5.71	2.03e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66639151	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.934	rs4655631	MIMAT0014979	hsa-miR-3117-3p	-5.71	2.05e-08	-0.28	-0.26	Presence of antiphospholipid antibodies;	chr1:66589224	chr1:66628485~66628505:+
PRAD	cis	rs34198350	0.59	rs7571905	MIMAT0031175	hsa-miR-548ba	-5.71	2.06e-08	-0.49	-0.26	QT interval in Tripanosoma cruzi seropositivity;	chr2:48232734	chr2:49059603~49059624:+
PRAD	cis	rs1712517	1	rs3123794	MIMAT0022727	hsa-miR-1307-5p	-5.71	2.09e-08	-0.2	-0.26	Migraine;	chr10:103273985	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.966	rs7542924	MIMAT0014979	hsa-miR-3117-3p	-5.71	2.1e-08	-0.27	-0.26	Presence of antiphospholipid antibodies;	chr1:66677372	chr1:66628485~66628505:+
PRAD	cis	rs34198350	0.636	rs11680162	MIMAT0031175	hsa-miR-548ba	5.7	2.13e-08	0.48	0.26	QT interval in Tripanosoma cruzi seropositivity;	chr2:48229835	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.584	rs7528182	MIMAT0014979	hsa-miR-3117-3p	-5.7	2.21e-08	-0.29	-0.26	Presence of antiphospholipid antibodies;	chr1:66601686	chr1:66628485~66628505:+
PRAD	cis	rs10454142	0.845	rs56391806	MIMAT0031175	hsa-miR-548ba	-5.69	2.22e-08	-0.34	-0.26	Sex hormone-binding globulin levels;	chr2:48404838	chr2:49059603~49059624:+
PRAD	cis	rs10454142	0.961	rs10454143	MIMAT0031175	hsa-miR-548ba	-5.68	2.37e-08	-0.35	-0.26	Sex hormone-binding globulin levels;	chr2:48419261	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.838	rs6584543	MIMAT0022727	hsa-miR-1307-5p	5.67	2.5e-08	0.2	0.26	Migraine;	chr10:103237257	chr10:103394341~103394361:-
PRAD	cis	rs10454142	1	rs10454142	MIMAT0031175	hsa-miR-548ba	-5.67	2.54e-08	-0.35	-0.26	Sex hormone-binding globulin levels;	chr2:48419260	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.836	rs7093039	MIMAT0022727	hsa-miR-1307-5p	-5.66	2.64e-08	-0.2	-0.26	Migraine;	chr10:103389790	chr10:103394341~103394361:-
PRAD	cis	rs1712517	0.904	rs7905968	MIMAT0022727	hsa-miR-1307-5p	-5.65	2.78e-08	-0.2	-0.26	Migraine;	chr10:103375562	chr10:103394341~103394361:-
PRAD	cis	rs34198350	0.574	rs6747738	MIMAT0031175	hsa-miR-548ba	-5.64	2.96e-08	-0.49	-0.26	QT interval in Tripanosoma cruzi seropositivity;	chr2:48244230	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.577	rs6705802	MIMAT0031175	hsa-miR-548ba	-5.64	3.07e-08	-0.32	-0.26	Joint mobility (Beighton score);	chr2:48376344	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.578	rs7577237	MIMAT0031175	hsa-miR-548ba	5.63	3.13e-08	0.32	0.26	Joint mobility (Beighton score);	chr2:48374677	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.934	rs4655635	MIMAT0014979	hsa-miR-3117-3p	-5.63	3.23e-08	-0.27	-0.26	Presence of antiphospholipid antibodies;	chr1:66602557	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.621	rs3750604	MIMAT0005878	hsa-miR-1287-5p	5.61	3.61e-08	0.31	0.25	Metabolite levels;	chr10:98415824	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.625	rs2872079	MIMAT0014979	hsa-miR-3117-3p	-5.59	3.92e-08	-0.28	-0.25	Presence of antiphospholipid antibodies;	chr1:66664388	chr1:66628485~66628505:+
PRAD	cis	rs1712517	1	rs1712517	MIMAT0022727	hsa-miR-1307-5p	-5.58	4.23e-08	-0.2	-0.25	Migraine;	chr10:103273258	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.763	rs12763326	MIMAT0005878	hsa-miR-1287-5p	-5.57	4.35e-08	-0.28	-0.25	Metabolite levels;	chr10:98407639	chr10:98395271~98395292:-
PRAD	cis	rs1018697	1	rs7909612	MIMAT0005951	hsa-miR-1307-3p	5.57	4.38e-08	0.18	0.25	Colorectal adenoma (advanced);	chr10:102801699	chr10:103394301~103394322:-
PRAD	cis	rs6681460	1	rs6656912	MIMAT0014979	hsa-miR-3117-3p	-5.57	4.47e-08	-0.29	-0.25	Presence of antiphospholipid antibodies;	chr1:66617988	chr1:66628485~66628505:+
PRAD	cis	rs7894407	0.856	rs10883855	MIMAT0022727	hsa-miR-1307-5p	-5.56	4.51e-08	-0.21	-0.25	White matter hyperintensity burden;	chr10:103332690	chr10:103394341~103394361:-
PRAD	cis	rs10454142	0.807	rs13399936	MIMAT0031175	hsa-miR-548ba	-5.56	4.52e-08	-0.34	-0.25	Sex hormone-binding globulin levels;	chr2:48426987	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.966	rs10889644	MIMAT0014979	hsa-miR-3117-3p	-5.56	4.53e-08	-0.27	-0.25	Presence of antiphospholipid antibodies;	chr1:66679639	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.966	rs10789215	MIMAT0014979	hsa-miR-3117-3p	5.56	4.57e-08	0.27	0.25	Presence of antiphospholipid antibodies;	chr1:66685502	chr1:66628485~66628505:+
PRAD	cis	rs8064299	0.934	rs895692	MIMAT0017994	hsa-miR-3615	-5.55	4.98e-08	-0.3	-0.25	Monocyte count;	chr17:74770113	chr17:74748663~74748683:+
PRAD	cis	rs6681460	0.625	rs4488004	MIMAT0014979	hsa-miR-3117-3p	-5.54	5.04e-08	-0.28	-0.25	Presence of antiphospholipid antibodies;	chr1:66607631	chr1:66628485~66628505:+
PRAD	cis	rs1018697	0.966	rs1475643	MIMAT0005951	hsa-miR-1307-3p	5.54	5.13e-08	0.18	0.25	Colorectal adenoma (advanced);	chr10:102786710	chr10:103394301~103394322:-
PRAD	cis	rs7894407	0.856	rs7093667	MIMAT0022727	hsa-miR-1307-5p	-5.53	5.48e-08	-0.21	-0.25	White matter hyperintensity burden;	chr10:103320818	chr10:103394341~103394361:-
PRAD	cis	rs4851551	0.543	rs35918372	MIMAT0019927	hsa-miR-4772-3p	-5.53	5.54e-08	-0.5	-0.25	Blood protein levels;	chr2:102202803	chr2:102432336~102432357:+
PRAD	cis	rs7894407	0.76	rs4917386	MIMAT0005951	hsa-miR-1307-3p	5.52	5.6e-08	0.19	0.25	White matter hyperintensity burden;	chr10:103247771	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.636	rs11889493	MIMAT0031175	hsa-miR-548ba	-5.52	5.72e-08	-0.47	-0.25	QT interval in Tripanosoma cruzi seropositivity;	chr2:48141526	chr2:49059603~49059624:+
PRAD	cis	rs1712517	1	rs1163084	MIMAT0022727	hsa-miR-1307-5p	-5.52	5.77e-08	-0.19	-0.25	Migraine;	chr10:103279291	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.621	rs11189595	MIMAT0005878	hsa-miR-1287-5p	5.51	6.04e-08	0.3	0.25	Metabolite levels;	chr10:98407565	chr10:98395271~98395292:-
PRAD	cis	rs6681460	0.932	rs602513	MIMAT0014979	hsa-miR-3117-3p	-5.51	6.07e-08	-0.26	-0.25	Presence of antiphospholipid antibodies;	chr1:66711587	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs523188	MIMAT0014979	hsa-miR-3117-3p	-5.51	6.12e-08	-0.26	-0.25	Presence of antiphospholipid antibodies;	chr1:66708739	chr1:66628485~66628505:+
PRAD	cis	rs77637988	0.578	rs11689645	MIMAT0031175	hsa-miR-548ba	-5.5	6.42e-08	-0.33	-0.25	Joint mobility (Beighton score);	chr2:48381420	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.76	rs1163072	MIMAT0022727	hsa-miR-1307-5p	5.49	6.63e-08	0.2	0.25	White matter hyperintensity burden;	chr10:103264621	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.966	rs2025595	MIMAT0014979	hsa-miR-3117-3p	-5.49	6.76e-08	-0.27	-0.25	Presence of antiphospholipid antibodies;	chr1:66686816	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.834	rs2916	MIMAT0014979	hsa-miR-3117-3p	5.48	7.04e-08	0.27	0.25	Presence of antiphospholipid antibodies;	chr1:66751014	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.834	rs1280310	MIMAT0014979	hsa-miR-3117-3p	5.48	7.04e-08	0.27	0.25	Presence of antiphospholipid antibodies;	chr1:66751140	chr1:66628485~66628505:+
PRAD	cis	rs10454142	0.7	rs4293602	MIMAT0031175	hsa-miR-548ba	-5.48	7.26e-08	-0.33	-0.25	Sex hormone-binding globulin levels;	chr2:48505805	chr2:49059603~49059624:+
PRAD	cis	rs10454142	0.771	rs7569575	MIMAT0031175	hsa-miR-548ba	-5.47	7.28e-08	-0.32	-0.25	Sex hormone-binding globulin levels;	chr2:48490591	chr2:49059603~49059624:+
PRAD	cis	rs7072216	0.727	rs7915108	MIMAT0005878	hsa-miR-1287-5p	5.47	7.59e-08	0.28	0.25	Metabolite levels;	chr10:98404684	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.727	rs7901577	MIMAT0005878	hsa-miR-1287-5p	5.47	7.59e-08	0.28	0.25	Metabolite levels;	chr10:98404685	chr10:98395271~98395292:-
PRAD	cis	rs1018697	0.966	rs10748831	MIMAT0005951	hsa-miR-1307-3p	5.46	7.66e-08	0.18	0.25	Colorectal adenoma (advanced);	chr10:102798986	chr10:103394301~103394322:-
PRAD	cis	rs1163656	0.559	rs12228291	MIMAT0003287	hsa-miR-618	-5.46	7.7e-08	-0.44	-0.25	Dental caries;	chr12:80918034	chr12:80935796~80935818:-
PRAD	cis	rs6681460	0.604	rs11208920	MIMAT0014979	hsa-miR-3117-3p	-5.46	7.89e-08	-0.28	-0.25	Presence of antiphospholipid antibodies;	chr1:66609629	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.899	rs502690	MIMAT0014979	hsa-miR-3117-3p	-5.46	8e-08	-0.26	-0.25	Presence of antiphospholipid antibodies;	chr1:66716720	chr1:66628485~66628505:+
PRAD	cis	rs1712517	0.904	rs4918007	MIMAT0022727	hsa-miR-1307-5p	5.45	8.12e-08	0.19	0.25	Migraine;	chr10:103347713	chr10:103394341~103394361:-
PRAD	cis	rs34198350	0.636	rs4530419	MIMAT0031175	hsa-miR-548ba	-5.45	8.44e-08	-0.47	-0.25	QT interval in Tripanosoma cruzi seropositivity;	chr2:48144061	chr2:49059603~49059624:+
PRAD	cis	rs1712517	0.838	rs1891293	MIMAT0022727	hsa-miR-1307-5p	5.44	8.51e-08	0.19	0.25	Migraine;	chr10:103242040	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.834	rs544258	MIMAT0014979	hsa-miR-3117-3p	5.44	8.63e-08	0.27	0.25	Presence of antiphospholipid antibodies;	chr1:66753526	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.625	rs6679568	MIMAT0014979	hsa-miR-3117-3p	-5.44	8.7e-08	-0.28	-0.25	Presence of antiphospholipid antibodies;	chr1:66608494	chr1:66628485~66628505:+
PRAD	cis	rs1018697	0.966	rs6584526	MIMAT0005951	hsa-miR-1307-3p	5.44	8.82e-08	0.18	0.25	Colorectal adenoma (advanced);	chr10:102806484	chr10:103394301~103394322:-
PRAD	cis	rs1163656	0.559	rs7136415	MIMAT0003287	hsa-miR-618	-5.44	8.85e-08	-0.44	-0.25	Dental caries;	chr12:80915511	chr12:80935796~80935818:-
PRAD	cis	rs77637988	0.578	rs6718068	MIMAT0031175	hsa-miR-548ba	-5.44	8.87e-08	-0.31	-0.25	Joint mobility (Beighton score);	chr2:48377839	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.604	rs6722246	MIMAT0031175	hsa-miR-548ba	-5.44	8.95e-08	-0.32	-0.25	Joint mobility (Beighton score);	chr2:48369906	chr2:49059603~49059624:+
PRAD	cis	rs77637988	0.604	rs78597273	MIMAT0031175	hsa-miR-548ba	-5.43	9.13e-08	-0.32	-0.25	Joint mobility (Beighton score);	chr2:48380665	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.671	rs628655	MIMAT0014979	hsa-miR-3117-3p	5.42	9.62e-08	0.27	0.25	Presence of antiphospholipid antibodies;	chr1:66747890	chr1:66628485~66628505:+
PRAD	cis	rs9663711	1	rs9663711	MIMAT0005951	hsa-miR-1307-3p	5.42	9.71e-08	0.18	0.25	Carotid plaque burden;	chr10:102787871	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.625	rs2312154	MIMAT0014979	hsa-miR-3117-3p	5.42	9.77e-08	0.28	0.25	Presence of antiphospholipid antibodies;	chr1:66607293	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs659291	MIMAT0014979	hsa-miR-3117-3p	-5.42	9.83e-08	-0.26	-0.25	Presence of antiphospholipid antibodies;	chr1:66715063	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.763	rs7914401	MIMAT0005878	hsa-miR-1287-5p	5.4	1.05e-07	0.28	0.25	Metabolite levels;	chr10:98404171	chr10:98395271~98395292:-
PRAD	cis	rs1018697	1	rs7092346	MIMAT0005951	hsa-miR-1307-3p	5.4	1.06e-07	0.18	0.25	Colorectal adenoma (advanced);	chr10:102800007	chr10:103394301~103394322:-
PRAD	cis	rs4851551	0.543	rs1997503	MIMAT0019927	hsa-miR-4772-3p	-5.4	1.07e-07	-0.44	-0.25	Blood protein levels;	chr2:102192775	chr2:102432336~102432357:+
PRAD	cis	rs74233809	0.748	rs10786736	MIMAT0005951	hsa-miR-1307-3p	-5.4	1.1e-07	-0.3	-0.25	Birth weight;	chr10:103089359	chr10:103394301~103394322:-
PRAD	cis	rs7894407	0.594	rs1163238	MIMAT0005951	hsa-miR-1307-3p	5.4	1.1e-07	0.19	0.25	White matter hyperintensity burden;	chr10:103184236	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.636	rs11679956	MIMAT0031175	hsa-miR-548ba	-5.39	1.13e-07	-0.46	-0.25	QT interval in Tripanosoma cruzi seropositivity;	chr2:48190143	chr2:49059603~49059624:+
PRAD	cis	rs4851551	0.619	rs34722443	MIMAT0019927	hsa-miR-4772-3p	-5.38	1.19e-07	-0.51	-0.25	Blood protein levels;	chr2:102223859	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.555	rs2296433	MIMAT0005878	hsa-miR-1287-5p	5.38	1.22e-07	0.29	0.24	Metabolite levels;	chr10:98424305	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.555	rs2296432	MIMAT0005878	hsa-miR-1287-5p	5.38	1.22e-07	0.29	0.24	Metabolite levels;	chr10:98424306	chr10:98395271~98395292:-
PRAD	cis	rs4851551	0.543	rs62156407	MIMAT0019927	hsa-miR-4772-3p	-5.36	1.32e-07	-0.51	-0.24	Blood protein levels;	chr2:102208162	chr2:102432336~102432357:+
PRAD	cis	rs6681460	0.966	rs4655506	MIMAT0014979	hsa-miR-3117-3p	-5.36	1.36e-07	-0.26	-0.24	Presence of antiphospholipid antibodies;	chr1:66685128	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs523132	MIMAT0014979	hsa-miR-3117-3p	5.35	1.36e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66708757	chr1:66628485~66628505:+
PRAD	cis	rs1018697	1	rs7086400	MIMAT0005951	hsa-miR-1307-3p	5.35	1.38e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102802340	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs7073114	MIMAT0005951	hsa-miR-1307-3p	5.35	1.42e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102795894	chr10:103394301~103394322:-
PRAD	cis	rs77637988	0.604	rs17855177	MIMAT0031175	hsa-miR-548ba	-5.34	1.46e-07	-0.32	-0.24	Joint mobility (Beighton score);	chr2:48375113	chr2:49059603~49059624:+
PRAD	cis	rs4851551	0.543	rs11887842	MIMAT0019927	hsa-miR-4772-3p	-5.33	1.52e-07	-0.46	-0.24	Blood protein levels;	chr2:102223018	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs6584525	MIMAT0005951	hsa-miR-1307-3p	5.33	1.53e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102792224	chr10:103394301~103394322:-
PRAD	cis	rs1163656	0.559	rs17007699	MIMAT0003287	hsa-miR-618	-5.33	1.55e-07	-0.43	-0.24	Dental caries;	chr12:80930007	chr12:80935796~80935818:-
PRAD	cis	rs1163656	0.559	rs17007693	MIMAT0003287	hsa-miR-618	-5.33	1.59e-07	-0.43	-0.24	Dental caries;	chr12:80925305	chr12:80935796~80935818:-
PRAD	cis	rs34198350	0.574	rs11695923	MIMAT0031175	hsa-miR-548ba	-5.32	1.66e-07	-0.47	-0.24	QT interval in Tripanosoma cruzi seropositivity;	chr2:48260068	chr2:49059603~49059624:+
PRAD	cis	rs1018697	0.761	rs7904281	MIMAT0005951	hsa-miR-1307-3p	5.31	1.68e-07	0.18	0.24	Colorectal adenoma (advanced);	chr10:102785079	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs2150928	MIMAT0005951	hsa-miR-1307-3p	5.31	1.69e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102791228	chr10:103394301~103394322:-
PRAD	cis	rs4851551	0.867	rs2228139	MIMAT0019927	hsa-miR-4772-3p	-5.3	1.78e-07	-0.5	-0.24	Blood protein levels;	chr2:102165189	chr2:102432336~102432357:+
PRAD	cis	rs1018697	0.966	rs11191396	MIMAT0005951	hsa-miR-1307-3p	5.3	1.83e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102793108	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs4919678	MIMAT0005951	hsa-miR-1307-3p	5.3	1.83e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102794606	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs11191397	MIMAT0005951	hsa-miR-1307-3p	5.3	1.83e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102798517	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs7092051	MIMAT0005951	hsa-miR-1307-3p	5.3	1.83e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102799720	chr10:103394301~103394322:-
PRAD	cis	rs1018697	0.966	rs1953930	MIMAT0005951	hsa-miR-1307-3p	5.3	1.84e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102789704	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.932	rs603750	MIMAT0014979	hsa-miR-3117-3p	-5.29	1.89e-07	-0.25	-0.24	Presence of antiphospholipid antibodies;	chr1:66711805	chr1:66628485~66628505:+
PRAD	cis	rs34198350	0.636	rs55802119	MIMAT0031175	hsa-miR-548ba	-5.29	1.91e-07	-0.45	-0.24	QT interval in Tripanosoma cruzi seropositivity;	chr2:48222213	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.898	rs1032634	MIMAT0014979	hsa-miR-3117-3p	5.29	1.91e-07	0.26	0.24	Presence of antiphospholipid antibodies;	chr1:66729509	chr1:66628485~66628505:+
PRAD	cis	rs1018697	0.897	rs2150929	MIMAT0005951	hsa-miR-1307-3p	5.29	1.94e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102791180	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.932	rs536410	MIMAT0014979	hsa-miR-3117-3p	-5.28	1.98e-07	-0.25	-0.24	Presence of antiphospholipid antibodies;	chr1:66725401	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.899	rs1280280	MIMAT0014979	hsa-miR-3117-3p	-5.28	1.99e-07	-0.25	-0.24	Presence of antiphospholipid antibodies;	chr1:66708220	chr1:66628485~66628505:+
PRAD	cis	rs1163656	0.534	rs11114656	MIMAT0003287	hsa-miR-618	-5.28	2.01e-07	-0.33	-0.24	Dental caries;	chr12:80925906	chr12:80935796~80935818:-
PRAD	cis	rs6681460	0.932	rs665319	MIMAT0014979	hsa-miR-3117-3p	-5.28	2.01e-07	-0.25	-0.24	Presence of antiphospholipid antibodies;	chr1:66709805	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs492109	MIMAT0014979	hsa-miR-3117-3p	5.28	2.02e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66721450	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs618093	MIMAT0014979	hsa-miR-3117-3p	-5.28	2.02e-07	-0.25	-0.24	Presence of antiphospholipid antibodies;	chr1:66712745	chr1:66628485~66628505:+
PRAD	cis	rs1018697	1	rs1018696	MIMAT0005951	hsa-miR-1307-3p	5.28	2.03e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102789309	chr10:103394301~103394322:-
PRAD	cis	rs17639215	0.55	rs4851003	MIMAT0019927	hsa-miR-4772-3p	-5.28	2.04e-07	-0.29	-0.24	Serum protein levels (sST2);	chr2:102292817	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs11191499	MIMAT0005951	hsa-miR-1307-3p	-5.27	2.08e-07	-0.34	-0.24	Birth weight;	chr10:103004514	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs7911528	MIMAT0005951	hsa-miR-1307-3p	5.26	2.19e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102791810	chr10:103394301~103394322:-
PRAD	cis	rs7894407	0.76	rs1163085	MIMAT0022727	hsa-miR-1307-5p	-5.26	2.19e-07	-0.19	-0.24	White matter hyperintensity burden;	chr10:103279484	chr10:103394341~103394361:-
PRAD	cis	rs6681460	0.899	rs499263	MIMAT0014979	hsa-miR-3117-3p	-5.26	2.2e-07	-0.26	-0.24	Presence of antiphospholipid antibodies;	chr1:66714254	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.898	rs1032635	MIMAT0014979	hsa-miR-3117-3p	5.26	2.22e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66729501	chr1:66628485~66628505:+
PRAD	cis	rs9807989	0.507	rs2041739	MIMAT0019927	hsa-miR-4772-3p	5.26	2.24e-07	0.25	0.24	Asthma;	chr2:102377873	chr2:102432336~102432357:+
PRAD	cis	rs6681460	0.898	rs2483704	MIMAT0014979	hsa-miR-3117-3p	5.26	2.26e-07	0.26	0.24	Presence of antiphospholipid antibodies;	chr1:66729670	chr1:66628485~66628505:+
PRAD	cis	rs1018697	1	rs7088711	MIMAT0005951	hsa-miR-1307-3p	-5.26	2.26e-07	-0.17	-0.24	Colorectal adenoma (advanced);	chr10:102799509	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.8	rs539014	MIMAT0014979	hsa-miR-3117-3p	5.26	2.28e-07	0.26	0.24	Presence of antiphospholipid antibodies;	chr1:66746204	chr1:66628485~66628505:+
PRAD	cis	rs9807989	0.507	rs1420105	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.35e-07	-0.25	-0.24	Asthma;	chr2:102418659	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1420096	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.35e-07	-0.25	-0.24	Asthma;	chr2:102394452	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs10203558	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.36e-07	-0.25	-0.24	Asthma;	chr2:102411180	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs10200952	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.36e-07	-0.25	-0.24	Asthma;	chr2:102411191	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs6732138	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.37e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102393202	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs4919677	MIMAT0005951	hsa-miR-1307-3p	5.25	2.38e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102794547	chr10:103394301~103394322:-
PRAD	cis	rs9807989	0.507	rs1833174	MIMAT0019927	hsa-miR-4772-3p	-5.25	2.4e-07	-0.25	-0.24	Asthma;	chr2:102418383	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs10439410	MIMAT0019927	hsa-miR-4772-3p	5.24	2.41e-07	0.25	0.24	Asthma;	chr2:102374328	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.548	rs6543127	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102411841	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1592459	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma;	chr2:102415109	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1592458	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma;	chr2:102415289	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2160201	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma;	chr2:102417501	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2293224	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma;	chr2:102419319	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6743516	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma;	chr2:102419875	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs1420100	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102420542	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.527	rs3771155	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.41e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102421366	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs1035125	MIMAT0019927	hsa-miR-4772-3p	-5.24	2.42e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102417379	chr2:102432336~102432357:+
PRAD	cis	rs6681460	0.932	rs2483705	MIMAT0014979	hsa-miR-3117-3p	5.24	2.46e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66725497	chr1:66628485~66628505:+
PRAD	cis	rs9807989	0.524	rs4851576	MIMAT0019927	hsa-miR-4772-3p	-5.23	2.54e-07	-0.25	-0.24	Asthma;	chr2:102412435	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs4851577	MIMAT0019927	hsa-miR-4772-3p	-5.23	2.54e-07	-0.25	-0.24	Asthma;	chr2:102412461	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs4851579	MIMAT0019927	hsa-miR-4772-3p	-5.23	2.54e-07	-0.25	-0.24	Asthma;	chr2:102412524	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.524	rs6543126	MIMAT0019927	hsa-miR-4772-3p	-5.23	2.56e-07	-0.25	-0.24	Asthma;	chr2:102410644	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs10748830	MIMAT0005951	hsa-miR-1307-3p	5.23	2.58e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102788625	chr10:103394301~103394322:-
PRAD	cis	rs4988958	0.565	rs885088	MIMAT0019927	hsa-miR-4772-3p	-5.23	2.62e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102422584	chr2:102432336~102432357:+
PRAD	cis	rs1163656	0.527	rs1402347	MIMAT0003287	hsa-miR-618	5.23	2.64e-07	0.41	0.24	Dental caries;	chr12:80913217	chr12:80935796~80935818:-
PRAD	cis	rs4988958	0.565	rs3755265	MIMAT0019927	hsa-miR-4772-3p	-5.22	2.75e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102436356	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs10206291	MIMAT0019927	hsa-miR-4772-3p	-5.21	2.87e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102422403	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs3771154	MIMAT0019927	hsa-miR-4772-3p	-5.21	2.87e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102422900	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2287033	MIMAT0019927	hsa-miR-4772-3p	5.21	2.88e-07	0.25	0.24	Asthma;	chr2:102394777	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs10786710	MIMAT0005951	hsa-miR-1307-3p	5.21	2.89e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102788982	chr10:103394301~103394322:-
PRAD	cis	rs9807989	0.524	rs6759479	MIMAT0019927	hsa-miR-4772-3p	-5.21	2.89e-07	-0.25	-0.24	Asthma;	chr2:102423587	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6543133	MIMAT0019927	hsa-miR-4772-3p	-5.21	2.89e-07	-0.25	-0.24	Asthma;	chr2:102423717	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs7896903	MIMAT0005951	hsa-miR-1307-3p	5.2	3.05e-07	0.17	0.24	Colorectal adenoma (advanced);	chr10:102806660	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.8	rs485543	MIMAT0014979	hsa-miR-3117-3p	5.19	3.12e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66728689	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.8	rs481681	MIMAT0014979	hsa-miR-3117-3p	5.19	3.2e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66728695	chr1:66628485~66628505:+
PRAD	cis	rs9807989	0.507	rs3732124	MIMAT0019927	hsa-miR-4772-3p	5.19	3.25e-07	0.25	0.24	Asthma;	chr2:102401592	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.525	rs3771159	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102388498	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.501	rs11903946	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102388870	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6706002	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102389644	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6749014	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102389988	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs12712146	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102392254	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1420094	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102399227	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs4851571	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102402540	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs4851572	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102402571	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1035129	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102403325	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.524	rs2110662	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102403679	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.524	rs7594402	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102404807	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6710034	MIMAT0019927	hsa-miR-4772-3p	-5.19	3.25e-07	-0.25	-0.24	Asthma;	chr2:102407218	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.574	rs11680657	MIMAT0031175	hsa-miR-548ba	-5.18	3.28e-07	-0.44	-0.24	QT interval in Tripanosoma cruzi seropositivity;	chr2:48247912	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.507	rs6745614	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.32e-07	-0.25	-0.24	Asthma;	chr2:102374753	chr2:102432336~102432357:+
PRAD	cis	rs10454142	0.771	rs4296472	MIMAT0031175	hsa-miR-548ba	5.18	3.33e-07	0.31	0.24	Sex hormone-binding globulin levels;	chr2:48519940	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.507	rs10208196	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma;	chr2:102379885	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs7584093	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma;	chr2:102381261	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs3213732	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma;	chr2:102381819	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs10204757	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma;	chr2:102382514	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.524	rs7591246	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma;	chr2:102382943	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.565	rs6760621	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102383492	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.527	rs11465641	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102384408	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.584	rs7589142	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.33e-07	-0.25	-0.24	Asthma (childhood onset);	chr2:102408200	chr2:102432336~102432357:+
PRAD	cis	rs17639215	0.55	rs9679297	MIMAT0019927	hsa-miR-4772-3p	-5.18	3.36e-07	-0.28	-0.24	Serum protein levels (sST2);	chr2:102298109	chr2:102432336~102432357:+
PRAD	cis	rs7894407	0.892	rs10883859	MIMAT0022727	hsa-miR-1307-5p	5.18	3.43e-07	0.2	0.24	White matter hyperintensity burden;	chr10:103368377	chr10:103394341~103394361:-
PRAD	cis	rs9807989	0.507	rs6758936	MIMAT0019927	hsa-miR-4772-3p	5.16	3.63e-07	0.25	0.24	Asthma;	chr2:102374909	chr2:102432336~102432357:+
PRAD	cis	rs1712517	0.904	rs10883863	MIMAT0022727	hsa-miR-1307-5p	5.16	3.63e-07	0.18	0.24	Migraine;	chr10:103402122	chr10:103394341~103394361:-
PRAD	cis	rs9807989	0.507	rs6734762	MIMAT0019927	hsa-miR-4772-3p	-5.16	3.71e-07	-0.24	-0.24	Asthma;	chr2:102446466	chr2:102432336~102432357:+
PRAD	cis	rs6681460	0.933	rs7554101	MIMAT0014979	hsa-miR-3117-3p	5.15	3.94e-07	0.25	0.24	Presence of antiphospholipid antibodies;	chr1:66690789	chr1:66628485~66628505:+
PRAD	cis	rs7851726	0.624	rs10993344	MIMAT0019208	hsa-miR-3074-5p	-5.14	4.04e-07	-0.21	-0.23	Urinary albumin-to-creatinine ratio;	chr9:94785653	chr9:95086063~95086083:-
PRAD	cis	rs6681460	0.932	rs2146904	MIMAT0014979	hsa-miR-3117-3p	5.14	4.09e-07	0.25	0.23	Presence of antiphospholipid antibodies;	chr1:66694653	chr1:66628485~66628505:+
PRAD	cis	rs11678825	0.852	rs11676078	MIMAT0031175	hsa-miR-548ba	-5.14	4.12e-07	-0.44	-0.23	Reticulocyte fraction of red cells;	chr2:48443067	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.507	rs6710528	MIMAT0019927	hsa-miR-4772-3p	5.13	4.24e-07	0.24	0.23	Asthma;	chr2:102399682	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs13021177	MIMAT0019927	hsa-miR-4772-3p	-5.13	4.34e-07	-0.24	-0.23	Asthma;	chr2:102440033	chr2:102432336~102432357:+
PRAD	cis	rs10454142	0.7	rs6545046	MIMAT0031175	hsa-miR-548ba	5.13	4.35e-07	0.32	0.23	Sex hormone-binding globulin levels;	chr2:48523271	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.932	rs523956	MIMAT0014979	hsa-miR-3117-3p	5.12	4.44e-07	0.25	0.23	Presence of antiphospholipid antibodies;	chr1:66722593	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.837	rs6669023	MIMAT0014979	hsa-miR-3117-3p	-5.12	4.5e-07	-0.25	-0.23	Presence of antiphospholipid antibodies;	chr1:66706185	chr1:66628485~66628505:+
PRAD	cis	rs6681460	0.932	rs524114	MIMAT0014979	hsa-miR-3117-3p	5.12	4.58e-07	0.25	0.23	Presence of antiphospholipid antibodies;	chr1:66722652	chr1:66628485~66628505:+
PRAD	cis	rs7072216	0.666	rs17109597	MIMAT0005878	hsa-miR-1287-5p	5.11	4.67e-07	0.29	0.23	Metabolite levels;	chr10:98382397	chr10:98395271~98395292:-
PRAD	cis	rs1018697	0.966	rs10748832	MIMAT0005951	hsa-miR-1307-3p	5.11	4.8e-07	0.17	0.23	Colorectal adenoma (advanced);	chr10:102808723	chr10:103394301~103394322:-
PRAD	cis	rs6681460	0.866	rs485521	MIMAT0014979	hsa-miR-3117-3p	5.1	4.9e-07	0.25	0.23	Presence of antiphospholipid antibodies;	chr1:66743879	chr1:66628485~66628505:+
PRAD	cis	rs34198350	0.504	rs11689736	MIMAT0031175	hsa-miR-548ba	-5.1	4.95e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48175823	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.507	rs11465721	MIMAT0019927	hsa-miR-4772-3p	-5.1	5.12e-07	-0.24	-0.23	Asthma;	chr2:102446780	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs1420097	MIMAT0019927	hsa-miR-4772-3p	5.08	5.55e-07	0.24	0.23	Asthma;	chr2:102392894	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.925	rs77902227	MIMAT0031175	hsa-miR-548ba	-5.08	5.61e-07	-0.52	-0.23	Reticulocyte fraction of red cells;	chr2:48528829	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.76	rs4917386	MIMAT0022727	hsa-miR-1307-5p	5.07	5.79e-07	0.19	0.23	White matter hyperintensity burden;	chr10:103247771	chr10:103394341~103394361:-
PRAD	cis	rs34198350	0.574	rs79575386	MIMAT0031175	hsa-miR-548ba	-5.07	5.81e-07	-0.44	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48173975	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs6759056	MIMAT0031175	hsa-miR-548ba	-5.07	5.88e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48134558	chr2:49059603~49059624:+
PRAD	cis	rs4988958	0.584	rs12712149	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.89e-07	-0.24	-0.23	Asthma (childhood onset);	chr2:102428733	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs3755266	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102426252	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2110659	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102427407	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs7605284	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102427715	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.584	rs7559845	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma (childhood onset);	chr2:102429754	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6755905	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102431747	chr2:102432336~102432357:+
PRAD	cis	rs4988958	0.527	rs6756161	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma (childhood onset);	chr2:102431957	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs6726985	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102432120	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2310300	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102432614	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs7581119	MIMAT0019927	hsa-miR-4772-3p	-5.07	5.92e-07	-0.24	-0.23	Asthma;	chr2:102433405	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs4851004	MIMAT0019927	hsa-miR-4772-3p	5.06	6.16e-07	0.24	0.23	Asthma;	chr2:102393077	chr2:102432336~102432357:+
PRAD	cis	rs4851551	0.867	rs3917299	MIMAT0019927	hsa-miR-4772-3p	-5.05	6.42e-07	-0.46	-0.23	Blood protein levels;	chr2:102169626	chr2:102432336~102432357:+
PRAD	cis	rs4851551	1	rs4851551	MIMAT0019927	hsa-miR-4772-3p	-5.05	6.42e-07	-0.46	-0.23	Blood protein levels;	chr2:102183770	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.507	rs2058659	MIMAT0019927	hsa-miR-4772-3p	5.05	6.48e-07	0.24	0.23	Asthma;	chr2:102438096	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.636	rs7581510	MIMAT0031175	hsa-miR-548ba	-5.05	6.51e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48152439	chr2:49059603~49059624:+
PRAD	cis	rs1163656	0.534	rs17007709	MIMAT0003287	hsa-miR-618	-5.04	6.68e-07	-0.31	-0.23	Dental caries;	chr12:80934267	chr12:80935796~80935818:-
PRAD	cis	rs34198350	0.636	rs13431982	MIMAT0031175	hsa-miR-548ba	5.04	6.71e-07	0.43	0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48205782	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.668	rs10821390	MIMAT0019208	hsa-miR-3074-5p	-5.04	6.71e-07	-0.2	-0.23	Urinary albumin-to-creatinine ratio;	chr9:94743305	chr9:95086063~95086083:-
PRAD	cis	rs10454142	0.633	rs7559431	MIMAT0031175	hsa-miR-548ba	-5.04	6.9e-07	-0.33	-0.23	Sex hormone-binding globulin levels;	chr2:48364468	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11675419	MIMAT0031175	hsa-miR-548ba	-5.03	7.19e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48157474	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs28896017	MIMAT0031175	hsa-miR-548ba	-5.03	7.19e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48158688	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.687	rs7583719	MIMAT0031175	hsa-miR-548ba	-5.02	7.39e-07	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48110831	chr2:49059603~49059624:+
PRAD	cis	rs1018697	1	rs7080587	MIMAT0005951	hsa-miR-1307-3p	5.01	7.73e-07	0.17	0.23	Colorectal adenoma (advanced);	chr10:102785517	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.925	rs80264308	MIMAT0031175	hsa-miR-548ba	-5	8.04e-07	-0.47	-0.23	Reticulocyte fraction of red cells;	chr2:48478753	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.625	rs58032869	MIMAT0031175	hsa-miR-548ba	-5	8.08e-07	-0.43	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48085636	chr2:49059603~49059624:+
PRAD	cis	rs6681460	0.898	rs536527	MIMAT0014979	hsa-miR-3117-3p	-4.99	8.45e-07	-0.24	-0.23	Presence of antiphospholipid antibodies;	chr1:66728110	chr1:66628485~66628505:+
PRAD	cis	rs4851551	0.543	rs11903354	MIMAT0019927	hsa-miR-4772-3p	-4.99	8.67e-07	-0.41	-0.23	Blood protein levels;	chr2:102193968	chr2:102432336~102432357:+
PRAD	cis	rs4851551	0.543	rs17026757	MIMAT0019927	hsa-miR-4772-3p	-4.99	8.67e-07	-0.41	-0.23	Blood protein levels;	chr2:102197452	chr2:102432336~102432357:+
PRAD	cis	rs8064299	0.574	rs1879455	MIMAT0017994	hsa-miR-3615	-4.98	8.86e-07	-0.27	-0.23	Monocyte count;	chr17:74778599	chr17:74748663~74748683:+
PRAD	cis	rs7894407	0.629	rs11598702	MIMAT0005951	hsa-miR-1307-3p	4.97	9.59e-07	0.17	0.23	White matter hyperintensity burden;	chr10:103138228	chr10:103394301~103394322:-
PRAD	cis	rs10454142	0.664	rs72820499	MIMAT0031175	hsa-miR-548ba	-4.96	1e-06	-0.3	-0.23	Sex hormone-binding globulin levels;	chr2:48435941	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs74893022	MIMAT0031175	hsa-miR-548ba	-4.96	1.02e-06	-0.45	-0.23	QT interval in Tripanosoma cruzi seropositivity;	chr2:48151300	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs75970938	MIMAT0005951	hsa-miR-1307-3p	-4.92	1.23e-06	-0.32	-0.23	Birth weight;	chr10:103033891	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs79668541	MIMAT0005951	hsa-miR-1307-3p	-4.92	1.23e-06	-0.32	-0.23	Birth weight;	chr10:103034147	chr10:103394301~103394322:-
PRAD	cis	rs1558648	0.858	rs13014004	MIMAT0019927	hsa-miR-4772-3p	-4.91	1.25e-06	-0.35	-0.22	Serum protein levels (sST2);	chr2:102224207	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs11191515	MIMAT0005951	hsa-miR-1307-3p	-4.91	1.26e-06	-0.32	-0.22	Birth weight;	chr10:103016770	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.575	rs56037709	MIMAT0031175	hsa-miR-548ba	-4.9	1.32e-06	-0.43	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48101503	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.597	rs3785539	MIMAT0017994	hsa-miR-3615	-4.9	1.36e-06	-0.27	-0.22	Monocyte count;	chr17:74778960	chr17:74748663~74748683:+
PRAD	cis	rs10454142	0.7	rs72820418	MIMAT0031175	hsa-miR-548ba	-4.89	1.38e-06	-0.32	-0.22	Sex hormone-binding globulin levels;	chr2:48349548	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.597	rs2053748	MIMAT0017994	hsa-miR-3615	4.88	1.46e-06	0.28	0.22	Monocyte count;	chr17:74779772	chr17:74748663~74748683:+
PRAD	cis	rs10454142	0.7	rs72820427	MIMAT0031175	hsa-miR-548ba	-4.88	1.47e-06	-0.32	-0.22	Sex hormone-binding globulin levels;	chr2:48358367	chr2:49059603~49059624:+
PRAD	cis	rs7503807	0.967	rs8064502	MIMAT0015066	hsa-miR-3065-5p	4.88	1.5e-06	0.26	0.22	Obesity;	chr17:80588634	chr17:81125886~81125908:+
PRAD	cis	rs9807989	0.507	rs4479442	MIMAT0019927	hsa-miR-4772-3p	-4.87	1.56e-06	-0.23	-0.22	Asthma;	chr2:102437614	chr2:102432336~102432357:+
PRAD	cis	rs8064299	0.636	rs9915279	MIMAT0017994	hsa-miR-3615	-4.86	1.6e-06	-0.27	-0.22	Monocyte count;	chr17:74776709	chr17:74748663~74748683:+
PRAD	cis	rs34198350	0.636	rs78268373	MIMAT0031175	hsa-miR-548ba	-4.86	1.61e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48215424	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs113752043	MIMAT0031175	hsa-miR-548ba	-4.86	1.61e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48217022	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11681876	MIMAT0031175	hsa-miR-548ba	-4.86	1.61e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48218189	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11687670	MIMAT0031175	hsa-miR-548ba	-4.86	1.61e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48225138	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs76752100	MIMAT0005951	hsa-miR-1307-3p	-4.86	1.63e-06	-0.32	-0.22	Birth weight;	chr10:103034329	chr10:103394301~103394322:-
PRAD	cis	rs1558648	0.858	rs12996377	MIMAT0019927	hsa-miR-4772-3p	-4.86	1.65e-06	-0.34	-0.22	Serum protein levels (sST2);	chr2:102214018	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.636	rs6733558	MIMAT0031175	hsa-miR-548ba	4.85	1.68e-06	0.43	0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48168347	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs11788697	MIMAT0019208	hsa-miR-3074-5p	-4.85	1.72e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94823083	chr9:95086063~95086083:-
PRAD	cis	rs7894407	0.623	rs10883846	MIMAT0005951	hsa-miR-1307-3p	4.85	1.72e-06	0.17	0.22	White matter hyperintensity burden;	chr10:103198487	chr10:103394301~103394322:-
PRAD	cis	rs8064299	0.597	rs6501736	MIMAT0017994	hsa-miR-3615	-4.85	1.72e-06	-0.27	-0.22	Monocyte count;	chr17:74779219	chr17:74748663~74748683:+
PRAD	cis	rs1018697	0.518	rs2482506	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.78e-06	-0.18	-0.22	Colorectal adenoma (advanced);	chr10:102803986	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.748	rs10786736	MIMAT0022727	hsa-miR-1307-5p	-4.84	1.79e-06	-0.3	-0.22	Birth weight;	chr10:103089359	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191519	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.79e-06	-0.32	-0.22	Birth weight;	chr10:103025161	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.852	rs11692537	MIMAT0031175	hsa-miR-548ba	-4.84	1.8e-06	-0.43	-0.22	Reticulocyte fraction of red cells;	chr2:48443032	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs76984715	MIMAT0031175	hsa-miR-548ba	-4.84	1.8e-06	-0.43	-0.22	Reticulocyte fraction of red cells;	chr2:48443863	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs77961213	MIMAT0031175	hsa-miR-548ba	-4.84	1.8e-06	-0.43	-0.22	Reticulocyte fraction of red cells;	chr2:48445228	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs75150625	MIMAT0031175	hsa-miR-548ba	-4.84	1.8e-06	-0.43	-0.22	Reticulocyte fraction of red cells;	chr2:48445234	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191502	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.82e-06	-0.32	-0.22	Birth weight;	chr10:103005737	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191505	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.82e-06	-0.32	-0.22	Birth weight;	chr10:103007134	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs74444347	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.82e-06	-0.32	-0.22	Birth weight;	chr10:103009518	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12221335	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.82e-06	-0.32	-0.22	Birth weight;	chr10:103009635	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs77787671	MIMAT0005951	hsa-miR-1307-3p	-4.84	1.82e-06	-0.32	-0.22	Birth weight;	chr10:103016448	chr10:103394301~103394322:-
PRAD	cis	rs75358501	0.636	rs12473690	MIMAT0014995	hsa-miR-3130-5p	4.83	1.87e-06	0.33	0.22	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206734939	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.636	rs12473690	MIMAT0014995_1	hsa-miR-3130-5p	4.83	1.87e-06	0.33	0.22	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206734939	chr2:206783246~206783266:+
PRAD	cis	rs4851551	1	rs3917329	MIMAT0019927	hsa-miR-4772-3p	4.83	1.88e-06	0.43	0.22	Blood protein levels;	chr2:102179403	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.789	rs10195717	MIMAT0031175	hsa-miR-548ba	-4.82	2.01e-06	-0.42	-0.22	Reticulocyte fraction of red cells;	chr2:48396295	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs77641353	MIMAT0031175	hsa-miR-548ba	-4.81	2.04e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48207871	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.687	rs17325048	MIMAT0031175	hsa-miR-548ba	-4.81	2.04e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48209427	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs75824932	MIMAT0031175	hsa-miR-548ba	-4.81	2.04e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48210490	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs76622043	MIMAT0031175	hsa-miR-548ba	-4.81	2.04e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48210799	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11674475	MIMAT0031175	hsa-miR-548ba	-4.81	2.06e-06	-0.45	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48175967	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs75732854	MIMAT0031175	hsa-miR-548ba	-4.81	2.09e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48480713	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs34026270	MIMAT0031175	hsa-miR-548ba	-4.81	2.09e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48486201	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs76272635	MIMAT0031175	hsa-miR-548ba	-4.81	2.09e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48486484	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs77008296	MIMAT0031175	hsa-miR-548ba	-4.81	2.09e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48487170	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs79558982	MIMAT0031175	hsa-miR-548ba	-4.81	2.09e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48487355	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.634	rs56060736	MIMAT0022727	hsa-miR-1307-5p	4.8	2.12e-06	0.22	0.22	White matter hyperintensity burden;	chr10:103310496	chr10:103394341~103394361:-
PRAD	cis	rs7894407	0.675	rs72846190	MIMAT0022727	hsa-miR-1307-5p	4.8	2.12e-06	0.22	0.22	White matter hyperintensity burden;	chr10:103319660	chr10:103394341~103394361:-
PRAD	cis	rs11678825	0.631	rs113596710	MIMAT0031175	hsa-miR-548ba	-4.8	2.12e-06	-0.41	-0.22	Reticulocyte fraction of red cells;	chr2:48385573	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.789	rs72889641	MIMAT0031175	hsa-miR-548ba	-4.8	2.12e-06	-0.41	-0.22	Reticulocyte fraction of red cells;	chr2:48392694	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs74233809	MIMAT0005951	hsa-miR-1307-3p	-4.8	2.12e-06	-0.31	-0.22	Birth weight;	chr10:103154183	chr10:103394301~103394322:-
PRAD	cis	rs10454142	0.7	rs11690845	MIMAT0031175	hsa-miR-548ba	4.79	2.23e-06	0.31	0.22	Sex hormone-binding globulin levels;	chr2:48357687	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs11690526	MIMAT0031175	hsa-miR-548ba	-4.78	2.38e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48512093	chr2:49059603~49059624:+
PRAD	cis	rs10454142	0.7	rs57537506	MIMAT0031175	hsa-miR-548ba	-4.78	2.39e-06	-0.31	-0.22	Sex hormone-binding globulin levels;	chr2:48349409	chr2:49059603~49059624:+
PRAD	cis	rs4851551	1	rs4851552	MIMAT0019927	hsa-miR-4772-3p	-4.78	2.42e-06	-0.44	-0.22	Blood protein levels;	chr2:102185873	chr2:102432336~102432357:+
PRAD	cis	rs10454142	0.666	rs11678403	MIMAT0031175	hsa-miR-548ba	-4.77	2.47e-06	-0.32	-0.22	Sex hormone-binding globulin levels;	chr2:48323358	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs7848139	MIMAT0019208	hsa-miR-3074-5p	-4.77	2.49e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94733185	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.852	rs11674217	MIMAT0031175	hsa-miR-548ba	-4.77	2.53e-06	-0.42	-0.22	Reticulocyte fraction of red cells;	chr2:48447352	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs12412038	MIMAT0005951	hsa-miR-1307-3p	-4.77	2.54e-06	-0.31	-0.22	Birth weight;	chr10:103096405	chr10:103394301~103394322:-
PRAD	cis	rs7503807	0.967	rs12949279	MIMAT0015066	hsa-miR-3065-5p	4.76	2.6e-06	0.26	0.22	Obesity;	chr17:80584611	chr17:81125886~81125908:+
PRAD	cis	rs74233809	1	rs11191580	MIMAT0005951	hsa-miR-1307-3p	4.75	2.71e-06	0.31	0.22	Birth weight;	chr10:103146454	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.687	rs11683689	MIMAT0031175	hsa-miR-548ba	4.75	2.71e-06	0.45	0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48196742	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs11687498	MIMAT0031175	hsa-miR-548ba	-4.75	2.79e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48510457	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.778	rs78938646	MIMAT0031175	hsa-miR-548ba	-4.75	2.79e-06	-0.45	-0.22	Reticulocyte fraction of red cells;	chr2:48510912	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.574	rs17397094	MIMAT0031175	hsa-miR-548ba	-4.74	2.82e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48240569	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.574	rs952468	MIMAT0031175	hsa-miR-548ba	-4.74	2.82e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48242993	chr2:49059603~49059624:+
PRAD	cis	rs10454142	0.568	rs57131168	MIMAT0031175	hsa-miR-548ba	-4.74	2.83e-06	-0.32	-0.22	Sex hormone-binding globulin levels;	chr2:48317972	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191555	MIMAT0005951	hsa-miR-1307-3p	-4.74	2.92e-06	-0.31	-0.22	Birth weight;	chr10:103097766	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191557	MIMAT0005951	hsa-miR-1307-3p	-4.74	2.92e-06	-0.31	-0.22	Birth weight;	chr10:103104857	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191558	MIMAT0005951	hsa-miR-1307-3p	-4.74	2.92e-06	-0.31	-0.22	Birth weight;	chr10:103104921	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.925	rs78058574	MIMAT0031175	hsa-miR-548ba	-4.73	2.96e-06	-0.44	-0.22	Reticulocyte fraction of red cells;	chr2:48513627	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs11689285	MIMAT0031175	hsa-miR-548ba	-4.73	3e-06	-0.44	-0.22	Reticulocyte fraction of red cells;	chr2:48472778	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs11683444	MIMAT0031175	hsa-miR-548ba	-4.73	3e-06	-0.44	-0.22	Reticulocyte fraction of red cells;	chr2:48472828	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs34542838	MIMAT0031175	hsa-miR-548ba	-4.73	3e-06	-0.44	-0.22	Reticulocyte fraction of red cells;	chr2:48473274	chr2:49059603~49059624:+
PRAD	cis	rs10454142	0.666	rs55761545	MIMAT0031175	hsa-miR-548ba	-4.73	3.02e-06	-0.31	-0.22	Sex hormone-binding globulin levels;	chr2:48328482	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs79629009	MIMAT0031175	hsa-miR-548ba	-4.73	3.04e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48235228	chr2:49059603~49059624:+
PRAD	cis	rs1163656	0.592	rs1795514	MIMAT0003287	hsa-miR-618	4.72	3.11e-06	0.34	0.22	Dental caries;	chr12:80939088	chr12:80935796~80935818:-
PRAD	cis	rs7851726	0.69	rs10821404	MIMAT0019208	hsa-miR-3074-5p	-4.72	3.13e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94834583	chr9:95086063~95086083:-
PRAD	cis	rs7851726	0.69	rs4743969	MIMAT0019208	hsa-miR-3074-5p	-4.72	3.13e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94836684	chr9:95086063~95086083:-
PRAD	cis	rs34198350	0.636	rs76334145	MIMAT0031175	hsa-miR-548ba	-4.72	3.18e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48156544	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs74720521	MIMAT0031175	hsa-miR-548ba	-4.72	3.18e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48159225	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs77725076	MIMAT0031175	hsa-miR-548ba	-4.72	3.2e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48221837	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.574	rs78311510	MIMAT0031175	hsa-miR-548ba	-4.71	3.23e-06	-0.48	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48241022	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs7027708	MIMAT0019208	hsa-miR-3074-5p	-4.71	3.26e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94748390	chr9:95086063~95086083:-
PRAD	cis	rs7851726	0.646	rs10821393	MIMAT0019208	hsa-miR-3074-5p	-4.71	3.26e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94754478	chr9:95086063~95086083:-
PRAD	cis	rs7851726	0.646	rs10739983	MIMAT0019208	hsa-miR-3074-5p	-4.71	3.26e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94764002	chr9:95086063~95086083:-
PRAD	cis	rs10454142	0.7	rs17037289	MIMAT0031175	hsa-miR-548ba	-4.71	3.29e-06	-0.3	-0.22	Sex hormone-binding globulin levels;	chr2:48360059	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs10821392	MIMAT0019208	hsa-miR-3074-5p	-4.71	3.3e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94746625	chr9:95086063~95086083:-
PRAD	cis	rs7072216	0.666	rs11598689	MIMAT0005878	hsa-miR-1287-5p	4.71	3.36e-06	0.26	0.22	Metabolite levels;	chr10:98396270	chr10:98395271~98395292:-
PRAD	cis	rs11678825	0.85	rs11675947	MIMAT0031175	hsa-miR-548ba	-4.7	3.38e-06	-0.47	-0.22	Reticulocyte fraction of red cells;	chr2:48522914	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs111902081	MIMAT0031175	hsa-miR-548ba	-4.7	3.5e-06	-0.47	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48233661	chr2:49059603~49059624:+
PRAD	cis	rs4851551	0.867	rs3917289	MIMAT0019927	hsa-miR-4772-3p	-4.7	3.51e-06	-0.4	-0.22	Blood protein levels;	chr2:102165451	chr2:102432336~102432357:+
PRAD	cis	rs7851726	0.652	rs7847277	MIMAT0019208	hsa-miR-3074-5p	-4.7	3.53e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94851146	chr9:95086063~95086083:-
PRAD	cis	rs34198350	0.636	rs79324045	MIMAT0031175	hsa-miR-548ba	-4.69	3.55e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48153780	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs76197661	MIMAT0031175	hsa-miR-548ba	-4.69	3.55e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48153894	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs78731001	MIMAT0031175	hsa-miR-548ba	-4.69	3.55e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48153988	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.966	rs7019822	MIMAT0019208	hsa-miR-3074-5p	-4.69	3.58e-06	-0.19	-0.22	Urinary albumin-to-creatinine ratio;	chr9:94720609	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.706	rs76955615	MIMAT0031175	hsa-miR-548ba	-4.69	3.6e-06	-0.44	-0.22	Reticulocyte fraction of red cells;	chr2:48507459	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.789	rs13398456	MIMAT0031175	hsa-miR-548ba	-4.69	3.62e-06	-0.41	-0.22	Reticulocyte fraction of red cells;	chr2:48391888	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs17324965	MIMAT0031175	hsa-miR-548ba	-4.69	3.64e-06	-0.45	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48184891	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11676381	MIMAT0031175	hsa-miR-548ba	-4.69	3.64e-06	-0.45	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48186785	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11691493	MIMAT0031175	hsa-miR-548ba	-4.69	3.64e-06	-0.45	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48187014	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs34135365	MIMAT0031175	hsa-miR-548ba	-4.69	3.64e-06	-0.45	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48187425	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs79039040	MIMAT0031175	hsa-miR-548ba	-4.69	3.65e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48169861	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs112809795	MIMAT0031175	hsa-miR-548ba	-4.69	3.65e-06	-0.46	-0.22	QT interval in Tripanosoma cruzi seropositivity;	chr2:48170018	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191607	MIMAT0005951	hsa-miR-1307-3p	-4.69	3.66e-06	-0.31	-0.22	Birth weight;	chr10:103199431	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191582	MIMAT0005951	hsa-miR-1307-3p	-4.68	3.74e-06	-0.31	-0.21	Birth weight;	chr10:103153896	chr10:103394301~103394322:-
PRAD	cis	rs1558648	1	rs1558648	MIMAT0019927	hsa-miR-4772-3p	-4.68	3.74e-06	-0.34	-0.21	Serum protein levels (sST2);	chr2:102193708	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.687	rs76915714	MIMAT0031175	hsa-miR-548ba	-4.68	3.77e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48178200	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs113418578	MIMAT0031175	hsa-miR-548ba	-4.68	3.77e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48182590	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs78039447	MIMAT0031175	hsa-miR-548ba	-4.68	3.77e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48182917	chr2:49059603~49059624:+
PRAD	cis	rs7072216	0.666	rs11189592	MIMAT0005878	hsa-miR-1287-5p	4.68	3.81e-06	0.25	0.21	Metabolite levels;	chr10:98395885	chr10:98395271~98395292:-
PRAD	cis	rs11678825	0.85	rs111440101	MIMAT0031175	hsa-miR-548ba	-4.68	3.82e-06	-0.48	-0.21	Reticulocyte fraction of red cells;	chr2:48525857	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs75678763	MIMAT0031175	hsa-miR-548ba	-4.68	3.83e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48123224	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs7561696	MIMAT0031175	hsa-miR-548ba	4.68	3.83e-06	0.4	0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48076712	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.789	rs10191938	MIMAT0031175	hsa-miR-548ba	-4.67	3.96e-06	-0.41	-0.21	Reticulocyte fraction of red cells;	chr2:48400817	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.789	rs10182093	MIMAT0031175	hsa-miR-548ba	-4.67	3.96e-06	-0.41	-0.21	Reticulocyte fraction of red cells;	chr2:48401171	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs10739982	MIMAT0019208	hsa-miR-3074-5p	-4.67	4.04e-06	-0.19	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94763966	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.852	rs11683202	MIMAT0031175	hsa-miR-548ba	-4.66	4.1e-06	-0.41	-0.21	Reticulocyte fraction of red cells;	chr2:48437521	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs12219304	MIMAT0005951	hsa-miR-1307-3p	-4.66	4.1e-06	-0.31	-0.21	Birth weight;	chr10:103171827	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs77420391	MIMAT0005951	hsa-miR-1307-3p	-4.66	4.1e-06	-0.31	-0.21	Birth weight;	chr10:103186066	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.925	rs76669685	MIMAT0031175	hsa-miR-548ba	-4.66	4.14e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48471867	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs113783549	MIMAT0031175	hsa-miR-548ba	-4.66	4.14e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48472287	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.69	rs4744386	MIMAT0019208	hsa-miR-3074-5p	-4.66	4.15e-06	-0.19	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94852359	chr9:95086063~95086083:-
PRAD	cis	rs74233809	1	rs12217501	MIMAT0005951	hsa-miR-1307-3p	-4.66	4.24e-06	-0.31	-0.21	Birth weight;	chr10:103092132	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12220743	MIMAT0005951	hsa-miR-1307-3p	-4.66	4.24e-06	-0.31	-0.21	Birth weight;	chr10:103092155	chr10:103394301~103394322:-
PRAD	cis	rs7851726	0.676	rs10821398	MIMAT0019208	hsa-miR-3074-5p	-4.65	4.28e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94815277	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.778	rs77137673	MIMAT0031175	hsa-miR-548ba	-4.65	4.36e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48490331	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.839	rs4988955	MIMAT0019927	hsa-miR-4772-3p	-4.65	4.37e-06	-0.22	-0.21	Asthma;	chr2:102351468	chr2:102432336~102432357:+
PRAD	cis	rs8064299	0.597	rs7210318	MIMAT0017994	hsa-miR-3615	-4.65	4.38e-06	-0.25	-0.21	Monocyte count;	chr17:74787246	chr17:74748663~74748683:+
PRAD	cis	rs34198350	0.636	rs17396793	MIMAT0031175	hsa-miR-548ba	-4.65	4.38e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48137879	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.597	rs2166703	MIMAT0017994	hsa-miR-3615	-4.63	4.76e-06	-0.25	-0.21	Monocyte count;	chr17:74785673	chr17:74748663~74748683:+
PRAD	cis	rs11678825	0.925	rs74720534	MIMAT0031175	hsa-miR-548ba	-4.63	4.76e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48475496	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs112436433	MIMAT0031175	hsa-miR-548ba	-4.63	4.81e-06	-0.43	-0.21	Reticulocyte fraction of red cells;	chr2:48466370	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191551	MIMAT0005951	hsa-miR-1307-3p	-4.63	4.86e-06	-0.31	-0.21	Birth weight;	chr10:103091078	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs17094683	MIMAT0005951	hsa-miR-1307-3p	-4.63	4.86e-06	-0.31	-0.21	Birth weight;	chr10:103091544	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.85	rs11687771	MIMAT0031175	hsa-miR-548ba	-4.62	4.9e-06	-0.48	-0.21	Reticulocyte fraction of red cells;	chr2:48528197	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.703	rs75604745	MIMAT0031175	hsa-miR-548ba	-4.62	4.92e-06	-0.48	-0.21	Reticulocyte fraction of red cells;	chr2:48534738	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.591	rs78989772	MIMAT0031175	hsa-miR-548ba	-4.62	4.93e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48172831	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs78607902	MIMAT0031175	hsa-miR-548ba	-4.62	4.93e-06	-0.48	-0.21	Reticulocyte fraction of red cells;	chr2:48527683	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.597	rs9944506	MIMAT0017994	hsa-miR-3615	-4.62	4.97e-06	-0.25	-0.21	Monocyte count;	chr17:74786587	chr17:74748663~74748683:+
PRAD	cis	rs8064299	0.597	rs2016126	MIMAT0017994	hsa-miR-3615	-4.62	5.03e-06	-0.25	-0.21	Monocyte count;	chr17:74788793	chr17:74748663~74748683:+
PRAD	cis	rs7594645	0.59	rs2359724	MIMAT0014995	hsa-miR-3130-5p	-4.62	5.04e-06	-0.4	-0.21	Episodic memory;	chr2:206750798	chr2:206783276~206783296:-
PRAD	cis	rs7594645	0.59	rs2359724	MIMAT0014995_1	hsa-miR-3130-5p	-4.62	5.04e-06	-0.4	-0.21	Episodic memory;	chr2:206750798	chr2:206783246~206783266:+
PRAD	cis	rs6584202	0.589	rs10883094	MIMAT0005878	hsa-miR-1287-5p	4.62	5.05e-06	0.24	0.21	Obesity-related traits;	chr10:98428349	chr10:98395271~98395292:-
PRAD	cis	rs34198350	0.636	rs78919296	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.43	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48168602	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs76016693	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48383732	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs116433538	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48395161	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs78208531	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48398300	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs79172039	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48412127	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.713	rs11682838	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48414016	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.777	rs77208413	MIMAT0031175	hsa-miR-548ba	-4.62	5.12e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48414147	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.584	rs2384957	MIMAT0017994	hsa-miR-3615	-4.61	5.26e-06	-0.25	-0.21	Monocyte count;	chr17:74788491	chr17:74748663~74748683:+
PRAD	cis	rs11678825	0.852	rs74744129	MIMAT0031175	hsa-miR-548ba	-4.61	5.33e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48372249	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs80138175	MIMAT0031175	hsa-miR-548ba	-4.61	5.34e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48515167	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs78529889	MIMAT0031175	hsa-miR-548ba	-4.6	5.39e-06	-0.42	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48165305	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs79588331	MIMAT0031175	hsa-miR-548ba	-4.6	5.39e-06	-0.42	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48166941	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs112420396	MIMAT0031175	hsa-miR-548ba	-4.6	5.39e-06	-0.42	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48167727	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.591	rs79412189	MIMAT0031175	hsa-miR-548ba	-4.6	5.39e-06	-0.42	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48169007	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.536	rs2290038	MIMAT0017994	hsa-miR-3615	4.6	5.46e-06	0.26	0.21	Monocyte count;	chr17:74790472	chr17:74748663~74748683:+
PRAD	cis	rs7851726	0.714	rs1867102	MIMAT0019208	hsa-miR-3074-5p	-4.6	5.51e-06	-0.19	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94865485	chr9:95086063~95086083:-
PRAD	cis	rs74233809	1	rs34747231	MIMAT0005951	hsa-miR-1307-3p	-4.6	5.58e-06	-0.3	-0.21	Birth weight;	chr10:103182487	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.85	rs77195144	MIMAT0031175	hsa-miR-548ba	-4.59	5.8e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48474355	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs2937	MIMAT0031175	hsa-miR-548ba	-4.59	5.86e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48477752	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs76435603	MIMAT0031175	hsa-miR-548ba	-4.59	5.86e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48487290	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs78704083	MIMAT0031175	hsa-miR-548ba	-4.58	5.96e-06	-0.43	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48189346	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs77596425	MIMAT0031175	hsa-miR-548ba	-4.58	5.97e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48498424	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.597	rs6501737	MIMAT0017994	hsa-miR-3615	4.58	6.1e-06	0.25	0.21	Monocyte count;	chr17:74784691	chr17:74748663~74748683:+
PRAD	cis	rs8064299	0.597	rs4789098	MIMAT0017994	hsa-miR-3615	-4.58	6.11e-06	-0.25	-0.21	Monocyte count;	chr17:74785153	chr17:74748663~74748683:+
PRAD	cis	rs7851726	0.646	rs2031698	MIMAT0019208	hsa-miR-3074-5p	-4.58	6.12e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94779050	chr9:95086063~95086083:-
PRAD	cis	rs34198350	0.504	rs77874419	MIMAT0031175	hsa-miR-548ba	-4.58	6.13e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48426222	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs78752476	MIMAT0031175	hsa-miR-548ba	-4.58	6.13e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48426773	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.504	rs77508671	MIMAT0031175	hsa-miR-548ba	-4.58	6.13e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48428752	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.504	rs112477875	MIMAT0031175	hsa-miR-548ba	-4.58	6.13e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48428955	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.634	rs755577	MIMAT0005951	hsa-miR-1307-3p	4.57	6.27e-06	0.17	0.21	White matter hyperintensity burden;	chr10:103464309	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.636	rs78984405	MIMAT0031175	hsa-miR-548ba	-4.57	6.39e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48187796	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs11693267	MIMAT0031175	hsa-miR-548ba	-4.57	6.39e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48188310	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.634	rs56060736	MIMAT0005951	hsa-miR-1307-3p	4.56	6.53e-06	0.19	0.21	White matter hyperintensity burden;	chr10:103310496	chr10:103394301~103394322:-
PRAD	cis	rs7894407	0.675	rs72846190	MIMAT0005951	hsa-miR-1307-3p	4.56	6.53e-06	0.19	0.21	White matter hyperintensity burden;	chr10:103319660	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.706	rs75289760	MIMAT0031175	hsa-miR-548ba	-4.56	6.73e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48458278	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs11694955	MIMAT0031175	hsa-miR-548ba	-4.56	6.73e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48459996	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs11678934	MIMAT0031175	hsa-miR-548ba	-4.56	6.73e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48464180	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs77437680	MIMAT0031175	hsa-miR-548ba	-4.56	6.73e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48465983	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs115829334	MIMAT0031175	hsa-miR-548ba	-4.56	6.73e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48466141	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.561	rs74806645	MIMAT0031175	hsa-miR-548ba	-4.55	6.87e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48540129	chr2:49059603~49059624:+
PRAD	cis	rs10993397	0.507	rs10993366	MIMAT0019208	hsa-miR-3074-5p	-4.55	6.91e-06	-0.18	-0.21	Polycystic ovary syndrome;	chr9:94844308	chr9:95086063~95086083:-
PRAD	cis	rs8064299	0.597	rs4789097	MIMAT0017994	hsa-miR-3615	4.55	6.99e-06	0.25	0.21	Monocyte count;	chr17:74785069	chr17:74748663~74748683:+
PRAD	cis	rs11678825	0.925	rs77595942	MIMAT0031175	hsa-miR-548ba	-4.55	7.05e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48492388	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs77751336	MIMAT0031175	hsa-miR-548ba	-4.54	7.11e-06	-0.43	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48111896	chr2:49059603~49059624:+
PRAD	cis	rs7503807	1	rs4890056	MIMAT0015066	hsa-miR-3065-5p	-4.54	7.13e-06	-0.25	-0.21	Obesity;	chr17:80617411	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.967	rs9915162	MIMAT0015066	hsa-miR-3065-5p	4.54	7.16e-06	0.24	0.21	Obesity;	chr17:80640526	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.905	rs9909449	MIMAT0015066	hsa-miR-3065-5p	4.54	7.16e-06	0.24	0.21	Obesity;	chr17:80640593	chr17:81125886~81125908:+
PRAD	cis	rs11678825	0.789	rs75250613	MIMAT0031175	hsa-miR-548ba	-4.54	7.16e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48377578	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs74427908	MIMAT0031175	hsa-miR-548ba	-4.54	7.16e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48379527	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs78694550	MIMAT0031175	hsa-miR-548ba	-4.54	7.16e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48393543	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.777	rs113103497	MIMAT0031175	hsa-miR-548ba	-4.54	7.16e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48394988	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.777	rs77376355	MIMAT0031175	hsa-miR-548ba	-4.54	7.16e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48396849	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.504	rs11679685	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48442025	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.636	rs76159992	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48443751	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs76874430	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48443880	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs4364065	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48445577	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs76329609	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48450031	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs74372386	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48452295	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs78436791	MIMAT0031175	hsa-miR-548ba	-4.54	7.17e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48452876	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.628	rs12338409	MIMAT0019208	hsa-miR-3074-5p	4.53	7.43e-06	0.18	0.21	Urinary albumin-to-creatinine ratio;	chr9:94928807	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.561	rs75841200	MIMAT0031175	hsa-miR-548ba	-4.53	7.43e-06	-0.48	-0.21	Reticulocyte fraction of red cells;	chr2:48535422	chr2:49059603~49059624:+
PRAD	cis	rs7209460	0.518	rs9894634	MIMAT0000426	hsa-miR-132-3p	4.53	7.48e-06	0.19	0.21	Coronary artery disease;Total body bone mineral density;	chr17:2064207	chr17:2049929~2049950:-
PRAD	cis	rs11678825	0.706	rs74428902	MIMAT0031175	hsa-miR-548ba	-4.52	7.73e-06	-0.47	-0.21	Reticulocyte fraction of red cells;	chr2:48530744	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.778	rs111588601	MIMAT0031175	hsa-miR-548ba	-4.52	7.73e-06	-0.47	-0.21	Reticulocyte fraction of red cells;	chr2:48533580	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs12413046	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103111447	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs10883832	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103111522	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.901	rs12416331	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103169157	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191587	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103169959	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191593	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103179458	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs79237883	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.79e-06	-0.3	-0.21	Birth weight;	chr10:103181189	chr10:103394301~103394322:-
PRAD	cis	rs4790312	0.935	rs3744274	MIMAT0000426	hsa-miR-132-3p	4.52	7.88e-06	0.2	0.21	Left atrial antero-posterior diameter;	chr17:2087665	chr17:2049929~2049950:-
PRAD	cis	rs11678825	0.852	rs76390426	MIMAT0031175	hsa-miR-548ba	-4.52	7.9e-06	-0.43	-0.21	Reticulocyte fraction of red cells;	chr2:48357906	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.706	rs77690821	MIMAT0031175	hsa-miR-548ba	-4.52	7.92e-06	-0.43	-0.21	Reticulocyte fraction of red cells;	chr2:48475861	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs79082900	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.92e-06	-0.3	-0.21	Birth weight;	chr10:103117545	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.786	rs11191564	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.92e-06	-0.3	-0.21	Birth weight;	chr10:103118786	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs1060240	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.92e-06	-0.3	-0.21	Birth weight;	chr10:103123580	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs10883835	MIMAT0005951	hsa-miR-1307-3p	-4.52	7.92e-06	-0.3	-0.21	Birth weight;	chr10:103124451	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.636	rs77214228	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48118924	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.59	rs79936906	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48123637	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs74463244	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48126435	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs75426309	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48129553	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs77243816	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48131854	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs79908000	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48131856	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs76731822	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48132480	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs74670219	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48135942	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.591	rs75792483	MIMAT0031175	hsa-miR-548ba	-4.52	7.96e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48137263	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs7584796	MIMAT0031175	hsa-miR-548ba	-4.52	7.99e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48399723	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs76121379	MIMAT0031175	hsa-miR-548ba	-4.52	7.99e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48403189	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs7573281	MIMAT0031175	hsa-miR-548ba	-4.52	7.99e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48403449	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.655	rs12797	MIMAT0017994	hsa-miR-3615	-4.51	8.18e-06	-0.25	-0.21	Monocyte count;	chr17:74770854	chr17:74748663~74748683:+
PRAD	cis	rs11678825	0.925	rs76587580	MIMAT0031175	hsa-miR-548ba	-4.51	8.22e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48454729	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs76915084	MIMAT0031175	hsa-miR-548ba	-4.51	8.24e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48522003	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.778	rs114627544	MIMAT0031175	hsa-miR-548ba	-4.51	8.24e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48522342	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.623	rs10883846	MIMAT0022727	hsa-miR-1307-5p	4.51	8.31e-06	0.17	0.21	White matter hyperintensity burden;	chr10:103198487	chr10:103394341~103394361:-
PRAD	cis	rs34198350	0.687	rs113773342	MIMAT0031175	hsa-miR-548ba	-4.51	8.32e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48124042	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.636	rs79380097	MIMAT0031175	hsa-miR-548ba	-4.51	8.32e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48131956	chr2:49059603~49059624:+
PRAD	cis	rs1018697	0.518	rs2790914	MIMAT0005951	hsa-miR-1307-3p	-4.51	8.43e-06	-0.18	-0.21	Colorectal adenoma (advanced);	chr10:102808261	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.777	rs78919694	MIMAT0031175	hsa-miR-548ba	-4.5	8.52e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48368779	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.574	rs17325209	MIMAT0031175	hsa-miR-548ba	4.5	8.66e-06	0.45	0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48252071	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.668	rs7862219	MIMAT0019208	hsa-miR-3074-5p	-4.5	8.7e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94889948	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.777	rs77919859	MIMAT0031175	hsa-miR-548ba	-4.5	8.7e-06	-0.43	-0.21	Reticulocyte fraction of red cells;	chr2:48342176	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.85	rs78556788	MIMAT0031175	hsa-miR-548ba	-4.5	8.76e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48519764	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs9633712	MIMAT0005951	hsa-miR-1307-3p	-4.5	8.76e-06	-0.3	-0.21	Birth weight;	chr10:103114004	chr10:103394301~103394322:-
PRAD	cis	rs7851726	0.565	rs10821413	MIMAT0019208	hsa-miR-3074-5p	-4.5	8.84e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94907034	chr9:95086063~95086083:-
PRAD	cis	rs990171	1	rs990171	MIMAT0019927	hsa-miR-4772-3p	-4.49	8.88e-06	-0.26	-0.21	Lymphocyte counts;	chr2:102470310	chr2:102432336~102432357:+
PRAD	cis	rs7894407	0.629	rs11598702	MIMAT0022727	hsa-miR-1307-5p	4.49	8.95e-06	0.17	0.21	White matter hyperintensity burden;	chr10:103138228	chr10:103394341~103394361:-
PRAD	cis	rs7209460	0.518	rs2236374	MIMAT0000426	hsa-miR-132-3p	4.49	9.03e-06	0.19	0.21	Coronary artery disease;Total body bone mineral density;	chr17:2086343	chr17:2049929~2049950:-
PRAD	cis	rs74233809	1	rs3781285	MIMAT0005951	hsa-miR-1307-3p	-4.49	9.19e-06	-0.3	-0.21	Birth weight;	chr10:103065908	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.59	rs112904523	MIMAT0031175	hsa-miR-548ba	-4.49	9.2e-06	-0.44	-0.21	QT interval in Tripanosoma cruzi seropositivity;	chr2:48177557	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.668	rs10217143	MIMAT0019208	hsa-miR-3074-5p	-4.48	9.28e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94876351	chr9:95086063~95086083:-
PRAD	cis	rs74233809	1	rs11191514	MIMAT0005951	hsa-miR-1307-3p	-4.48	9.3e-06	-0.29	-0.21	Birth weight;	chr10:103013607	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.706	rs615552	MIMAT0004504	hsa-miR-31-3p	4.48	9.33e-06	0.2	0.21	Type 2 diabetes;	chr9:22026078	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.561	rs11674683	MIMAT0031175	hsa-miR-548ba	-4.48	9.35e-06	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48546595	chr2:49059603~49059624:+
PRAD	cis	rs11678825	1	rs11678825	MIMAT0031175	hsa-miR-548ba	-4.48	9.38e-06	-0.42	-0.21	Reticulocyte fraction of red cells;	chr2:48464072	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.729	rs10170583	MIMAT0019927	hsa-miR-4772-3p	-4.48	9.4e-06	-0.21	-0.21	Asthma;	chr2:102358304	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs10173193	MIMAT0019927	hsa-miR-4772-3p	-4.48	9.4e-06	-0.21	-0.21	Asthma;	chr2:102358590	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs10176664	MIMAT0019927	hsa-miR-4772-3p	-4.48	9.4e-06	-0.21	-0.21	Asthma;	chr2:102359712	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs6543123	MIMAT0019927	hsa-miR-4772-3p	-4.48	9.4e-06	-0.21	-0.21	Asthma;	chr2:102360736	chr2:102432336~102432357:+
PRAD	cis	rs7594645	0.59	rs61258471	MIMAT0014995	hsa-miR-3130-5p	4.48	9.51e-06	0.39	0.21	Episodic memory;	chr2:206751133	chr2:206783276~206783296:-
PRAD	cis	rs7594645	0.59	rs61258471	MIMAT0014995_1	hsa-miR-3130-5p	4.48	9.51e-06	0.39	0.21	Episodic memory;	chr2:206751133	chr2:206783246~206783266:+
PRAD	cis	rs11678825	0.561	rs11677350	MIMAT0031175	hsa-miR-548ba	4.47	9.71e-06	0.43	0.21	Reticulocyte fraction of red cells;	chr2:48544466	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.668	rs10761361	MIMAT0019208	hsa-miR-3074-5p	-4.47	9.75e-06	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94882260	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.703	rs111584174	MIMAT0031175	hsa-miR-548ba	-4.47	9.88e-06	-0.44	-0.21	Reticulocyte fraction of red cells;	chr2:48359574	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191575	MIMAT0005951	hsa-miR-1307-3p	-4.46	1.01e-05	-0.29	-0.21	Birth weight;	chr10:103138580	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs79993475	MIMAT0005951	hsa-miR-1307-3p	-4.46	1.01e-05	-0.29	-0.21	Birth weight;	chr10:103141274	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12220375	MIMAT0005951	hsa-miR-1307-3p	-4.46	1.01e-05	-0.29	-0.21	Birth weight;	chr10:103141734	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs732998	MIMAT0005951	hsa-miR-1307-3p	4.46	1.01e-05	0.29	0.21	Birth weight;	chr10:103138144	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.852	rs74467138	MIMAT0031175	hsa-miR-548ba	-4.46	1.02e-05	-0.45	-0.21	Reticulocyte fraction of red cells;	chr2:48406216	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.868	rs7865618	MIMAT0004504	hsa-miR-31-3p	4.46	1.02e-05	0.2	0.21	Type 2 diabetes;	chr9:22031006	chr9:21512121~21512142:-
PRAD	cis	rs7851726	0.668	rs10081676	MIMAT0019208	hsa-miR-3074-5p	-4.46	1.03e-05	-0.18	-0.21	Urinary albumin-to-creatinine ratio;	chr9:94892954	chr9:95086063~95086083:-
PRAD	cis	rs11678825	0.852	rs77520628	MIMAT0031175	hsa-miR-548ba	-4.45	1.06e-05	-0.4	-0.2	Reticulocyte fraction of red cells;	chr2:48436809	chr2:49059603~49059624:+
PRAD	cis	rs7503807	0.967	rs12947696	MIMAT0015066	hsa-miR-3065-5p	4.45	1.06e-05	0.23	0.2	Obesity;	chr17:80622993	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.935	rs62068348	MIMAT0015066	hsa-miR-3065-5p	4.45	1.07e-05	0.23	0.2	Obesity;	chr17:80634775	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.935	rs9910745	MIMAT0015066	hsa-miR-3065-5p	4.45	1.07e-05	0.23	0.2	Obesity;	chr17:80636743	chr17:81125886~81125908:+
PRAD	cis	rs34198350	0.574	rs76116339	MIMAT0031175	hsa-miR-548ba	-4.45	1.08e-05	-0.44	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48255290	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.708	rs6543124	MIMAT0019927	hsa-miR-4772-3p	-4.45	1.08e-05	-0.21	-0.2	Asthma;	chr2:102370999	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.77	rs1739	MIMAT0005878	hsa-miR-1287-5p	4.45	1.09e-05	0.21	0.2	Metabolite levels;	chr10:98416582	chr10:98395271~98395292:-
PRAD	cis	rs1018697	0.518	rs284843	MIMAT0005951	hsa-miR-1307-3p	-4.44	1.11e-05	-0.17	-0.2	Colorectal adenoma (advanced);	chr10:102793809	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.852	rs75006397	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48400912	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.703	rs115933010	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48402508	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs11691302	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48403645	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs11691407	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48403908	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs76049688	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48407964	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs77376840	MIMAT0031175	hsa-miR-548ba	-4.44	1.13e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48408256	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.668	rs10821410	MIMAT0019208	hsa-miR-3074-5p	-4.44	1.14e-05	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr9:94880731	chr9:95086063~95086083:-
PRAD	cis	rs8064299	0.597	rs9893035	MIMAT0017994	hsa-miR-3615	-4.44	1.15e-05	-0.25	-0.2	Monocyte count;	chr17:74787659	chr17:74748663~74748683:+
PRAD	cis	rs11678825	0.852	rs11694094	MIMAT0031175	hsa-miR-548ba	-4.43	1.16e-05	-0.45	-0.2	Reticulocyte fraction of red cells;	chr2:48389613	chr2:49059603~49059624:+
PRAD	cis	rs1018697	0.518	rs284846	MIMAT0005951	hsa-miR-1307-3p	-4.43	1.17e-05	-0.17	-0.2	Colorectal adenoma (advanced);	chr10:102797533	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.852	rs17397449	MIMAT0031175	hsa-miR-548ba	4.43	1.18e-05	0.43	0.2	Reticulocyte fraction of red cells;	chr2:48417203	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.714	rs79950691	MIMAT0031175	hsa-miR-548ba	-4.43	1.19e-05	-0.43	-0.2	Reticulocyte fraction of red cells;	chr2:48415574	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.614	rs597816	MIMAT0004504	hsa-miR-31-3p	4.43	1.19e-05	0.21	0.2	Type 2 diabetes;	chr9:22021173	chr9:21512121~21512142:-
PRAD	cis	rs7851726	0.646	rs10993387	MIMAT0019208	hsa-miR-3074-5p	-4.43	1.19e-05	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr9:94900214	chr9:95086063~95086083:-
PRAD	cis	rs34198350	0.751	rs75820366	MIMAT0031175	hsa-miR-548ba	-4.43	1.21e-05	-0.41	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48062692	chr2:49059603~49059624:+
PRAD	cis	rs7209460	0.556	rs4790312	MIMAT0000426	hsa-miR-132-3p	4.43	1.21e-05	0.19	0.2	Coronary artery disease;Total body bone mineral density;	chr17:2078186	chr17:2049929~2049950:-
PRAD	cis	rs7503807	1	rs12939613	MIMAT0015066	hsa-miR-3065-5p	4.43	1.21e-05	0.24	0.2	Obesity;	chr17:80614402	chr17:81125886~81125908:+
PRAD	cis	rs9807989	0.839	rs4988957	MIMAT0019927	hsa-miR-4772-3p	4.42	1.22e-05	0.21	0.2	Asthma;	chr2:102351615	chr2:102432336~102432357:+
PRAD	cis	rs7503807	0.905	rs62068345	MIMAT0015066	hsa-miR-3065-5p	4.42	1.22e-05	0.23	0.2	Obesity;	chr17:80634240	chr17:81125886~81125908:+
PRAD	cis	rs1018697	0.518	rs2250301	MIMAT0005951	hsa-miR-1307-3p	-4.42	1.22e-05	-0.17	-0.2	Colorectal adenoma (advanced);	chr10:102788636	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.789	rs11687401	MIMAT0031175	hsa-miR-548ba	-4.42	1.23e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48274366	chr2:49059603~49059624:+
PRAD	cis	rs7894407	0.594	rs1163238	MIMAT0022727	hsa-miR-1307-5p	4.42	1.24e-05	0.17	0.2	White matter hyperintensity burden;	chr10:103184236	chr10:103394341~103394361:-
PRAD	cis	rs8064299	0.655	rs11655219	MIMAT0017994	hsa-miR-3615	-4.42	1.24e-05	-0.25	-0.2	Monocyte count;	chr17:74775154	chr17:74748663~74748683:+
PRAD	cis	rs34198350	0.574	rs80029858	MIMAT0031175	hsa-miR-548ba	-4.42	1.24e-05	-0.44	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48256639	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.585	rs7870160	MIMAT0019208	hsa-miR-3074-5p	-4.42	1.26e-05	-0.18	-0.2	Urinary albumin-to-creatinine ratio;	chr9:94950249	chr9:95086063~95086083:-
PRAD	cis	rs7072216	0.587	rs2296435	MIMAT0005878	hsa-miR-1287-5p	-4.41	1.28e-05	-0.24	-0.2	Metabolite levels;	chr10:98422528	chr10:98395271~98395292:-
PRAD	cis	rs74233809	1	rs943037	MIMAT0005951	hsa-miR-1307-3p	-4.41	1.28e-05	-0.29	-0.2	Birth weight;	chr10:103076162	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12219901	MIMAT0005951	hsa-miR-1307-3p	-4.41	1.28e-05	-0.29	-0.2	Birth weight;	chr10:103081210	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs10458729	MIMAT0005951	hsa-miR-1307-3p	-4.41	1.28e-05	-0.29	-0.2	Birth weight;	chr10:103081722	chr10:103394301~103394322:-
PRAD	cis	rs9807989	0.801	rs11123925	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102361051	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10204837	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102361270	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs3755276	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102361999	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs9308857	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102363164	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs1420099	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102364083	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10182710	MIMAT0019927	hsa-miR-4772-3p	-4.41	1.28e-05	-0.21	-0.2	Asthma;	chr2:102364846	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.777	rs11687851	MIMAT0031175	hsa-miR-548ba	-4.41	1.29e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48352647	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs77310067	MIMAT0031175	hsa-miR-548ba	-4.41	1.29e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48365663	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.561	rs79591643	MIMAT0031175	hsa-miR-548ba	-4.41	1.31e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48545526	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs77779306	MIMAT0031175	hsa-miR-548ba	-4.41	1.31e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48357020	chr2:49059603~49059624:+
PRAD	cis	rs915364	1	rs17662523	MIMAT0000722	hsa-miR-370-3p	4.4	1.35e-05	0.21	0.2	Magnesium levels;	chr14:101130787	chr14:100911186~100911207:+
PRAD	cis	rs7503807	1	rs8079537	MIMAT0015066	hsa-miR-3065-5p	4.4	1.35e-05	0.23	0.2	Obesity;	chr17:80627018	chr17:81125886~81125908:+
PRAD	cis	rs11678825	0.925	rs76366416	MIMAT0031175	hsa-miR-548ba	-4.4	1.36e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48508116	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs78619716	MIMAT0031175	hsa-miR-548ba	-4.4	1.38e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48510899	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs79094296	MIMAT0031175	hsa-miR-548ba	-4.4	1.38e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48511232	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs28505584	MIMAT0031175	hsa-miR-548ba	-4.39	1.4e-05	-0.42	-0.2	Reticulocyte fraction of red cells;	chr2:48401889	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs78373988	MIMAT0031175	hsa-miR-548ba	-4.39	1.4e-05	-0.43	-0.2	Reticulocyte fraction of red cells;	chr2:48495855	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.56	rs11077763	MIMAT0017994	hsa-miR-3615	-4.39	1.4e-05	-0.24	-0.2	Monocyte count;	chr17:74789890	chr17:74748663~74748683:+
PRAD	cis	rs9807989	0.801	rs4851566	MIMAT0019927	hsa-miR-4772-3p	-4.39	1.41e-05	-0.21	-0.2	Asthma;	chr2:102356339	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.777	rs111725400	MIMAT0031175	hsa-miR-548ba	-4.39	1.41e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48347290	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs77545871	MIMAT0031175	hsa-miR-548ba	-4.39	1.41e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48348346	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs79425636	MIMAT0031175	hsa-miR-548ba	-4.39	1.41e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48348708	chr2:49059603~49059624:+
PRAD	cis	rs7503807	0.967	rs4889867	MIMAT0015066	hsa-miR-3065-5p	4.39	1.42e-05	0.23	0.2	Obesity;	chr17:80619258	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.967	rs7215486	MIMAT0015066	hsa-miR-3065-5p	4.39	1.42e-05	0.23	0.2	Obesity;	chr17:80638234	chr17:81125886~81125908:+
PRAD	cis	rs1163656	0.605	rs10778771	MIMAT0003287	hsa-miR-618	-4.39	1.43e-05	-0.29	-0.2	Dental caries;	chr12:80924235	chr12:80935796~80935818:-
PRAD	cis	rs4851551	0.867	rs3917330	MIMAT0019927	hsa-miR-4772-3p	-4.39	1.44e-05	-0.37	-0.2	Blood protein levels;	chr2:102179965	chr2:102432336~102432357:+
PRAD	cis	rs4851551	0.867	rs3917331	MIMAT0019927	hsa-miR-4772-3p	-4.39	1.44e-05	-0.37	-0.2	Blood protein levels;	chr2:102179966	chr2:102432336~102432357:+
PRAD	cis	rs75358501	0.551	rs28619220	MIMAT0014995	hsa-miR-3130-5p	-4.38	1.45e-05	-0.29	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206720891	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.551	rs28619220	MIMAT0014995_1	hsa-miR-3130-5p	-4.38	1.45e-05	-0.29	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206720891	chr2:206783246~206783266:+
PRAD	cis	rs11678825	0.777	rs11687461	MIMAT0031175	hsa-miR-548ba	-4.38	1.46e-05	-0.44	-0.2	Reticulocyte fraction of red cells;	chr2:48334857	chr2:49059603~49059624:+
PRAD	cis	rs6011674	0.572	rs112329898	MIMAT0016888	hsa-miR-4326	-4.38	1.46e-05	-0.38	-0.2	Response to cytadine analogues (cytosine arabinoside);	chr20:63159089	chr20:63286818~63286837:+
PRAD	cis	rs8064299	0.655	rs895691	MIMAT0017994	hsa-miR-3615	-4.38	1.48e-05	-0.24	-0.2	Monocyte count;	chr17:74770161	chr17:74748663~74748683:+
PRAD	cis	rs75358501	0.551	rs79761690	MIMAT0014995	hsa-miR-3130-5p	-4.38	1.48e-05	-0.29	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206717731	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.551	rs79761690	MIMAT0014995_1	hsa-miR-3130-5p	-4.38	1.48e-05	-0.29	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206717731	chr2:206783246~206783266:+
PRAD	cis	rs7503807	1	rs12936076	MIMAT0015066	hsa-miR-3065-5p	4.38	1.49e-05	0.23	0.2	Obesity;	chr17:80627395	chr17:81125886~81125908:+
PRAD	cis	rs9807989	0.773	rs72823661	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102352256	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs72823663	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102352278	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs67088699	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102352291	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.773	rs5010059	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102352366	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.765	rs13424006	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102350776	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.765	rs6751967	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102350953	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.765	rs6751977	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102350970	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.765	rs6704565	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102350971	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs4988956	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102351547	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs4988958	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102351825	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10192157	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102351896	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10206753	MIMAT0019927	hsa-miR-4772-3p	-4.37	1.53e-05	-0.21	-0.2	Asthma;	chr2:102351902	chr2:102432336~102432357:+
PRAD	cis	rs7503807	0.967	rs12940622	MIMAT0015066	hsa-miR-3065-5p	4.37	1.53e-05	0.23	0.2	Obesity;	chr17:80641771	chr17:81125886~81125908:+
PRAD	cis	rs74233809	1	rs11191454	MIMAT0005951	hsa-miR-1307-3p	-4.37	1.55e-05	-0.29	-0.2	Birth weight;	chr10:102900247	chr10:103394301~103394322:-
PRAD	cis	rs9807989	0.839	rs11695627	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102353645	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs7558339	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102353783	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs7608638	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102353829	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs4485584	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102354290	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs4485585	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102354299	chr2:102432336~102432357:+
PRAD	cis	rs9807989	1	rs9807989	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102354740	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs9808453	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102354846	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs4851565	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102355021	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.765	rs9807962	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102355204	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs6734742	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102351397	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.801	rs6752482	MIMAT0019927	hsa-miR-4772-3p	-4.36	1.59e-05	-0.21	-0.2	Asthma;	chr2:102351398	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.925	rs7570877	MIMAT0031175	hsa-miR-548ba	4.36	1.6e-05	0.39	0.2	Reticulocyte fraction of red cells;	chr2:48515912	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.925	rs75220404	MIMAT0031175	hsa-miR-548ba	-4.36	1.61e-05	-0.43	-0.2	Reticulocyte fraction of red cells;	chr2:48484860	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.9	rs2157719	MIMAT0004504	hsa-miR-31-3p	-4.36	1.62e-05	-0.2	-0.2	Type 2 diabetes;	chr9:22033367	chr9:21512121~21512142:-
PRAD	cis	rs74233809	1	rs77860422	MIMAT0005951	hsa-miR-1307-3p	-4.36	1.63e-05	-0.29	-0.2	Birth weight;	chr10:102988252	chr10:103394301~103394322:-
PRAD	cis	rs4790312	0.905	rs4790311	MIMAT0000426	hsa-miR-132-3p	4.35	1.65e-05	0.19	0.2	Left atrial antero-posterior diameter;	chr17:2075894	chr17:2049929~2049950:-
PRAD	cis	rs34198350	0.808	rs76444985	MIMAT0031175	hsa-miR-548ba	-4.35	1.66e-05	-0.39	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48089090	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.624	rs12347649	MIMAT0019208	hsa-miR-3074-5p	-4.35	1.69e-05	-0.17	-0.2	Urinary albumin-to-creatinine ratio;	chr9:94901286	chr9:95086063~95086083:-
PRAD	cis	rs9807989	0.839	rs7603730	MIMAT0019927	hsa-miR-4772-3p	-4.35	1.69e-05	-0.21	-0.2	Asthma;	chr2:102357911	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs6749114	MIMAT0019927	hsa-miR-4772-3p	-4.35	1.7e-05	-0.21	-0.2	Asthma;	chr2:102351127	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.687	rs2840147	MIMAT0031175	hsa-miR-548ba	-4.34	1.73e-05	-0.41	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48086732	chr2:49059603~49059624:+
PRAD	cis	rs9807989	0.839	rs13392100	MIMAT0019927	hsa-miR-4772-3p	-4.34	1.73e-05	-0.21	-0.2	Asthma;	chr2:102365634	chr2:102432336~102432357:+
PRAD	cis	rs7503807	0.967	rs12939549	MIMAT0015066	hsa-miR-3065-5p	-4.34	1.75e-05	-0.23	-0.2	Obesity;	chr17:80637924	chr17:81125886~81125908:+
PRAD	cis	rs4790312	0.935	rs3865240	MIMAT0000426	hsa-miR-132-3p	4.34	1.75e-05	0.19	0.2	Left atrial antero-posterior diameter;	chr17:2088166	chr17:2049929~2049950:-
PRAD	cis	rs9807989	0.811	rs11688559	MIMAT0019927	hsa-miR-4772-3p	-4.34	1.77e-05	-0.21	-0.2	Asthma;	chr2:102353453	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs11688568	MIMAT0019927	hsa-miR-4772-3p	-4.34	1.77e-05	-0.21	-0.2	Asthma;	chr2:102353489	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs11688573	MIMAT0019927	hsa-miR-4772-3p	-4.34	1.77e-05	-0.21	-0.2	Asthma;	chr2:102353511	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.811	rs11689730	MIMAT0019927	hsa-miR-4772-3p	-4.34	1.77e-05	-0.21	-0.2	Asthma;	chr2:102353524	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.7	rs80350685	MIMAT0031175	hsa-miR-548ba	-4.34	1.79e-05	-0.4	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48102147	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs76828665	MIMAT0031175	hsa-miR-548ba	-4.33	1.83e-05	-0.42	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48062020	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs79209256	MIMAT0031175	hsa-miR-548ba	-4.33	1.83e-05	-0.42	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48062554	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs78647158	MIMAT0031175	hsa-miR-548ba	-4.33	1.83e-05	-0.42	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48067154	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs78299150	MIMAT0031175	hsa-miR-548ba	-4.33	1.83e-05	-0.42	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48068792	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs11680404	MIMAT0031175	hsa-miR-548ba	-4.33	1.83e-05	-0.42	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48068966	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs10883815	MIMAT0005951	hsa-miR-1307-3p	-4.33	1.85e-05	-0.29	-0.2	Birth weight;	chr10:102979422	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs112390216	MIMAT0005951	hsa-miR-1307-3p	-4.33	1.85e-05	-0.29	-0.2	Birth weight;	chr10:102981274	chr10:103394301~103394322:-
PRAD	cis	rs4851551	0.867	rs3171845	MIMAT0019927	hsa-miR-4772-3p	-4.33	1.86e-05	-0.36	-0.2	Blood protein levels;	chr2:102174921	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs3771166	MIMAT0019927	hsa-miR-4772-3p	-4.33	1.87e-05	-0.21	-0.2	Asthma;	chr2:102369762	chr2:102432336~102432357:+
PRAD	cis	rs12765878	0.58	rs10786772	MIMAT0005951	hsa-miR-1307-3p	4.32	1.89e-05	0.15	0.2	Coronary artery disease;	chr10:103850568	chr10:103394301~103394322:-
PRAD	cis	rs9807989	0.839	rs1974675	MIMAT0019927	hsa-miR-4772-3p	-4.32	1.9e-05	-0.21	-0.2	Asthma;	chr2:102369915	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs2041756	MIMAT0019927	hsa-miR-4772-3p	4.31	1.97e-05	0.25	0.2	Lymphocyte counts;	chr2:102433450	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs55664618	MIMAT0019927	hsa-miR-4772-3p	4.31	2.01e-05	0.21	0.2	Blood protein levels;	chr2:102399756	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.925	rs78545674	MIMAT0031175	hsa-miR-548ba	-4.31	2.02e-05	-0.43	-0.2	Reticulocyte fraction of red cells;	chr2:48510721	chr2:49059603~49059624:+
PRAD	cis	rs7594645	0.59	rs879472	MIMAT0014995	hsa-miR-3130-5p	-4.31	2.02e-05	-0.38	-0.2	Episodic memory;	chr2:206787058	chr2:206783276~206783296:-
PRAD	cis	rs7594645	0.59	rs879472	MIMAT0014995_1	hsa-miR-3130-5p	-4.31	2.02e-05	-0.38	-0.2	Episodic memory;	chr2:206787058	chr2:206783246~206783266:+
PRAD	cis	rs944801	0.769	rs564398	MIMAT0004504	hsa-miR-31-3p	4.3	2.07e-05	0.2	0.2	Type 2 diabetes;	chr9:22029548	chr9:21512121~21512142:-
PRAD	cis	rs74233809	1	rs11191453	MIMAT0005951	hsa-miR-1307-3p	-4.3	2.08e-05	-0.29	-0.2	Birth weight;	chr10:102900095	chr10:103394301~103394322:-
PRAD	cis	rs7503807	0.935	rs7215534	MIMAT0015066	hsa-miR-3065-5p	4.3	2.1e-05	0.23	0.2	Obesity;	chr17:80638319	chr17:81125886~81125908:+
PRAD	cis	rs7851726	0.624	rs12338859	MIMAT0019208	hsa-miR-3074-5p	4.3	2.11e-05	0.17	0.2	Urinary albumin-to-creatinine ratio;	chr9:94901338	chr9:95086063~95086083:-
PRAD	cis	rs7851726	0.628	rs12344211	MIMAT0019208	hsa-miR-3074-5p	4.3	2.13e-05	0.17	0.2	Urinary albumin-to-creatinine ratio;	chr9:94928822	chr9:95086063~95086083:-
PRAD	cis	rs7072216	0.666	rs2274248	MIMAT0005878	hsa-miR-1287-5p	4.29	2.15e-05	0.23	0.2	Metabolite levels;	chr10:98388785	chr10:98395271~98395292:-
PRAD	cis	rs62084913	0.511	rs895690	MIMAT0017994	hsa-miR-3615	-4.29	2.21e-05	-0.24	-0.2	Breast cancer;	chr17:74788510	chr17:74748663~74748683:+
PRAD	cis	rs74233809	0.901	rs17878846	MIMAT0022727	hsa-miR-1307-5p	-4.29	2.23e-05	-0.31	-0.2	Birth weight;	chr10:102870655	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191607	MIMAT0022727	hsa-miR-1307-5p	-4.28	2.25e-05	-0.31	-0.2	Birth weight;	chr10:103199431	chr10:103394341~103394361:-
PRAD	cis	rs4851551	0.619	rs35952417	MIMAT0019927	hsa-miR-4772-3p	-4.28	2.27e-05	-0.36	-0.2	Blood protein levels;	chr2:102188758	chr2:102432336~102432357:+
PRAD	cis	rs8064299	0.655	rs2305214	MIMAT0017994	hsa-miR-3615	-4.28	2.28e-05	-0.24	-0.2	Monocyte count;	chr17:74772831	chr17:74748663~74748683:+
PRAD	cis	rs2302612	0.58	rs11123913	MIMAT0019927	hsa-miR-4772-3p	-4.28	2.33e-05	-0.24	-0.2	Serum protein levels (sST2);	chr2:102209019	chr2:102432336~102432357:+
PRAD	cis	rs4790312	0.901	rs8078625	MIMAT0000426	hsa-miR-132-3p	4.28	2.33e-05	0.18	0.2	Left atrial antero-posterior diameter;	chr17:2075040	chr17:2049929~2049950:-
PRAD	cis	rs4790312	0.875	rs9901671	MIMAT0000426	hsa-miR-132-3p	4.28	2.33e-05	0.18	0.2	Left atrial antero-posterior diameter;	chr17:2075190	chr17:2049929~2049950:-
PRAD	cis	rs74233809	1	rs12219304	MIMAT0022727	hsa-miR-1307-5p	-4.27	2.36e-05	-0.31	-0.2	Birth weight;	chr10:103171827	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs77420391	MIMAT0022727	hsa-miR-1307-5p	-4.27	2.36e-05	-0.31	-0.2	Birth weight;	chr10:103186066	chr10:103394341~103394361:-
PRAD	cis	rs944801	0.802	rs679038	MIMAT0004504	hsa-miR-31-3p	4.27	2.37e-05	0.19	0.2	Type 2 diabetes;	chr9:22029081	chr9:21512121~21512142:-
PRAD	cis	rs6011674	0.562	rs78889597	MIMAT0016888	hsa-miR-4326	-4.27	2.39e-05	-0.37	-0.2	Response to cytadine analogues (cytosine arabinoside);	chr20:63161058	chr20:63286818~63286837:+
PRAD	cis	rs990171	0.955	rs6708413	MIMAT0019927	hsa-miR-4772-3p	-4.27	2.4e-05	-0.25	-0.2	Lymphocyte counts;	chr2:102446909	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs10509759	MIMAT0005951	hsa-miR-1307-3p	-4.27	2.42e-05	-0.29	-0.2	Birth weight;	chr10:102929908	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs5011520	MIMAT0005951	hsa-miR-1307-3p	-4.27	2.42e-05	-0.29	-0.2	Birth weight;	chr10:102937759	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191472	MIMAT0005951	hsa-miR-1307-3p	-4.27	2.42e-05	-0.29	-0.2	Birth weight;	chr10:102947259	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.913	rs4851009	MIMAT0019927	hsa-miR-4772-3p	-4.27	2.42e-05	-0.25	-0.2	Lymphocyte counts;	chr2:102439184	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.802	rs1558650	MIMAT0019927	hsa-miR-4772-3p	-4.27	2.42e-05	-0.25	-0.2	Lymphocyte counts;	chr2:102443564	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs6734736	MIMAT0019927	hsa-miR-4772-3p	-4.27	2.42e-05	-0.25	-0.2	Lymphocyte counts;	chr2:102446420	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10192036	MIMAT0019927	hsa-miR-4772-3p	-4.26	2.47e-05	-0.2	-0.2	Asthma;	chr2:102351751	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs10204137	MIMAT0019927	hsa-miR-4772-3p	-4.26	2.47e-05	-0.2	-0.2	Asthma;	chr2:102351752	chr2:102432336~102432357:+
PRAD	cis	rs2277912	0.865	rs111954117	MIMAT0014995	hsa-miR-3130-5p	4.26	2.49e-05	0.28	0.2	Height;	chr2:206793017	chr2:206783276~206783296:-
PRAD	cis	rs2277912	0.865	rs111954117	MIMAT0014995_1	hsa-miR-3130-5p	4.26	2.49e-05	0.28	0.2	Height;	chr2:206793017	chr2:206783246~206783266:+
PRAD	cis	rs11825709	1	rs2460047	MIMAT0022720	hsa-miR-1304-3p	-4.26	2.53e-05	-0.48	-0.2	Obesity-related traits;	chr11:93945770	chr11:93733691~93733712:-
PRAD	cis	rs4790312	0.668	rs1048483	MIMAT0000426	hsa-miR-132-3p	4.25	2.59e-05	0.19	0.2	Left atrial antero-posterior diameter;	chr17:2063163	chr17:2049929~2049950:-
PRAD	cis	rs7594645	1	rs73070048	MIMAT0014995	hsa-miR-3130-5p	4.25	2.59e-05	0.38	0.2	Episodic memory;	chr2:206776670	chr2:206783276~206783296:-
PRAD	cis	rs7594645	1	rs73070048	MIMAT0014995_1	hsa-miR-3130-5p	4.25	2.59e-05	0.38	0.2	Episodic memory;	chr2:206776670	chr2:206783246~206783266:+
PRAD	cis	rs75358501	0.551	rs12471939	MIMAT0014995	hsa-miR-3130-5p	-4.25	2.6e-05	-0.28	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206723545	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.551	rs12471939	MIMAT0014995_1	hsa-miR-3130-5p	-4.25	2.6e-05	-0.28	-0.2	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206723545	chr2:206783246~206783266:+
PRAD	cis	rs34198350	0.751	rs77494763	MIMAT0031175	hsa-miR-548ba	-4.25	2.62e-05	-0.41	-0.2	QT interval in Tripanosoma cruzi seropositivity;	chr2:48086535	chr2:49059603~49059624:+
PRAD	cis	rs8064299	0.503	rs62084914	MIMAT0017994	hsa-miR-3615	-4.25	2.63e-05	-0.24	-0.2	Monocyte count;	chr17:74776971	chr17:74748663~74748683:+
PRAD	cis	rs8064299	0.503	rs11653346	MIMAT0017994	hsa-miR-3615	-4.25	2.63e-05	-0.24	-0.2	Monocyte count;	chr17:74777194	chr17:74748663~74748683:+
PRAD	cis	rs74233809	1	rs35125602	MIMAT0005951	hsa-miR-1307-3p	-4.24	2.66e-05	-0.28	-0.2	Birth weight;	chr10:102896282	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.77	rs1737	MIMAT0005878	hsa-miR-1287-5p	4.24	2.67e-05	0.2	0.2	Metabolite levels;	chr10:98416609	chr10:98395271~98395292:-
PRAD	cis	rs11678825	0.852	rs75349859	MIMAT0031175	hsa-miR-548ba	-4.24	2.76e-05	-0.43	-0.2	Reticulocyte fraction of red cells;	chr2:48265019	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.834	rs1008878	MIMAT0004504	hsa-miR-31-3p	-4.24	2.77e-05	-0.19	-0.2	Type 2 diabetes;	chr9:22036113	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.852	rs11674317	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48308772	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs114909321	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48309090	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs11677205	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48310277	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs74656784	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48312143	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.777	rs11680968	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48321240	chr2:49059603~49059624:+
PRAD	cis	rs11678825	0.852	rs11687276	MIMAT0031175	hsa-miR-548ba	-4.23	2.83e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48327299	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.678	rs523096	MIMAT0004504	hsa-miR-31-3p	4.23	2.84e-05	0.19	0.19	Type 2 diabetes;	chr9:22019130	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.852	rs77643074	MIMAT0031175	hsa-miR-548ba	-4.23	2.85e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48273331	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191560	MIMAT0005951	hsa-miR-1307-3p	-4.23	2.86e-05	-0.28	-0.19	Birth weight;	chr10:103109281	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.843	rs4400721	MIMAT0005878	hsa-miR-1287-5p	4.22	2.9e-05	0.22	0.19	Metabolite levels;	chr10:98387340	chr10:98395271~98395292:-
PRAD	cis	rs990171	1	rs2110734	MIMAT0019927	hsa-miR-4772-3p	-4.22	2.92e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102435746	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6746271	MIMAT0019927	hsa-miR-4772-3p	-4.22	2.92e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102436535	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs2058660	MIMAT0019927	hsa-miR-4772-3p	-4.22	2.92e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102437989	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs2058658	MIMAT0019927	hsa-miR-4772-3p	-4.22	2.93e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102438343	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.751	rs58136909	MIMAT0031175	hsa-miR-548ba	-4.22	2.97e-05	-0.37	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48092370	chr2:49059603~49059624:+
PRAD	cis	rs75358501	0.551	rs13394079	MIMAT0014995	hsa-miR-3130-5p	-4.22	3e-05	-0.28	-0.19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206729470	chr2:206783276~206783296:-
PRAD	cis	rs75358501	0.551	rs13394079	MIMAT0014995_1	hsa-miR-3130-5p	-4.22	3e-05	-0.28	-0.19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:206729470	chr2:206783246~206783266:+
PRAD	cis	rs11678825	0.852	rs77967989	MIMAT0031175	hsa-miR-548ba	-4.21	3.03e-05	-0.42	-0.19	Reticulocyte fraction of red cells;	chr2:48271850	chr2:49059603~49059624:+
PRAD	cis	rs990171	1	rs11677107	MIMAT0019927	hsa-miR-4772-3p	-4.21	3.03e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102440627	chr2:102432336~102432357:+
PRAD	cis	rs2302612	0.58	rs11123912	MIMAT0019927	hsa-miR-4772-3p	-4.21	3.05e-05	-0.24	-0.19	Serum protein levels (sST2);	chr2:102200076	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.852	rs74318372	MIMAT0031175	hsa-miR-548ba	-4.21	3.05e-05	-0.38	-0.19	Reticulocyte fraction of red cells;	chr2:48444175	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs76305712	MIMAT0031175	hsa-miR-548ba	-4.21	3.05e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48084040	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs78526604	MIMAT0031175	hsa-miR-548ba	-4.21	3.05e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48084429	chr2:49059603~49059624:+
PRAD	cis	rs990171	0.913	rs1403554	MIMAT0019927	hsa-miR-4772-3p	-4.21	3.05e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102466993	chr2:102432336~102432357:+
PRAD	cis	rs8064299	0.565	rs12453550	MIMAT0017994	hsa-miR-3615	-4.21	3.06e-05	-0.24	-0.19	Monocyte count;	chr17:74789947	chr17:74748663~74748683:+
PRAD	cis	rs990171	1	rs2110735	MIMAT0019927	hsa-miR-4772-3p	-4.21	3.08e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102434465	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.513	rs77047969	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48095703	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.504	rs75214477	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48095714	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs77498476	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48097385	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs76534186	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48097999	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs74661050	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48098956	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.872	rs75204730	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48099838	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs77968976	MIMAT0031175	hsa-miR-548ba	-4.21	3.1e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48100520	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs12411886	MIMAT0005951	hsa-miR-1307-3p	-4.21	3.13e-05	-0.29	-0.19	Birth weight;	chr10:102925542	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.771	rs613312	MIMAT0004504	hsa-miR-31-3p	4.2	3.17e-05	0.19	0.19	Type 2 diabetes;	chr9:22026595	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.771	rs543830	MIMAT0004504	hsa-miR-31-3p	4.2	3.17e-05	0.19	0.19	Type 2 diabetes;	chr9:22026640	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.802	rs599452	MIMAT0004504	hsa-miR-31-3p	4.2	3.17e-05	0.19	0.19	Type 2 diabetes;	chr9:22027403	chr9:21512121~21512142:-
PRAD	cis	rs990171	0.955	rs10165460	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.23e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102469171	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs11123931	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.23e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102469200	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6755786	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.26e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102431643	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6713618	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.26e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102431977	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6716784	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.26e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102432007	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6543134	MIMAT0019927	hsa-miR-4772-3p	-4.2	3.26e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102433998	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs11191531	MIMAT0005951	hsa-miR-1307-3p	-4.2	3.28e-05	-0.28	-0.19	Birth weight;	chr10:103047141	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12219027	MIMAT0005951	hsa-miR-1307-3p	-4.2	3.28e-05	-0.28	-0.19	Birth weight;	chr10:103051446	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191543	MIMAT0005951	hsa-miR-1307-3p	-4.2	3.28e-05	-0.28	-0.19	Birth weight;	chr10:103064630	chr10:103394301~103394322:-
PRAD	cis	rs990171	1	rs7603250	MIMAT0019927	hsa-miR-4772-3p	-4.19	3.31e-05	-0.25	-0.19	Lymphocyte counts;	chr2:102452374	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.625	rs11689818	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48071852	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs76978278	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48076234	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs77233271	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48077659	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs78205496	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48078147	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs74652866	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48079013	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.751	rs11687989	MIMAT0031175	hsa-miR-548ba	-4.19	3.39e-05	-0.41	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48079508	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.899	rs1556515	MIMAT0004504	hsa-miR-31-3p	-4.18	3.45e-05	-0.19	-0.19	Type 2 diabetes;	chr9:22036368	chr9:21512121~21512142:-
PRAD	cis	rs990171	1	rs4851584	MIMAT0019927	hsa-miR-4772-3p	-4.18	3.46e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102443853	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs11694658	MIMAT0019927	hsa-miR-4772-3p	-4.18	3.49e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102428560	chr2:102432336~102432357:+
PRAD	cis	rs7503807	1	rs901064	MIMAT0015066	hsa-miR-3065-5p	-4.18	3.49e-05	-0.22	-0.19	Obesity;	chr17:80622240	chr17:81125886~81125908:+
PRAD	cis	rs804280	0.662	rs11250164	MIMAT0003266	hsa-miR-598-3p	-4.18	3.54e-05	-0.22	-0.19	Myopia (pathological);	chr8:11753177	chr8:11035221~11035242:-
PRAD	cis	rs74233809	1	rs11191582	MIMAT0022727	hsa-miR-1307-5p	-4.18	3.57e-05	-0.3	-0.19	Birth weight;	chr10:103153896	chr10:103394341~103394361:-
PRAD	cis	rs944801	0.678	rs518394	MIMAT0004504	hsa-miR-31-3p	4.17	3.61e-05	0.19	0.19	Type 2 diabetes;	chr9:22019674	chr9:21512121~21512142:-
PRAD	cis	rs990171	1	rs2160232	MIMAT0019927	hsa-miR-4772-3p	-4.17	3.66e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102430420	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs10197881	MIMAT0019927	hsa-miR-4772-3p	-4.16	3.74e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102475256	chr2:102432336~102432357:+
PRAD	cis	rs9807989	0.839	rs1362348	MIMAT0019927	hsa-miR-4772-3p	-4.16	3.81e-05	-0.2	-0.19	Asthma;	chr2:102368164	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs12221193	MIMAT0005951	hsa-miR-1307-3p	-4.16	3.83e-05	-0.28	-0.19	Birth weight;	chr10:102905510	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs77180047	MIMAT0005951	hsa-miR-1307-3p	-4.16	3.83e-05	-0.28	-0.19	Birth weight;	chr10:102907000	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs12221064	MIMAT0005951	hsa-miR-1307-3p	-4.16	3.83e-05	-0.28	-0.19	Birth weight;	chr10:102917369	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.913	rs2075185	MIMAT0019927	hsa-miR-4772-3p	-4.16	3.89e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102454528	chr2:102432336~102432357:+
PRAD	cis	rs7851726	0.628	rs4744412	MIMAT0019208	hsa-miR-3074-5p	4.15	3.92e-05	0.17	0.19	Urinary albumin-to-creatinine ratio;	chr9:94928219	chr9:95086063~95086083:-
PRAD	cis	rs74233809	1	rs9633712	MIMAT0022727	hsa-miR-1307-5p	-4.15	3.93e-05	-0.3	-0.19	Birth weight;	chr10:103114004	chr10:103394341~103394361:-
PRAD	cis	rs990171	0.954	rs6543137	MIMAT0019927	hsa-miR-4772-3p	-4.15	3.95e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102449448	chr2:102432336~102432357:+
PRAD	cis	rs34198350	0.7	rs79965367	MIMAT0031175	hsa-miR-548ba	-4.15	3.98e-05	-0.4	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48101912	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.7	rs79169137	MIMAT0031175	hsa-miR-548ba	-4.15	3.98e-05	-0.4	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48101952	chr2:49059603~49059624:+
PRAD	cis	rs34198350	0.7	rs74875686	MIMAT0031175	hsa-miR-548ba	-4.15	3.98e-05	-0.4	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48104126	chr2:49059603~49059624:+
PRAD	cis	rs1163656	0.536	rs7306751	MIMAT0003287	hsa-miR-618	-4.15	4.03e-05	-0.26	-0.19	Dental caries;	chr12:80922459	chr12:80935796~80935818:-
PRAD	cis	rs990171	1	rs1468791	MIMAT0019927	hsa-miR-4772-3p	-4.14	4.14e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102475562	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.77	rs1739	MIMAT0026738	hsa-miR-1287-3p	4.14	4.15e-05	0.14	0.19	Metabolite levels;	chr10:98416582	chr10:98395232~98395253:-
PRAD	cis	rs12765878	0.58	rs2295786	MIMAT0005951	hsa-miR-1307-3p	-4.13	4.24e-05	-0.14	-0.19	Coronary artery disease;	chr10:103856724	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs17115213	MIMAT0005951	hsa-miR-1307-3p	-4.13	4.26e-05	-0.28	-0.19	Birth weight;	chr10:102921386	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs77602510	MIMAT0005951	hsa-miR-1307-3p	-4.13	4.26e-05	-0.28	-0.19	Birth weight;	chr10:102922845	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs78821730	MIMAT0005951	hsa-miR-1307-3p	-4.13	4.26e-05	-0.28	-0.19	Birth weight;	chr10:102924787	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.541	rs7091346	MIMAT0005951	hsa-miR-1307-3p	-4.13	4.37e-05	-0.14	-0.19	Coronary artery disease;	chr10:103849066	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191515	MIMAT0022727	hsa-miR-1307-5p	-4.13	4.38e-05	-0.3	-0.19	Birth weight;	chr10:103016770	chr10:103394341~103394361:-
PRAD	cis	rs915364	1	rs17662541	MIMAT0000722	hsa-miR-370-3p	4.12	4.56e-05	0.19	0.19	Magnesium levels;	chr14:101130840	chr14:100911186~100911207:+
PRAD	cis	rs74233809	1	rs11191514	MIMAT0022727	hsa-miR-1307-5p	-4.12	4.58e-05	-0.29	-0.19	Birth weight;	chr10:103013607	chr10:103394341~103394361:-
PRAD	cis	rs34198350	0.504	rs11676925	MIMAT0031175	hsa-miR-548ba	-4.11	4.65e-05	-0.43	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48262698	chr2:49059603~49059624:+
PRAD	cis	rs12765878	0.557	rs10883928	MIMAT0005951	hsa-miR-1307-3p	-4.11	4.66e-05	-0.14	-0.19	Coronary artery disease;	chr10:103855316	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.802	rs8181050	MIMAT0004504	hsa-miR-31-3p	-4.1	4.83e-05	-0.19	-0.19	Type 2 diabetes;	chr9:22064392	chr9:21512121~21512142:-
PRAD	cis	rs7503807	1	rs4889775	MIMAT0015066	hsa-miR-3065-5p	4.1	4.84e-05	0.22	0.19	Obesity;	chr17:80618487	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.688	rs12600403	MIMAT0015066	hsa-miR-3065-5p	4.09	5.04e-05	0.22	0.19	Obesity;	chr17:80628677	chr17:81125886~81125908:+
PRAD	cis	rs74233809	1	rs34747231	MIMAT0022727	hsa-miR-1307-5p	-4.08	5.3e-05	-0.3	-0.19	Birth weight;	chr10:103182487	chr10:103394341~103394361:-
PRAD	cis	rs12765878	0.603	rs2475213	MIMAT0005951	hsa-miR-1307-3p	4.08	5.38e-05	0.14	0.19	Coronary artery disease;	chr10:103904701	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.58	rs11191833	MIMAT0005951	hsa-miR-1307-3p	-4.07	5.46e-05	-0.14	-0.19	Coronary artery disease;	chr10:103859920	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191502	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.47e-05	-0.29	-0.19	Birth weight;	chr10:103005737	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191505	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.47e-05	-0.29	-0.19	Birth weight;	chr10:103007134	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs74444347	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.47e-05	-0.29	-0.19	Birth weight;	chr10:103009518	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12221335	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.47e-05	-0.29	-0.19	Birth weight;	chr10:103009635	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs77787671	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.47e-05	-0.29	-0.19	Birth weight;	chr10:103016448	chr10:103394341~103394361:-
PRAD	cis	rs944801	0.776	rs1537378	MIMAT0004504	hsa-miR-31-3p	-4.07	5.55e-05	-0.19	-0.19	Type 2 diabetes;	chr9:22061615	chr9:21512121~21512142:-
PRAD	cis	rs74233809	1	rs75970938	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.59e-05	-0.29	-0.19	Birth weight;	chr10:103033891	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs79668541	MIMAT0022727	hsa-miR-1307-5p	-4.07	5.59e-05	-0.29	-0.19	Birth weight;	chr10:103034147	chr10:103394341~103394361:-
PRAD	cis	rs7503807	1	rs7503807	MIMAT0015066	hsa-miR-3065-5p	-4.07	5.62e-05	-0.21	-0.19	Obesity;	chr17:80617311	chr17:81125886~81125908:+
PRAD	cis	rs74233809	0.515	rs72841270	MIMAT0005951	hsa-miR-1307-3p	-4.07	5.62e-05	-0.2	-0.19	Birth weight;	chr10:102882480	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.58	rs11191829	MIMAT0005951	hsa-miR-1307-3p	-4.06	5.75e-05	-0.14	-0.19	Coronary artery disease;	chr10:103854694	chr10:103394301~103394322:-
PRAD	cis	rs2284932	0.875	rs764487	MIMAT0016895	hsa-miR-2355-5p	4.06	5.77e-05	0.2	0.19	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207136544	chr2:207110043~207110063:-
PRAD	cis	rs990171	1	rs6737668	MIMAT0019927	hsa-miR-4772-3p	-4.06	5.87e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102476622	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs10469840	MIMAT0019927	hsa-miR-4772-3p	-4.06	5.87e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102476784	chr2:102432336~102432357:+
PRAD	cis	rs7914558	0.505	rs12260436	MIMAT0005951	hsa-miR-1307-3p	-4.05	5.91e-05	-0.15	-0.19	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia;	chr10:102981357	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs76752100	MIMAT0022727	hsa-miR-1307-5p	-4.05	5.94e-05	-0.29	-0.19	Birth weight;	chr10:103034329	chr10:103394341~103394361:-
PRAD	cis	rs12765878	0.557	rs2984133	MIMAT0005951	hsa-miR-1307-3p	-4.05	6.07e-05	-0.13	-0.19	Coronary artery disease;	chr10:103911090	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.769	rs1412829	MIMAT0004504	hsa-miR-31-3p	4.05	6.08e-05	0.19	0.19	Type 2 diabetes;	chr9:22043927	chr9:21512121~21512142:-
PRAD	cis	rs1163656	0.559	rs1163657	MIMAT0003287	hsa-miR-618	4.04	6.21e-05	0.3	0.19	Dental caries;	chr12:80943890	chr12:80935796~80935818:-
PRAD	cis	rs7503807	0.701	rs1485329	MIMAT0015066	hsa-miR-3065-5p	4.04	6.29e-05	0.23	0.19	Obesity;	chr17:80669761	chr17:81125886~81125908:+
PRAD	cis	rs990171	1	rs7561487	MIMAT0019927	hsa-miR-4772-3p	-4.04	6.36e-05	-0.24	-0.19	Lymphocyte counts;	chr2:102461434	chr2:102432336~102432357:+
PRAD	cis	rs7209460	0.556	rs12449600	MIMAT0000426	hsa-miR-132-3p	4.04	6.41e-05	0.18	0.19	Coronary artery disease;Total body bone mineral density;	chr17:2078952	chr17:2049929~2049950:-
PRAD	cis	rs74233809	1	rs11191555	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.46e-05	-0.29	-0.19	Birth weight;	chr10:103097766	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191557	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.46e-05	-0.29	-0.19	Birth weight;	chr10:103104857	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191558	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.46e-05	-0.29	-0.19	Birth weight;	chr10:103104921	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12412038	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.57e-05	-0.29	-0.19	Birth weight;	chr10:103096405	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12413046	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103111447	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs10883832	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103111522	chr10:103394341~103394361:-
PRAD	cis	rs74233809	0.901	rs12416331	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103169157	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191587	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103169959	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191593	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103179458	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs79237883	MIMAT0022727	hsa-miR-1307-5p	-4.03	6.59e-05	-0.29	-0.19	Birth weight;	chr10:103181189	chr10:103394341~103394361:-
PRAD	cis	rs12765878	0.603	rs10883944	MIMAT0005951	hsa-miR-1307-3p	-4.03	6.62e-05	-0.14	-0.19	Coronary artery disease;	chr10:103891899	chr10:103394301~103394322:-
PRAD	cis	rs1163656	0.536	rs4261347	MIMAT0003287	hsa-miR-618	-4.02	6.68e-05	-0.25	-0.19	Dental caries;	chr12:80921546	chr12:80935796~80935818:-
PRAD	cis	rs944801	0.966	rs1360589	MIMAT0004504	hsa-miR-31-3p	-4.02	6.72e-05	-0.19	-0.19	Type 2 diabetes;	chr9:22045318	chr9:21512121~21512142:-
PRAD	cis	rs4918072	0.754	rs4918065	MIMAT0005951	hsa-miR-1307-3p	4.02	6.75e-05	0.16	0.19	Coronary artery disease;	chr10:103857820	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.71	rs4147157	MIMAT0005951	hsa-miR-1307-3p	-4.02	6.87e-05	-0.28	-0.19	Birth weight;	chr10:102776603	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.711	rs581876	MIMAT0004504	hsa-miR-31-3p	4.02	6.87e-05	0.19	0.19	Type 2 diabetes;	chr9:22022377	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.852	rs11679518	MIMAT0031175	hsa-miR-548ba	-4.02	6.9e-05	-0.41	-0.19	Reticulocyte fraction of red cells;	chr2:48290413	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs79082900	MIMAT0022727	hsa-miR-1307-5p	-4.02	6.94e-05	-0.29	-0.19	Birth weight;	chr10:103117545	chr10:103394341~103394361:-
PRAD	cis	rs74233809	0.786	rs11191564	MIMAT0022727	hsa-miR-1307-5p	-4.02	6.94e-05	-0.29	-0.19	Birth weight;	chr10:103118786	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs1060240	MIMAT0022727	hsa-miR-1307-5p	-4.02	6.94e-05	-0.29	-0.19	Birth weight;	chr10:103123580	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs10883835	MIMAT0022727	hsa-miR-1307-5p	-4.02	6.94e-05	-0.29	-0.19	Birth weight;	chr10:103124451	chr10:103394341~103394361:-
PRAD	cis	rs421490	1	rs385137	MIMAT0004557	hsa-miR-34a-3p	4.01	6.96e-05	0.32	0.19	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr1:8214903	chr1:9151693~9151714:-
PRAD	cis	rs74233809	1	rs11191519	MIMAT0022727	hsa-miR-1307-5p	-4.01	6.98e-05	-0.29	-0.19	Birth weight;	chr10:103025161	chr10:103394341~103394361:-
PRAD	cis	rs11678825	0.683	rs80016200	MIMAT0031175	hsa-miR-548ba	-4.01	6.99e-05	-0.33	-0.19	Reticulocyte fraction of red cells;	chr2:48462338	chr2:49059603~49059624:+
PRAD	cis	rs7503807	0.664	rs11150736	MIMAT0015066	hsa-miR-3065-5p	4.01	7.03e-05	0.21	0.19	Obesity;	chr17:80639707	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.688	rs731452	MIMAT0015066	hsa-miR-3065-5p	4.01	7.06e-05	0.22	0.19	Obesity;	chr17:80625252	chr17:81125886~81125908:+
PRAD	cis	rs34198350	0.751	rs79647847	MIMAT0031175	hsa-miR-548ba	-4.01	7.08e-05	-0.39	-0.19	QT interval in Tripanosoma cruzi seropositivity;	chr2:48088907	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191580	MIMAT0022727	hsa-miR-1307-5p	4	7.37e-05	0.29	0.18	Birth weight;	chr10:103146454	chr10:103394341~103394361:-
PRAD	cis	rs11678825	0.683	rs56226059	MIMAT0031175	hsa-miR-548ba	-4	7.47e-05	-0.34	-0.18	Reticulocyte fraction of red cells;	chr2:48452796	chr2:49059603~49059624:+
PRAD	cis	rs4790312	0.729	rs9912392	MIMAT0000426	hsa-miR-132-3p	3.99	7.55e-05	0.17	0.18	Left atrial antero-posterior diameter;	chr17:2092317	chr17:2049929~2049950:-
PRAD	cis	rs4790312	0.561	rs4790309	MIMAT0000426	hsa-miR-132-3p	3.99	7.56e-05	0.18	0.18	Left atrial antero-posterior diameter;	chr17:2063595	chr17:2049929~2049950:-
PRAD	cis	rs74233809	1	rs12411886	MIMAT0022727	hsa-miR-1307-5p	-3.99	7.58e-05	-0.3	-0.18	Birth weight;	chr10:102925542	chr10:103394341~103394361:-
PRAD	cis	rs12765878	0.603	rs1570221	MIMAT0005951	hsa-miR-1307-3p	-3.99	7.69e-05	-0.14	-0.18	Coronary artery disease;	chr10:103897116	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.802	rs2383205	MIMAT0004504	hsa-miR-31-3p	-3.99	7.77e-05	-0.19	-0.18	Type 2 diabetes;	chr9:22060936	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.789	rs112492778	MIMAT0031175	hsa-miR-548ba	-3.99	7.81e-05	-0.34	-0.18	Reticulocyte fraction of red cells;	chr2:48440788	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.899	rs1333037	MIMAT0004504	hsa-miR-31-3p	-3.99	7.81e-05	-0.18	-0.18	Type 2 diabetes;	chr9:22040766	chr9:21512121~21512142:-
PRAD	cis	rs990171	1	rs917997	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102454108	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.913	rs4851587	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102457014	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs4851588	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102457045	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs4070554	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102458033	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs6761825	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102459101	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6705001	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102459750	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6543141	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102459891	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs4241210	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102462280	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs6720564	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102462837	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.865	rs6717915	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102463159	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.913	rs6718157	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102463354	chr2:102432336~102432357:+
PRAD	cis	rs2075184	1	rs2075184	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Pediatric autoimmune diseases;	chr2:102464132	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs917996	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102465813	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.908	rs731628	MIMAT0019927	hsa-miR-4772-3p	-3.98	7.89e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102466111	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs11191551	MIMAT0022727	hsa-miR-1307-5p	-3.98	8.09e-05	-0.29	-0.18	Birth weight;	chr10:103091078	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs17094683	MIMAT0022727	hsa-miR-1307-5p	-3.98	8.09e-05	-0.29	-0.18	Birth weight;	chr10:103091544	chr10:103394341~103394361:-
PRAD	cis	rs944801	0.769	rs634537	MIMAT0004504	hsa-miR-31-3p	3.98	8.13e-05	0.18	0.18	Type 2 diabetes;	chr9:22032153	chr9:21512121~21512142:-
PRAD	cis	rs74233809	1	rs12217501	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.21e-05	-0.29	-0.18	Birth weight;	chr10:103092132	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12220743	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.21e-05	-0.29	-0.18	Birth weight;	chr10:103092155	chr10:103394341~103394361:-
PRAD	cis	rs11678825	0.683	rs74684569	MIMAT0031175	hsa-miR-548ba	-3.97	8.24e-05	-0.33	-0.18	Reticulocyte fraction of red cells;	chr2:48435911	chr2:49059603~49059624:+
PRAD	cis	rs4790312	0.765	rs3760230	MIMAT0000426	hsa-miR-132-3p	3.97	8.28e-05	0.17	0.18	Left atrial antero-posterior diameter;	chr17:2090777	chr17:2049929~2049950:-
PRAD	cis	rs74233809	1	rs943037	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.28e-05	-0.29	-0.18	Birth weight;	chr10:103076162	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12219901	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.28e-05	-0.29	-0.18	Birth weight;	chr10:103081210	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs10458729	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.28e-05	-0.29	-0.18	Birth weight;	chr10:103081722	chr10:103394341~103394361:-
PRAD	cis	rs990171	1	rs7559479	MIMAT0019927	hsa-miR-4772-3p	-3.97	8.31e-05	-0.23	-0.18	Lymphocyte counts;	chr2:102452327	chr2:102432336~102432357:+
PRAD	cis	rs12765878	0.564	rs2073338	MIMAT0005951	hsa-miR-1307-3p	-3.97	8.39e-05	-0.13	-0.18	Coronary artery disease;	chr10:103883045	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.603	rs10786773	MIMAT0005951	hsa-miR-1307-3p	-3.97	8.39e-05	-0.13	-0.18	Coronary artery disease;	chr10:103884517	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.603	rs2475216	MIMAT0005951	hsa-miR-1307-3p	-3.97	8.42e-05	-0.13	-0.18	Coronary artery disease;	chr10:103900893	chr10:103394301~103394322:-
PRAD	cis	rs2823615	0.821	rs80134195	MIMAT0000064	hsa-let-7c-5p	-3.97	8.46e-05	-0.17	-0.18	Obesity-related traits;	chr21:16095701	chr21:16539838~16539859:+
PRAD	cis	rs74233809	1	rs3781285	MIMAT0022727	hsa-miR-1307-5p	-3.97	8.51e-05	-0.29	-0.18	Birth weight;	chr10:103065908	chr10:103394341~103394361:-
PRAD	cis	rs684232	0.933	rs2474694	MIMAT0004495	hsa-miR-22-5p	3.96	8.53e-05	0.16	0.18	Prostate cancer;	chr17:714799	chr17:1713952~1713973:-
PRAD	cis	rs684232	0.901	rs1741275	MIMAT0004495	hsa-miR-22-5p	-3.96	8.55e-05	-0.16	-0.18	Prostate cancer;	chr17:727123	chr17:1713952~1713973:-
PRAD	cis	rs74233809	1	rs10883806	MIMAT0005951	hsa-miR-1307-3p	-3.96	8.58e-05	-0.27	-0.18	Birth weight;	chr10:102953319	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs10883808	MIMAT0005951	hsa-miR-1307-3p	-3.96	8.58e-05	-0.27	-0.18	Birth weight;	chr10:102961369	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs78260931	MIMAT0005951	hsa-miR-1307-3p	-3.96	8.58e-05	-0.27	-0.18	Birth weight;	chr10:102962205	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs11191479	MIMAT0005951	hsa-miR-1307-3p	-3.96	8.58e-05	-0.27	-0.18	Birth weight;	chr10:102963863	chr10:103394301~103394322:-
PRAD	cis	rs2823615	1	rs13051266	MIMAT0000064	hsa-let-7c-5p	-3.96	8.62e-05	-0.16	-0.18	Obesity-related traits;	chr21:16100520	chr21:16539838~16539859:+
PRAD	cis	rs1018697	0.966	rs1475643	MIMAT0022727	hsa-miR-1307-5p	3.96	8.68e-05	0.14	0.18	Colorectal adenoma (advanced);	chr10:102786710	chr10:103394341~103394361:-
PRAD	cis	rs4790312	0.513	rs2232486	MIMAT0000426	hsa-miR-132-3p	3.96	8.74e-05	0.2	0.18	Left atrial antero-posterior diameter;	chr17:2065689	chr17:2049929~2049950:-
PRAD	cis	rs7503807	0.651	rs901065	MIMAT0015066	hsa-miR-3065-5p	3.96	8.76e-05	0.21	0.18	Obesity;	chr17:80625855	chr17:81125886~81125908:+
PRAD	cis	rs2277912	1	rs17214385	MIMAT0014995	hsa-miR-3130-5p	3.96	8.78e-05	0.28	0.18	Height;	chr2:206816879	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs17214385	MIMAT0014995_1	hsa-miR-3130-5p	3.96	8.78e-05	0.28	0.18	Height;	chr2:206816879	chr2:206783246~206783266:+
PRAD	cis	rs11678825	0.733	rs11686769	MIMAT0031175	hsa-miR-548ba	-3.95	8.89e-05	-0.33	-0.18	Reticulocyte fraction of red cells;	chr2:48455374	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs10883815	MIMAT0022727	hsa-miR-1307-5p	-3.95	8.93e-05	-0.29	-0.18	Birth weight;	chr10:102979422	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs112390216	MIMAT0022727	hsa-miR-1307-5p	-3.95	8.93e-05	-0.29	-0.18	Birth weight;	chr10:102981274	chr10:103394341~103394361:-
PRAD	cis	rs8064299	0.655	rs16978176	MIMAT0017994	hsa-miR-3615	-3.95	8.97e-05	-0.23	-0.18	Monocyte count;	chr17:74765103	chr17:74748663~74748683:+
PRAD	cis	rs74233809	1	rs77860422	MIMAT0022727	hsa-miR-1307-5p	-3.95	9.17e-05	-0.29	-0.18	Birth weight;	chr10:102988252	chr10:103394341~103394361:-
PRAD	cis	rs79387448	0.701	rs3752659	MIMAT0019927	hsa-miR-4772-3p	-3.95	9.19e-05	-0.27	-0.18	Gut microbiota (bacterial taxa);	chr2:102385138	chr2:102432336~102432357:+
PRAD	cis	rs12765878	0.603	rs9420904	MIMAT0005951	hsa-miR-1307-3p	-3.94	9.26e-05	-0.13	-0.18	Coronary artery disease;	chr10:103906987	chr10:103394301~103394322:-
PRAD	cis	rs684232	1	rs684232	MIMAT0004495	hsa-miR-22-5p	3.94	9.27e-05	0.16	0.18	Prostate cancer;	chr17:715725	chr17:1713952~1713973:-
PRAD	cis	rs74233809	0.892	rs11191447	MIMAT0005951	hsa-miR-1307-3p	-3.94	9.33e-05	-0.27	-0.18	Birth weight;	chr10:102892566	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs74233296	MIMAT0005951	hsa-miR-1307-3p	-3.94	9.33e-05	-0.27	-0.18	Birth weight;	chr10:102895593	chr10:103394301~103394322:-
PRAD	cis	rs990171	1	rs7597819	MIMAT0019927	hsa-miR-4772-3p	-3.94	9.43e-05	-0.24	-0.18	Lymphocyte counts;	chr2:102476447	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs17115213	MIMAT0022727	hsa-miR-1307-5p	-3.94	9.43e-05	-0.29	-0.18	Birth weight;	chr10:102921386	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs77602510	MIMAT0022727	hsa-miR-1307-5p	-3.94	9.43e-05	-0.29	-0.18	Birth weight;	chr10:102922845	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs78821730	MIMAT0022727	hsa-miR-1307-5p	-3.94	9.43e-05	-0.29	-0.18	Birth weight;	chr10:102924787	chr10:103394341~103394361:-
PRAD	cis	rs7594645	0.59	rs73068058	MIMAT0014995	hsa-miR-3130-5p	3.94	9.61e-05	0.36	0.18	Episodic memory;	chr2:206752613	chr2:206783276~206783296:-
PRAD	cis	rs7594645	0.59	rs73068058	MIMAT0014995_1	hsa-miR-3130-5p	3.94	9.61e-05	0.36	0.18	Episodic memory;	chr2:206752613	chr2:206783246~206783266:+
PRAD	cis	rs74233809	1	rs12221193	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.63e-05	-0.29	-0.18	Birth weight;	chr10:102905510	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs77180047	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.63e-05	-0.29	-0.18	Birth weight;	chr10:102907000	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12221064	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.63e-05	-0.29	-0.18	Birth weight;	chr10:102917369	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs10509759	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.84e-05	-0.29	-0.18	Birth weight;	chr10:102929908	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs5011520	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.84e-05	-0.29	-0.18	Birth weight;	chr10:102937759	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191472	MIMAT0022727	hsa-miR-1307-5p	-3.93	9.84e-05	-0.29	-0.18	Birth weight;	chr10:102947259	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.77	rs1061123	MIMAT0005878	hsa-miR-1287-5p	3.93	9.9e-05	0.19	0.18	Metabolite levels;	chr10:98417240	chr10:98395271~98395292:-
PRAD	cis	rs4918072	0.606	rs78381949	MIMAT0005951	hsa-miR-1307-3p	3.92	0.000101	0.16	0.18	Coronary artery disease;	chr10:103852660	chr10:103394301~103394322:-
PRAD	cis	rs7149242	0.5	rs10144381	MIMAT0001629	hsa-miR-329-3p	-3.92	0.000102	-0.23	-0.18	Platelet count;	chr14:100706960	chr14:101026834~101026855:+
PRAD	cis	rs7149242	0.5	rs10144381	MIMAT0001629_1	hsa-miR-329-3p	-3.92	0.000102	-0.23	-0.18	Platelet count;	chr14:100706960	chr14:101027151~101027172:+
PRAD	cis	rs11678825	0.683	rs74483911	MIMAT0031175	hsa-miR-548ba	-3.92	0.000103	-0.33	-0.18	Reticulocyte fraction of red cells;	chr2:48436480	chr2:49059603~49059624:+
PRAD	cis	rs1163656	0.559	rs1183656	MIMAT0003287	hsa-miR-618	3.92	0.000104	0.3	0.18	Dental caries;	chr12:80944131	chr12:80935796~80935818:-
PRAD	cis	rs74233809	1	rs74233809	MIMAT0022727	hsa-miR-1307-5p	-3.91	0.000105	-0.27	-0.18	Birth weight;	chr10:103154183	chr10:103394341~103394361:-
PRAD	cis	rs7209460	0.518	rs6503222	MIMAT0000426	hsa-miR-132-3p	3.91	0.000106	0.17	0.18	Coronary artery disease;Total body bone mineral density;	chr17:2074568	chr17:2049929~2049950:-
PRAD	cis	rs11678825	0.789	rs56088423	MIMAT0031175	hsa-miR-548ba	-3.91	0.000107	-0.33	-0.18	Reticulocyte fraction of red cells;	chr2:48452359	chr2:49059603~49059624:+
PRAD	cis	rs7851726	0.738	rs4744370	MIMAT0019208	hsa-miR-3074-5p	3.91	0.000107	0.16	0.18	Urinary albumin-to-creatinine ratio;	chr9:94715511	chr9:95086063~95086083:-
PRAD	cis	rs74233809	1	rs732998	MIMAT0022727	hsa-miR-1307-5p	3.91	0.000107	0.28	0.18	Birth weight;	chr10:103138144	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191575	MIMAT0022727	hsa-miR-1307-5p	-3.91	0.000107	-0.28	-0.18	Birth weight;	chr10:103138580	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs79993475	MIMAT0022727	hsa-miR-1307-5p	-3.91	0.000107	-0.28	-0.18	Birth weight;	chr10:103141274	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12220375	MIMAT0022727	hsa-miR-1307-5p	-3.91	0.000107	-0.28	-0.18	Birth weight;	chr10:103141734	chr10:103394341~103394361:-
PRAD	cis	rs2284932	0.875	rs1320929	MIMAT0016895	hsa-miR-2355-5p	3.91	0.000108	0.19	0.18	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207136098	chr2:207110043~207110063:-
PRAD	cis	rs7209460	0.556	rs2316513	MIMAT0000426	hsa-miR-132-3p	3.91	0.000108	0.18	0.18	Coronary artery disease;Total body bone mineral density;	chr17:2085083	chr17:2049929~2049950:-
PRAD	cis	rs944801	0.747	rs4977755	MIMAT0004504	hsa-miR-31-3p	-3.91	0.000108	-0.18	-0.18	Type 2 diabetes;	chr9:22066364	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.966	rs6475604	MIMAT0004504	hsa-miR-31-3p	-3.9	0.00011	-0.19	-0.18	Type 2 diabetes;	chr9:22052735	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.777	rs11678229	MIMAT0031175	hsa-miR-548ba	-3.9	0.00011	-0.41	-0.18	Reticulocyte fraction of red cells;	chr2:48283959	chr2:49059603~49059624:+
PRAD	cis	rs684232	0.901	rs461251	MIMAT0004495	hsa-miR-22-5p	3.9	0.000111	0.15	0.18	Prostate cancer;	chr17:715922	chr17:1713952~1713973:-
PRAD	cis	rs7594645	1	rs73985728	MIMAT0014995	hsa-miR-3130-5p	3.9	0.000111	0.43	0.18	Episodic memory;	chr2:206803521	chr2:206783276~206783296:-
PRAD	cis	rs7594645	1	rs73985728	MIMAT0014995_1	hsa-miR-3130-5p	3.9	0.000111	0.43	0.18	Episodic memory;	chr2:206803521	chr2:206783246~206783266:+
PRAD	cis	rs11678825	0.639	rs77134676	MIMAT0031175	hsa-miR-548ba	-3.9	0.000113	-0.3	-0.18	Reticulocyte fraction of red cells;	chr2:48440510	chr2:49059603~49059624:+
PRAD	cis	rs6011674	1	rs45469101	MIMAT0016888	hsa-miR-4326	-3.89	0.000113	-0.37	-0.18	Response to cytadine analogues (cytosine arabinoside);	chr20:63243655	chr20:63286818~63286837:+
PRAD	cis	rs7072216	0.587	rs3814141	MIMAT0026738	hsa-miR-1287-3p	3.89	0.000113	0.14	0.18	Metabolite levels;	chr10:98411271	chr10:98395232~98395253:-
PRAD	cis	rs4918072	0.797	rs7071685	MIMAT0005951	hsa-miR-1307-3p	3.89	0.000114	0.15	0.18	Coronary artery disease;	chr10:103936625	chr10:103394301~103394322:-
PRAD	cis	rs12712135	0.652	rs11465727	MIMAT0019927	hsa-miR-4772-3p	3.89	0.000116	0.19	0.18	Blood protein levels;	chr2:102448043	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs11465729	MIMAT0019927	hsa-miR-4772-3p	3.89	0.000116	0.19	0.18	Blood protein levels;	chr2:102448052	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs11465728	MIMAT0019927	hsa-miR-4772-3p	3.88	0.000119	0.19	0.18	Blood protein levels;	chr2:102448051	chr2:102432336~102432357:+
PRAD	cis	rs12712133	0.552	rs10200945	MIMAT0019927	hsa-miR-4772-3p	3.88	0.000119	0.21	0.18	Primary biliary cholangitis;	chr2:102268297	chr2:102432336~102432357:+
PRAD	cis	rs944801	1	rs944801	MIMAT0004504	hsa-miR-31-3p	-3.88	0.00012	-0.18	-0.18	Type 2 diabetes;	chr9:22051671	chr9:21512121~21512142:-
PRAD	cis	rs74233809	0.901	rs3824754	MIMAT0022727	hsa-miR-1307-5p	-3.88	0.00012	-0.28	-0.18	Birth weight;	chr10:102854593	chr10:103394341~103394361:-
PRAD	cis	rs7851726	1	rs943393	MIMAT0019208	hsa-miR-3074-5p	-3.88	0.00012	-0.16	-0.18	Urinary albumin-to-creatinine ratio;	chr9:94737144	chr9:95086063~95086083:-
PRAD	cis	rs4790312	0.513	rs9912609	MIMAT0000426	hsa-miR-132-3p	3.88	0.00012	0.19	0.18	Left atrial antero-posterior diameter;	chr17:2064326	chr17:2049929~2049950:-
PRAD	cis	rs7072216	0.77	rs1061115	MIMAT0005878	hsa-miR-1287-5p	3.88	0.000121	0.19	0.18	Metabolite levels;	chr10:98417292	chr10:98395271~98395292:-
PRAD	cis	rs2284932	1	rs2284932	MIMAT0016895	hsa-miR-2355-5p	3.88	0.000121	0.19	0.18	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;	chr2:207147785	chr2:207110043~207110063:-
PRAD	cis	rs1018697	1	rs10748830	MIMAT0022727	hsa-miR-1307-5p	3.88	0.000121	0.14	0.18	Colorectal adenoma (advanced);	chr10:102788625	chr10:103394341~103394361:-
PRAD	cis	rs990171	0.54	rs759381	MIMAT0019927	hsa-miR-4772-3p	-3.88	0.000122	-0.23	-0.18	Lymphocyte counts;	chr2:102477864	chr2:102432336~102432357:+
PRAD	cis	rs10454142	0.633	rs72818477	MIMAT0031175	hsa-miR-548ba	-3.87	0.000125	-0.27	-0.18	Sex hormone-binding globulin levels;	chr2:48268641	chr2:49059603~49059624:+
PRAD	cis	rs74233809	1	rs11191453	MIMAT0022727	hsa-miR-1307-5p	-3.87	0.000125	-0.28	-0.18	Birth weight;	chr10:102900095	chr10:103394341~103394361:-
PRAD	cis	rs2823615	1	rs11701525	MIMAT0000064	hsa-let-7c-5p	-3.87	0.000126	-0.16	-0.18	Obesity-related traits;	chr21:16101623	chr21:16539838~16539859:+
PRAD	cis	rs2823615	1	rs11701527	MIMAT0000064	hsa-let-7c-5p	-3.87	0.000126	-0.16	-0.18	Obesity-related traits;	chr21:16101667	chr21:16539838~16539859:+
PRAD	cis	rs1018697	1	rs7073114	MIMAT0022727	hsa-miR-1307-5p	3.87	0.000127	0.14	0.18	Colorectal adenoma (advanced);	chr10:102795894	chr10:103394341~103394361:-
PRAD	cis	rs17027258	0.609	rs4851005	MIMAT0019926	hsa-miR-4772-5p	3.86	0.000129	0.2	0.18	White blood cell types;	chr2:102395092	chr2:102432300~102432321:+
PRAD	cis	rs74233809	0.892	rs11191447	MIMAT0022727	hsa-miR-1307-5p	-3.86	0.00013	-0.28	-0.18	Birth weight;	chr10:102892566	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs74233296	MIMAT0022727	hsa-miR-1307-5p	-3.86	0.00013	-0.28	-0.18	Birth weight;	chr10:102895593	chr10:103394341~103394361:-
PRAD	cis	rs7851726	1	rs446540	MIMAT0019208	hsa-miR-3074-5p	-3.86	0.00013	-0.16	-0.18	Urinary albumin-to-creatinine ratio;	chr9:94746917	chr9:95086063~95086083:-
PRAD	cis	rs2277912	1	rs72957112	MIMAT0014995	hsa-miR-3130-5p	3.85	0.000134	0.27	0.18	Height;	chr2:206830729	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs72957112	MIMAT0014995_1	hsa-miR-3130-5p	3.85	0.000134	0.27	0.18	Height;	chr2:206830729	chr2:206783246~206783266:+
PRAD	cis	rs74233809	1	rs10883806	MIMAT0022727	hsa-miR-1307-5p	-3.85	0.000135	-0.28	-0.18	Birth weight;	chr10:102953319	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs10883808	MIMAT0022727	hsa-miR-1307-5p	-3.85	0.000135	-0.28	-0.18	Birth weight;	chr10:102961369	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs78260931	MIMAT0022727	hsa-miR-1307-5p	-3.85	0.000135	-0.28	-0.18	Birth weight;	chr10:102962205	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191479	MIMAT0022727	hsa-miR-1307-5p	-3.85	0.000135	-0.28	-0.18	Birth weight;	chr10:102963863	chr10:103394341~103394361:-
PRAD	cis	rs7536201	0.524	rs7527098	MIMAT0018191	hsa-miR-3917	-3.84	0.000138	-0.23	-0.18	Psoriasis vulgaris;	chr1:24958175	chr1:25906384~25906403:-
PRAD	cis	rs2257205	0.667	rs8070407	MIMAT0000433	hsa-miR-142-5p	3.84	0.000139	0.18	0.18	Pancreatic cancer;	chr17:58631811	chr17:58331283~58331303:-
PRAD	cis	rs684232	0.901	rs450289	MIMAT0004495	hsa-miR-22-5p	-3.84	0.000139	-0.15	-0.18	Prostate cancer;	chr17:726656	chr17:1713952~1713973:-
PRAD	cis	rs216303	1	rs216299	MIMAT0000617	hsa-miR-200c-3p	3.84	0.00014	0.19	0.18	Low vWF levels;	chr12:6047469	chr12:6963742~6963764:+
PRAD	cis	rs74233809	0.901	rs3824754	MIMAT0005951	hsa-miR-1307-3p	-3.84	0.000141	-0.26	-0.18	Birth weight;	chr10:102854593	chr10:103394301~103394322:-
PRAD	cis	rs7536201	0.5	rs6600245	MIMAT0018191	hsa-miR-3917	-3.84	0.000141	-0.23	-0.18	Psoriasis vulgaris;	chr1:24958187	chr1:25906384~25906403:-
PRAD	cis	rs2277912	0.762	rs72960734	MIMAT0014995	hsa-miR-3130-5p	3.84	0.000143	0.25	0.18	Height;	chr2:206713279	chr2:206783276~206783296:-
PRAD	cis	rs2277912	0.762	rs72960734	MIMAT0014995_1	hsa-miR-3130-5p	3.84	0.000143	0.25	0.18	Height;	chr2:206713279	chr2:206783246~206783266:+
PRAD	cis	rs4918072	0.637	rs61861137	MIMAT0005951	hsa-miR-1307-3p	3.83	0.000143	0.15	0.18	Coronary artery disease;	chr10:103853625	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.901	rs7098825	MIMAT0022727	hsa-miR-1307-5p	-3.83	0.000144	-0.26	-0.18	Birth weight;	chr10:102868477	chr10:103394341~103394361:-
PRAD	cis	rs1018697	0.966	rs10748832	MIMAT0022727	hsa-miR-1307-5p	3.83	0.000144	0.14	0.18	Colorectal adenoma (advanced);	chr10:102808723	chr10:103394341~103394361:-
PRAD	cis	rs7503807	0.664	rs8068637	MIMAT0015066	hsa-miR-3065-5p	3.83	0.000145	0.2	0.18	Obesity;	chr17:80640670	chr17:81125886~81125908:+
PRAD	cis	rs1018697	0.761	rs7904281	MIMAT0022727	hsa-miR-1307-5p	3.83	0.000145	0.14	0.18	Colorectal adenoma (advanced);	chr10:102785079	chr10:103394341~103394361:-
PRAD	cis	rs990171	0.566	rs1523198	MIMAT0019927	hsa-miR-4772-3p	-3.83	0.000145	-0.2	-0.18	Lymphocyte counts;	chr2:102482015	chr2:102432336~102432357:+
PRAD	cis	rs4790312	0.875	rs9303241	MIMAT0000426	hsa-miR-132-3p	3.83	0.000147	0.17	0.18	Left atrial antero-posterior diameter;	chr17:2075669	chr17:2049929~2049950:-
PRAD	cis	rs7503807	0.688	rs7503186	MIMAT0015066	hsa-miR-3065-5p	3.83	0.000148	0.21	0.18	Obesity;	chr17:80616672	chr17:81125886~81125908:+
PRAD	cis	rs9290936	0.572	rs16865566	MIMAT0004987	hsa-miR-944	3.83	0.000148	0.35	0.18	Waist circumference;	chr3:190535164	chr3:189829975~189829996:+
PRAD	cis	rs12712133	0.552	rs11123915	MIMAT0019927	hsa-miR-4772-3p	3.82	0.000149	0.2	0.18	Primary biliary cholangitis;	chr2:102264363	chr2:102432336~102432357:+
PRAD	cis	rs4918072	0.637	rs61861138	MIMAT0005951	hsa-miR-1307-3p	3.82	0.00015	0.15	0.18	Coronary artery disease;	chr10:103853659	chr10:103394301~103394322:-
PRAD	cis	rs7142002	0.568	rs3783370	MIMAT0001621	hsa-miR-369-5p	-3.82	0.00015	-0.23	-0.18	Autism;	chr14:101919120	chr14:101065606~101065627:+
PRAD	cis	rs4790312	0.782	rs4790310	MIMAT0000426	hsa-miR-132-3p	3.82	0.000151	0.17	0.18	Left atrial antero-posterior diameter;	chr17:2063626	chr17:2049929~2049950:-
PRAD	cis	rs1018697	0.897	rs2150929	MIMAT0022727	hsa-miR-1307-5p	3.82	0.000151	0.14	0.18	Colorectal adenoma (advanced);	chr10:102791180	chr10:103394341~103394361:-
PRAD	cis	rs145929329	1	rs145929329	MIMAT0004504	hsa-miR-31-3p	-3.82	0.000152	-0.17	-0.18	Glioblastoma;	chr9:22066214	chr9:21512121~21512142:-
PRAD	cis	rs216303	0.63	rs4764533	MIMAT0000617	hsa-miR-200c-3p	3.82	0.000152	0.19	0.18	Low vWF levels;	chr12:6051578	chr12:6963742~6963764:+
PRAD	cis	rs7894407	0.522	rs2274341	MIMAT0005951	hsa-miR-1307-3p	3.81	0.000156	0.16	0.18	White matter hyperintensity burden;	chr10:103093746	chr10:103394301~103394322:-
PRAD	cis	rs34198350	0.751	rs78399617	MIMAT0031175	hsa-miR-548ba	-3.81	0.000157	-0.37	-0.18	QT interval in Tripanosoma cruzi seropositivity;	chr2:48092036	chr2:49059603~49059624:+
PRAD	cis	rs12541595	0.808	rs10105974	MIMAT0019731	hsa-miR-4662a-5p	3.81	0.000157	0.18	0.18	Left ventricle diastolic internal dimension;	chr8:124842273	chr8:124821990~124822011:+
PRAD	cis	rs8008758	0.517	rs1772028	MIMAT0002813	hsa-miR-493-5p	3.81	0.000157	0.15	0.18	Body mass index (alcohol intake interaction);	chr14:101227524	chr14:100869075~100869096:+
PRAD	cis	rs7072216	0.77	rs3830020	MIMAT0005878	hsa-miR-1287-5p	-3.81	0.000158	-0.18	-0.18	Metabolite levels;	chr10:98416858	chr10:98395271~98395292:-
PRAD	cis	rs12712133	0.514	rs10188022	MIMAT0019927	hsa-miR-4772-3p	3.81	0.000158	0.2	0.18	Primary biliary cholangitis;	chr2:102258406	chr2:102432336~102432357:+
PRAD	cis	rs7851726	1	rs7851726	MIMAT0019208	hsa-miR-3074-5p	-3.81	0.00016	-0.16	-0.18	Urinary albumin-to-creatinine ratio;	chr9:94741703	chr9:95086063~95086083:-
PRAD	cis	rs944801	0.966	rs7030641	MIMAT0004504	hsa-miR-31-3p	-3.81	0.00016	-0.18	-0.18	Type 2 diabetes;	chr9:22054041	chr9:21512121~21512142:-
PRAD	cis	rs2823615	0.926	rs11908735	MIMAT0000064	hsa-let-7c-5p	-3.81	0.000161	-0.15	-0.18	Obesity-related traits;	chr21:16104686	chr21:16539838~16539859:+
PRAD	cis	rs7851726	1	rs183066	MIMAT0019208	hsa-miR-3074-5p	-3.8	0.000162	-0.16	-0.18	Urinary albumin-to-creatinine ratio;	chr9:94755150	chr9:95086063~95086083:-
PRAD	cis	rs7851726	0.934	rs368138	MIMAT0019208	hsa-miR-3074-5p	-3.8	0.000162	-0.16	-0.18	Urinary albumin-to-creatinine ratio;	chr9:94761301	chr9:95086063~95086083:-
PRAD	cis	rs2823615	1	rs2823603	MIMAT0000064	hsa-let-7c-5p	-3.8	0.000162	-0.15	-0.18	Obesity-related traits;	chr21:16080746	chr21:16539838~16539859:+
PRAD	cis	rs990171	1	rs4851575	MIMAT0019927	hsa-miR-4772-3p	-3.8	0.000164	-0.22	-0.18	Lymphocyte counts;	chr2:102408743	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs11465730	MIMAT0019927	hsa-miR-4772-3p	3.8	0.000166	0.19	0.18	Blood protein levels;	chr2:102450398	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs1035127	MIMAT0019927	hsa-miR-4772-3p	3.8	0.000166	0.22	0.18	Lymphocyte counts;	chr2:102403459	chr2:102432336~102432357:+
PRAD	cis	rs12541595	0.836	rs6980573	MIMAT0019731	hsa-miR-4662a-5p	-3.79	0.000169	-0.18	-0.18	Left ventricle diastolic internal dimension;	chr8:124840111	chr8:124821990~124822011:+
PRAD	cis	rs7026071	1	rs7026071	MIMAT0019208	hsa-miR-3074-5p	-3.79	0.000169	-0.16	-0.18	Atrial fibrillation;	chr9:94730238	chr9:95086063~95086083:-
PRAD	cis	rs6537837	0.762	rs6691984	MIMAT0000227	hsa-miR-197-3p	-3.79	0.000169	-0.15	-0.18	Major depressive disorder;	chr1:109601402	chr1:109598940~109598961:+
PRAD	cis	rs8064299	0.655	rs734232	MIMAT0017994	hsa-miR-3615	-3.79	0.00017	-0.22	-0.18	Monocyte count;	chr17:74769592	chr17:74748663~74748683:+
PRAD	cis	rs1018697	1	rs7896903	MIMAT0022727	hsa-miR-1307-5p	3.79	0.000172	0.14	0.18	Colorectal adenoma (advanced);	chr10:102806660	chr10:103394341~103394361:-
PRAD	cis	rs4918072	0.716	rs2902638	MIMAT0005951	hsa-miR-1307-3p	3.79	0.000173	0.15	0.18	Coronary artery disease;	chr10:103877231	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.695	rs759382	MIMAT0019927	hsa-miR-4772-3p	-3.78	0.000179	-0.22	-0.17	Lymphocyte counts;	chr2:102477754	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.652	rs11189600	MIMAT0005878	hsa-miR-1287-5p	-3.78	0.00018	-0.19	-0.17	Metabolite levels;	chr10:98419517	chr10:98395271~98395292:-
PRAD	cis	rs421490	1	rs411654	MIMAT0004557	hsa-miR-34a-3p	3.77	0.000182	0.3	0.17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr1:8214747	chr1:9151693~9151714:-
PRAD	cis	rs944801	0.776	rs2184061	MIMAT0004504	hsa-miR-31-3p	-3.77	0.000183	-0.17	-0.17	Type 2 diabetes;	chr9:22061563	chr9:21512121~21512142:-
PRAD	cis	rs4790312	0.819	rs4061659	MIMAT0000426	hsa-miR-132-3p	3.77	0.000184	0.16	0.17	Left atrial antero-posterior diameter;	chr17:2094150	chr17:2049929~2049950:-
PRAD	cis	rs7072216	0.77	rs1737	MIMAT0026738	hsa-miR-1287-3p	3.77	0.000186	0.12	0.17	Metabolite levels;	chr10:98416609	chr10:98395232~98395253:-
PRAD	cis	rs9290936	0.572	rs11921538	MIMAT0004987	hsa-miR-944	3.77	0.000186	0.33	0.17	Waist circumference;	chr3:190536592	chr3:189829975~189829996:+
PRAD	cis	rs7149242	0.697	rs12882815	MIMAT0001629	hsa-miR-329-3p	3.77	0.000188	0.22	0.17	Platelet count;	chr14:100716805	chr14:101026834~101026855:+
PRAD	cis	rs7149242	0.697	rs12882815	MIMAT0001629_1	hsa-miR-329-3p	3.77	0.000188	0.22	0.17	Platelet count;	chr14:100716805	chr14:101027151~101027172:+
PRAD	cis	rs12765878	0.58	rs11191839	MIMAT0005951	hsa-miR-1307-3p	-3.76	0.00019	-0.13	-0.17	Coronary artery disease;	chr10:103875137	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.58	rs11191840	MIMAT0005951	hsa-miR-1307-3p	-3.76	0.00019	-0.13	-0.17	Coronary artery disease;	chr10:103875138	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.838	rs1063192	MIMAT0004504	hsa-miR-31-3p	-3.76	0.00019	-0.17	-0.17	Type 2 diabetes;	chr9:22003368	chr9:21512121~21512142:-
PRAD	cis	rs12765878	0.58	rs4918058	MIMAT0005951	hsa-miR-1307-3p	-3.76	0.000191	-0.13	-0.17	Coronary artery disease;	chr10:103836883	chr10:103394301~103394322:-
PRAD	cis	rs977145	0.721	rs6682125	MIMAT0000456	hsa-miR-186-5p	3.76	0.000195	0.13	0.17	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);	chr1:71361839	chr1:71067681~71067702:-
PRAD	cis	rs1018697	1	rs10786710	MIMAT0022727	hsa-miR-1307-5p	3.76	0.000195	0.14	0.17	Colorectal adenoma (advanced);	chr10:102788982	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191531	MIMAT0022727	hsa-miR-1307-5p	-3.75	0.000198	-0.28	-0.17	Birth weight;	chr10:103047141	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12219027	MIMAT0022727	hsa-miR-1307-5p	-3.75	0.000198	-0.28	-0.17	Birth weight;	chr10:103051446	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs11191543	MIMAT0022727	hsa-miR-1307-5p	-3.75	0.000198	-0.28	-0.17	Birth weight;	chr10:103064630	chr10:103394341~103394361:-
PRAD	cis	rs12765878	0.729	rs12573103	MIMAT0005951	hsa-miR-1307-3p	3.75	0.000199	0.12	0.17	Coronary artery disease;	chr10:103879483	chr10:103394301~103394322:-
PRAD	cis	rs74233809	1	rs35125602	MIMAT0022727	hsa-miR-1307-5p	-3.75	2e-04	-0.27	-0.17	Birth weight;	chr10:102896282	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs2150928	MIMAT0022727	hsa-miR-1307-5p	3.75	2e-04	0.14	0.17	Colorectal adenoma (advanced);	chr10:102791228	chr10:103394341~103394361:-
PRAD	cis	rs977145	0.812	rs72674979	MIMAT0000456	hsa-miR-186-5p	3.75	0.000203	0.14	0.17	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);	chr1:71432373	chr1:71067681~71067702:-
PRAD	cis	rs4790312	0.729	rs9906546	MIMAT0000426	hsa-miR-132-3p	3.74	0.000204	0.16	0.17	Left atrial antero-posterior diameter;	chr17:2092320	chr17:2049929~2049950:-
PRAD	cis	rs7503807	0.837	rs9915667	MIMAT0015066	hsa-miR-3065-5p	-3.74	0.000204	-0.2	-0.17	Obesity;	chr17:80780540	chr17:81125886~81125908:+
PRAD	cis	rs1018697	1	rs7909612	MIMAT0022727	hsa-miR-1307-5p	3.74	0.000205	0.13	0.17	Colorectal adenoma (advanced);	chr10:102801699	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs7092346	MIMAT0022727	hsa-miR-1307-5p	3.74	0.000206	0.13	0.17	Colorectal adenoma (advanced);	chr10:102800007	chr10:103394341~103394361:-
PRAD	cis	rs16952006	0.568	rs55815331	MIMAT0000269	hsa-miR-212-3p	3.74	0.000209	0.25	0.17	Breast cancer;	chr17:2042400	chr17:2050290~2050310:-
PRAD	cis	rs6011674	0.666	rs111590347	MIMAT0016888	hsa-miR-4326	-3.74	0.00021	-0.33	-0.17	Response to cytadine analogues (cytosine arabinoside);	chr20:63168107	chr20:63286818~63286837:+
PRAD	cis	rs684232	0.897	rs1237094	MIMAT0004495	hsa-miR-22-5p	3.73	0.000212	0.15	0.17	Prostate cancer;	chr17:716602	chr17:1713952~1713973:-
PRAD	cis	rs9663711	1	rs9663711	MIMAT0022727	hsa-miR-1307-5p	3.73	0.000212	0.14	0.17	Carotid plaque burden;	chr10:102787871	chr10:103394341~103394361:-
PRAD	cis	rs79600951	1	rs59542880	MIMAT0000430	hsa-miR-138-5p	3.73	0.000212	0.32	0.17	HDL cholesterol;	chr16:56814959	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs59542880	MIMAT0000430_1	hsa-miR-138-5p	3.73	0.000212	0.32	0.17	HDL cholesterol;	chr16:56814959	chr3:44114234~44114256:+
PRAD	cis	rs74233809	0.901	rs17115100	MIMAT0005951	hsa-miR-1307-3p	-3.73	0.000215	-0.24	-0.17	Birth weight;	chr10:102831636	chr10:103394301~103394322:-
PRAD	cis	rs11678825	0.733	rs55707610	MIMAT0031175	hsa-miR-548ba	-3.73	0.000216	-0.31	-0.17	Reticulocyte fraction of red cells;	chr2:48452676	chr2:49059603~49059624:+
PRAD	cis	rs7503807	0.688	rs12952285	MIMAT0015066	hsa-miR-3065-5p	-3.73	0.000216	-0.2	-0.17	Obesity;	chr17:80622358	chr17:81125886~81125908:+
PRAD	cis	rs4889855	0.53	rs78550371	MIMAT0015066	hsa-miR-3065-5p	-3.73	0.000217	-0.23	-0.17	Fractional excretion of uric acid;	chr17:80760286	chr17:81125886~81125908:+
PRAD	cis	rs74233809	1	rs3740390	MIMAT0022727	hsa-miR-1307-5p	-3.73	0.000217	-0.27	-0.17	Birth weight;	chr10:102878723	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.881	rs2147896	MIMAT0005878	hsa-miR-1287-5p	3.73	0.000218	0.19	0.17	Metabolite levels;	chr10:98388419	chr10:98395271~98395292:-
PRAD	cis	rs421490	1	rs421490	MIMAT0004557	hsa-miR-34a-3p	3.73	0.00022	0.3	0.17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr1:8215224	chr1:9151693~9151714:-
PRAD	cis	rs4918072	0.753	rs1114994	MIMAT0005951	hsa-miR-1307-3p	3.72	0.000221	0.14	0.17	Coronary artery disease;	chr10:103949792	chr10:103394301~103394322:-
PRAD	cis	rs12712133	0.552	rs1115281	MIMAT0019927	hsa-miR-4772-3p	3.72	0.000222	0.2	0.17	Primary biliary cholangitis;	chr2:102274647	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.621	rs3750605	MIMAT0026738	hsa-miR-1287-3p	3.72	0.000223	0.14	0.17	Metabolite levels;	chr10:98415897	chr10:98395232~98395253:-
PRAD	cis	rs990171	0.538	rs1403548	MIMAT0019927	hsa-miR-4772-3p	-3.72	0.000224	-0.2	-0.17	Lymphocyte counts;	chr2:102493916	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs7591878	MIMAT0019927	hsa-miR-4772-3p	-3.72	0.000224	-0.2	-0.17	Lymphocyte counts;	chr2:102496199	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs11123934	MIMAT0019927	hsa-miR-4772-3p	-3.72	0.000224	-0.2	-0.17	Lymphocyte counts;	chr2:102499109	chr2:102432336~102432357:+
PRAD	cis	rs17730929	0.659	rs1033095	MIMAT0005923	hsa-miR-1269a	3.72	0.000225	0.35	0.17	Colorectal cancer (SNP x SNP interaction);	chr4:66366293	chr4:66276890~66276911:+
PRAD	cis	rs7536201	0.5	rs1848186	MIMAT0018191	hsa-miR-3917	-3.72	0.000226	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956365	chr1:25906384~25906403:-
PRAD	cis	rs74233809	1	rs11191454	MIMAT0022727	hsa-miR-1307-5p	-3.72	0.000226	-0.27	-0.17	Birth weight;	chr10:102900247	chr10:103394341~103394361:-
PRAD	cis	rs7072216	0.922	rs4488133	MIMAT0005878	hsa-miR-1287-5p	-3.72	0.000227	-0.19	-0.17	Metabolite levels;	chr10:98399379	chr10:98395271~98395292:-
PRAD	cis	rs7503807	0.688	rs901061	MIMAT0015066	hsa-miR-3065-5p	3.72	0.000228	0.2	0.17	Obesity;	chr17:80621528	chr17:81125886~81125908:+
PRAD	cis	rs7503807	0.688	rs901062	MIMAT0015066	hsa-miR-3065-5p	3.72	0.000228	0.2	0.17	Obesity;	chr17:80621874	chr17:81125886~81125908:+
PRAD	cis	rs1018697	0.966	rs10748831	MIMAT0022727	hsa-miR-1307-5p	3.71	0.00023	0.13	0.17	Colorectal adenoma (advanced);	chr10:102798986	chr10:103394341~103394361:-
PRAD	cis	rs7536201	0.5	rs1848185	MIMAT0018191	hsa-miR-3917	-3.71	0.00023	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956470	chr1:25906384~25906403:-
PRAD	cis	rs7536201	0.5	rs11249207	MIMAT0018191	hsa-miR-3917	-3.71	0.00023	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956578	chr1:25906384~25906403:-
PRAD	cis	rs7536201	0.5	rs11249208	MIMAT0018191	hsa-miR-3917	-3.71	0.00023	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956635	chr1:25906384~25906403:-
PRAD	cis	rs7536201	0.524	rs10903116	MIMAT0018191	hsa-miR-3917	-3.71	0.00023	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956671	chr1:25906384~25906403:-
PRAD	cis	rs1018697	1	rs1018696	MIMAT0022727	hsa-miR-1307-5p	3.71	0.000231	0.13	0.17	Colorectal adenoma (advanced);	chr10:102789309	chr10:103394341~103394361:-
PRAD	cis	rs1018697	0.966	rs11191396	MIMAT0022727	hsa-miR-1307-5p	3.71	0.000231	0.13	0.17	Colorectal adenoma (advanced);	chr10:102793108	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs4919678	MIMAT0022727	hsa-miR-1307-5p	3.71	0.000231	0.13	0.17	Colorectal adenoma (advanced);	chr10:102794606	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs11191397	MIMAT0022727	hsa-miR-1307-5p	3.71	0.000231	0.13	0.17	Colorectal adenoma (advanced);	chr10:102798517	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs7092051	MIMAT0022727	hsa-miR-1307-5p	3.71	0.000231	0.13	0.17	Colorectal adenoma (advanced);	chr10:102799720	chr10:103394341~103394361:-
PRAD	cis	rs990171	1	rs3860444	MIMAT0019927	hsa-miR-4772-3p	-3.71	0.000234	-0.22	-0.17	Lymphocyte counts;	chr2:102391163	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs12712145	MIMAT0019927	hsa-miR-4772-3p	-3.71	0.000234	-0.22	-0.17	Lymphocyte counts;	chr2:102392250	chr2:102432336~102432357:+
PRAD	cis	rs17428041	0.521	rs13255951	MIMAT0000510	hsa-miR-320a-3p	3.71	0.000235	0.13	0.17	Neuropathic pain in type 2 diabetes;	chr8:21865487	chr8:22244975~22244996:-
PRAD	cis	rs17730929	0.591	rs7676695	MIMAT0005923	hsa-miR-1269a	-3.71	0.000235	-0.35	-0.17	Colorectal cancer (SNP x SNP interaction);	chr4:66365085	chr4:66276890~66276911:+
PRAD	cis	rs4790312	0.513	rs12939002	MIMAT0000426	hsa-miR-132-3p	3.71	0.000237	0.19	0.17	Left atrial antero-posterior diameter;	chr17:2061802	chr17:2049929~2049950:-
PRAD	cis	rs12765878	0.58	rs67764572	MIMAT0005951	hsa-miR-1307-3p	-3.7	0.000239	-0.13	-0.17	Coronary artery disease;	chr10:103836249	chr10:103394301~103394322:-
PRAD	cis	rs16952006	0.614	rs1051322	MIMAT0000269	hsa-miR-212-3p	3.7	0.000239	0.23	0.17	Breast cancer;	chr17:2043209	chr17:2050290~2050310:-
PRAD	cis	rs7536201	0.524	rs12031692	MIMAT0018191	hsa-miR-3917	-3.7	0.000241	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956783	chr1:25906384~25906403:-
PRAD	cis	rs74233809	0.901	rs17878846	MIMAT0005951	hsa-miR-1307-3p	-3.7	0.000242	-0.24	-0.17	Birth weight;	chr10:102870655	chr10:103394301~103394322:-
PRAD	cis	rs1018697	1	rs7911528	MIMAT0022727	hsa-miR-1307-5p	3.7	0.000242	0.13	0.17	Colorectal adenoma (advanced);	chr10:102791810	chr10:103394341~103394361:-
PRAD	cis	rs990171	0.687	rs2005881	MIMAT0019927	hsa-miR-4772-3p	-3.7	0.000243	-0.22	-0.17	Lymphocyte counts;	chr2:102556600	chr2:102432336~102432357:+
PRAD	cis	rs1018697	1	rs6584525	MIMAT0022727	hsa-miR-1307-5p	3.7	0.000244	0.13	0.17	Colorectal adenoma (advanced);	chr10:102792224	chr10:103394341~103394361:-
PRAD	cis	rs1018697	1	rs7086400	MIMAT0022727	hsa-miR-1307-5p	3.69	0.000249	0.13	0.17	Colorectal adenoma (advanced);	chr10:102802340	chr10:103394341~103394361:-
PRAD	cis	rs4790312	0.513	rs12451211	MIMAT0000426	hsa-miR-132-3p	-3.69	0.00025	-0.18	-0.17	Left atrial antero-posterior diameter;	chr17:2062248	chr17:2049929~2049950:-
PRAD	cis	rs990171	0.913	rs6543132	MIMAT0019927	hsa-miR-4772-3p	-3.69	0.000251	-0.22	-0.17	Lymphocyte counts;	chr2:102412950	chr2:102432336~102432357:+
PRAD	cis	rs4918072	0.883	rs1418317	MIMAT0005951	hsa-miR-1307-3p	3.69	0.000253	0.14	0.17	Coronary artery disease;	chr10:103936142	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.922	rs4539242	MIMAT0005878	hsa-miR-1287-5p	3.69	0.000253	0.19	0.17	Metabolite levels;	chr10:98388301	chr10:98395271~98395292:-
PRAD	cis	rs990171	1	rs1807782	MIMAT0019927	hsa-miR-4772-3p	-3.69	0.000254	-0.22	-0.17	Lymphocyte counts;	chr2:102416687	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs3755268	MIMAT0019927	hsa-miR-4772-3p	-3.69	0.000254	-0.22	-0.17	Lymphocyte counts;	chr2:102422067	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.677	rs6705385	MIMAT0019927	hsa-miR-4772-3p	3.68	0.000256	0.18	0.17	Blood protein levels;	chr2:102460109	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs12463588	MIMAT0019927	hsa-miR-4772-3p	3.68	0.000256	0.18	0.17	Blood protein levels;	chr2:102468797	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs2310302	MIMAT0019927	hsa-miR-4772-3p	3.68	0.000256	0.18	0.17	Blood protein levels;	chr2:102469589	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs10195075	MIMAT0019927	hsa-miR-4772-3p	3.68	0.000256	0.18	0.17	Blood protein levels;	chr2:102471192	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs1403553	MIMAT0019927	hsa-miR-4772-3p	3.68	0.000256	0.18	0.17	Blood protein levels;	chr2:102471202	chr2:102432336~102432357:+
PRAD	cis	rs2236553	1	rs2236553	MIMAT0016888	hsa-miR-4326	-3.68	0.000257	-0.21	-0.17	Menopause (age at onset);	chr20:62658391	chr20:63286818~63286837:+
PRAD	cis	rs6011674	1	rs41282998	MIMAT0016888	hsa-miR-4326	-3.68	0.000257	-0.35	-0.17	Response to cytadine analogues (cytosine arabinoside);	chr20:63244161	chr20:63286818~63286837:+
PRAD	cis	rs941853	0.85	rs3802734	MIMAT0010133	hsa-miR-2110	-3.68	0.000257	-0.23	-0.17	Obesity-related traits;	chr10:114434451	chr10:114174151~114174172:-
PRAD	cis	rs7594645	1	rs7594645	MIMAT0014995	hsa-miR-3130-5p	3.68	0.000258	0.39	0.17	Episodic memory;	chr2:206781950	chr2:206783276~206783296:-
PRAD	cis	rs7594645	1	rs7594645	MIMAT0014995_1	hsa-miR-3130-5p	3.68	0.000258	0.39	0.17	Episodic memory;	chr2:206781950	chr2:206783246~206783266:+
PRAD	cis	rs990171	1	rs2270297	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102376215	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6753717	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102376701	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs6750020	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102378254	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.913	rs6729638	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102379562	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs3755274	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102385935	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.913	rs2241117	MIMAT0019927	hsa-miR-4772-3p	-3.68	0.00026	-0.22	-0.17	Lymphocyte counts;	chr2:102386583	chr2:102432336~102432357:+
PRAD	cis	rs1163656	0.605	rs7487519	MIMAT0003287	hsa-miR-618	-3.68	0.00026	-0.22	-0.17	Dental caries;	chr12:80921469	chr12:80935796~80935818:-
PRAD	cis	rs1163656	0.572	rs7303026	MIMAT0003287	hsa-miR-618	-3.68	0.00026	-0.22	-0.17	Dental caries;	chr12:80921967	chr12:80935796~80935818:-
PRAD	cis	rs1163656	0.572	rs7134652	MIMAT0003287	hsa-miR-618	-3.68	0.00026	-0.22	-0.17	Dental caries;	chr12:80922054	chr12:80935796~80935818:-
PRAD	cis	rs1163656	0.572	rs7134827	MIMAT0003287	hsa-miR-618	-3.68	0.00026	-0.22	-0.17	Dental caries;	chr12:80922229	chr12:80935796~80935818:-
PRAD	cis	rs7894407	0.634	rs755577	MIMAT0022727	hsa-miR-1307-5p	3.68	0.00026	0.15	0.17	White matter hyperintensity burden;	chr10:103464309	chr10:103394341~103394361:-
PRAD	cis	rs7536201	0.5	rs4288539	MIMAT0018191	hsa-miR-3917	-3.68	0.000262	-0.22	-0.17	Psoriasis vulgaris;	chr1:24956502	chr1:25906384~25906403:-
PRAD	cis	rs1163656	0.572	rs1402349	MIMAT0003287	hsa-miR-618	-3.68	0.000263	-0.22	-0.17	Dental caries;	chr12:80919985	chr12:80935796~80935818:-
PRAD	cis	rs4918072	0.793	rs7074532	MIMAT0005951	hsa-miR-1307-3p	3.68	0.000265	0.14	0.17	Coronary artery disease;	chr10:103942284	chr10:103394301~103394322:-
PRAD	cis	rs4918072	0.753	rs36069350	MIMAT0005951	hsa-miR-1307-3p	3.68	0.000265	0.14	0.17	Coronary artery disease;	chr10:103943075	chr10:103394301~103394322:-
PRAD	cis	rs4918072	0.793	rs4615949	MIMAT0005951	hsa-miR-1307-3p	3.68	0.000265	0.14	0.17	Coronary artery disease;	chr10:103944853	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.605	rs999867	MIMAT0005951	hsa-miR-1307-3p	-3.68	0.000265	-0.24	-0.17	Birth weight;	chr10:102744807	chr10:103394301~103394322:-
PRAD	cis	rs1018697	0.966	rs1953930	MIMAT0022727	hsa-miR-1307-5p	3.67	0.00027	0.13	0.17	Colorectal adenoma (advanced);	chr10:102789704	chr10:103394341~103394361:-
PRAD	cis	rs74233809	0.901	rs3824755	MIMAT0005951	hsa-miR-1307-3p	-3.67	0.000271	-0.22	-0.17	Birth weight;	chr10:102836092	chr10:103394301~103394322:-
PRAD	cis	rs4790312	0.748	rs4790873	MIMAT0000426	hsa-miR-132-3p	3.67	0.000273	0.16	0.17	Left atrial antero-posterior diameter;	chr17:2091672	chr17:2049929~2049950:-
PRAD	cis	rs4918072	0.793	rs12784155	MIMAT0005951	hsa-miR-1307-3p	3.67	0.000274	0.14	0.17	Coronary artery disease;	chr10:103948552	chr10:103394301~103394322:-
PRAD	cis	rs2307449	0.929	rs1981623	MIMAT0000252	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263479	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs1981623	MIMAT0000252_1	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263479	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs1981623	MIMAT0000252_2	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263479	chr9:83969811~83969834:-
PRAD	cis	rs2307449	0.892	rs1981624	MIMAT0000252	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263490	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.892	rs1981624	MIMAT0000252_1	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263490	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.892	rs1981624	MIMAT0000252_2	hsa-miR-7-5p	-3.67	0.000275	-0.2	-0.17	Menopause (age at onset);	chr15:89263490	chr9:83969811~83969834:-
PRAD	cis	rs11678825	0.852	rs79691009	MIMAT0031175	hsa-miR-548ba	-3.66	0.000278	-0.38	-0.17	Reticulocyte fraction of red cells;	chr2:48271959	chr2:49059603~49059624:+
PRAD	cis	rs1018697	1	rs4919677	MIMAT0022727	hsa-miR-1307-5p	3.66	0.000279	0.13	0.17	Colorectal adenoma (advanced);	chr10:102794547	chr10:103394341~103394361:-
PRAD	cis	rs7851726	1	rs414253	MIMAT0019208	hsa-miR-3074-5p	-3.66	0.000279	-0.15	-0.17	Urinary albumin-to-creatinine ratio;	chr9:94724740	chr9:95086063~95086083:-
PRAD	cis	rs1163656	0.572	rs1402348	MIMAT0003287	hsa-miR-618	-3.66	0.000279	-0.21	-0.17	Dental caries;	chr12:80919695	chr12:80935796~80935818:-
PRAD	cis	rs990171	1	rs2272129	MIMAT0019927	hsa-miR-4772-3p	-3.66	0.000281	-0.21	-0.17	Lymphocyte counts;	chr2:102423789	chr2:102432336~102432357:+
PRAD	cis	rs12765878	0.58	rs55983834	MIMAT0005951	hsa-miR-1307-3p	-3.66	0.000282	-0.13	-0.17	Coronary artery disease;	chr10:103841452	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.675	rs3752946	MIMAT0005951	hsa-miR-1307-3p	3.66	0.000284	0.12	0.17	Coronary artery disease;	chr10:103911091	chr10:103394301~103394322:-
PRAD	cis	rs2302612	0.687	rs3755285	MIMAT0019927	hsa-miR-4772-3p	-3.66	0.000284	-0.2	-0.17	Serum protein levels (sST2);	chr2:102227560	chr2:102432336~102432357:+
PRAD	cis	rs7594645	0.59	rs12467191	MIMAT0014995	hsa-miR-3130-5p	3.65	0.00029	0.31	0.17	Episodic memory;	chr2:206776999	chr2:206783276~206783296:-
PRAD	cis	rs7594645	0.59	rs12467191	MIMAT0014995_1	hsa-miR-3130-5p	3.65	0.00029	0.31	0.17	Episodic memory;	chr2:206776999	chr2:206783246~206783266:+
PRAD	cis	rs12712135	0.677	rs11678721	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102456778	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs11677555	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102456833	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.651	rs12712150	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102458353	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs6705498	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102460210	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs6719196	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102460428	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs11676236	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102465235	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.677	rs11687013	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102465261	chr2:102432336~102432357:+
PRAD	cis	rs12712135	0.709	rs4140786	MIMAT0019927	hsa-miR-4772-3p	3.65	0.000292	0.18	0.17	Blood protein levels;	chr2:102471716	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.566	rs10172588	MIMAT0019927	hsa-miR-4772-3p	-3.65	0.000294	-0.2	-0.17	Lymphocyte counts;	chr2:102486838	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs6543154	MIMAT0019927	hsa-miR-4772-3p	-3.65	0.000298	-0.2	-0.17	Lymphocyte counts;	chr2:102497875	chr2:102432336~102432357:+
PRAD	cis	rs12712133	0.552	rs10469856	MIMAT0019927	hsa-miR-4772-3p	-3.64	0.000299	-0.19	-0.17	Primary biliary cholangitis;	chr2:102272369	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.545	rs10811643	MIMAT0004504	hsa-miR-31-3p	-3.64	0.000299	-0.16	-0.17	Type 2 diabetes;	chr9:22024967	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.545	rs10811644	MIMAT0004504	hsa-miR-31-3p	-3.64	0.000299	-0.16	-0.17	Type 2 diabetes;	chr9:22025068	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.526	rs7035484	MIMAT0004504	hsa-miR-31-3p	-3.64	0.000299	-0.16	-0.17	Type 2 diabetes;	chr9:22025241	chr9:21512121~21512142:-
PRAD	cis	rs74233809	0.901	rs1004467	MIMAT0005951	hsa-miR-1307-3p	-3.64	0.000299	-0.22	-0.17	Birth weight;	chr10:102834750	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.691	rs10786419	MIMAT0005878	hsa-miR-1287-5p	3.64	0.000302	0.18	0.17	Metabolite levels;	chr10:98421183	chr10:98395271~98395292:-
PRAD	cis	rs216303	1	rs216301	MIMAT0000617	hsa-miR-200c-3p	3.64	0.000303	0.18	0.17	Low vWF levels;	chr12:6048822	chr12:6963742~6963764:+
PRAD	cis	rs216303	1	rs216302	MIMAT0000617	hsa-miR-200c-3p	3.64	0.000303	0.18	0.17	Low vWF levels;	chr12:6048856	chr12:6963742~6963764:+
PRAD	cis	rs944801	0.565	rs8181047	MIMAT0004504	hsa-miR-31-3p	-3.64	0.000304	-0.18	-0.17	Type 2 diabetes;	chr9:22064466	chr9:21512121~21512142:-
PRAD	cis	rs1163656	0.534	rs12311427	MIMAT0003287	hsa-miR-618	-3.64	0.000306	-0.21	-0.17	Dental caries;	chr12:80934053	chr12:80935796~80935818:-
PRAD	cis	rs7851726	1	rs1016013	MIMAT0019208	hsa-miR-3074-5p	-3.64	0.000308	-0.15	-0.17	Urinary albumin-to-creatinine ratio;	chr9:94714202	chr9:95086063~95086083:-
PRAD	cis	rs4927850	0.723	rs7630825	MIMAT0003235	hsa-miR-570-3p	3.64	0.000309	0.21	0.17	Pancreatic cancer;	chr3:196026869	chr3:195699460~195699481:+
PRAD	cis	rs74233809	1	rs12413409	MIMAT0022727	hsa-miR-1307-5p	-3.64	0.000309	-0.26	-0.17	Birth weight;	chr10:102959339	chr10:103394341~103394361:-
PRAD	cis	rs990171	0.687	rs9989842	MIMAT0019927	hsa-miR-4772-3p	-3.64	0.00031	-0.2	-0.17	Lymphocyte counts;	chr2:102507174	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.687	rs9989749	MIMAT0019927	hsa-miR-4772-3p	-3.64	0.00031	-0.2	-0.17	Lymphocyte counts;	chr2:102507183	chr2:102432336~102432357:+
PRAD	cis	rs74233809	1	rs3740390	MIMAT0005951	hsa-miR-1307-3p	-3.63	0.00031	-0.24	-0.17	Birth weight;	chr10:102878723	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.955	rs3817465	MIMAT0019927	hsa-miR-4772-3p	-3.63	0.000312	-0.21	-0.17	Lymphocyte counts;	chr2:102423124	chr2:102432336~102432357:+
PRAD	cis	rs3826656	1	rs200656	MIMAT0000443	hsa-miR-125a-5p	3.63	0.000312	0.13	0.17	Alzheimer's disease;Cerebrospinal fluid biomarker levels;	chr19:51221070	chr19:51693268~51693291:+
PRAD	cis	rs7072216	0.922	rs10786415	MIMAT0005878	hsa-miR-1287-5p	3.63	0.000312	0.18	0.17	Metabolite levels;	chr10:98391509	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.922	rs942814	MIMAT0005878	hsa-miR-1287-5p	3.63	0.000312	0.18	0.17	Metabolite levels;	chr10:98391548	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.922	rs6584191	MIMAT0005878	hsa-miR-1287-5p	3.63	0.000316	0.18	0.17	Metabolite levels;	chr10:98392298	chr10:98395271~98395292:-
PRAD	cis	rs7072216	0.922	rs7905265	MIMAT0005878	hsa-miR-1287-5p	3.63	0.000317	0.19	0.17	Metabolite levels;	chr10:98383436	chr10:98395271~98395292:-
PRAD	cis	rs4927850	0.752	rs7618864	MIMAT0003235	hsa-miR-570-3p	3.63	0.000319	0.21	0.17	Pancreatic cancer;	chr3:196022690	chr3:195699460~195699481:+
PRAD	cis	rs944801	0.561	rs573687	MIMAT0004504	hsa-miR-31-3p	3.63	0.000319	0.17	0.17	Type 2 diabetes;	chr9:22011643	chr9:21512121~21512142:-
PRAD	cis	rs1409313	0.585	rs12771352	MIMAT0004766	hsa-miR-146b-3p	-3.63	0.00032	-0.21	-0.17	Autism spectrum disorder-related traits;	chr10:102314583	chr10:102436557~102436578:+
PRAD	cis	rs12765878	0.58	rs11191822	MIMAT0005951	hsa-miR-1307-3p	-3.63	0.000321	-0.13	-0.17	Coronary artery disease;	chr10:103840012	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.538	rs4851012	MIMAT0019927	hsa-miR-4772-3p	3.62	0.000323	0.19	0.17	Lymphocyte counts;	chr2:102499456	chr2:102432336~102432357:+
PRAD	cis	rs4918072	0.793	rs7918848	MIMAT0005951	hsa-miR-1307-3p	3.62	0.000327	0.14	0.17	Coronary artery disease;	chr10:103941507	chr10:103394301~103394322:-
PRAD	cis	rs4918072	0.793	rs7912975	MIMAT0005951	hsa-miR-1307-3p	3.62	0.000327	0.14	0.17	Coronary artery disease;	chr10:103945432	chr10:103394301~103394322:-
PRAD	cis	rs2307449	0.929	rs16942918	MIMAT0000252	hsa-miR-7-5p	-3.62	0.000327	-0.2	-0.17	Menopause (age at onset);	chr15:89260880	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs16942918	MIMAT0000252_1	hsa-miR-7-5p	-3.62	0.000327	-0.2	-0.17	Menopause (age at onset);	chr15:89260880	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs16942918	MIMAT0000252_2	hsa-miR-7-5p	-3.62	0.000327	-0.2	-0.17	Menopause (age at onset);	chr15:89260880	chr9:83969811~83969834:-
PRAD	cis	rs990171	0.955	rs4851008	MIMAT0019927	hsa-miR-4772-3p	-3.62	0.000329	-0.21	-0.17	Lymphocyte counts;	chr2:102410151	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.589	rs62560774	MIMAT0004504	hsa-miR-31-3p	3.62	0.000329	0.18	0.17	Type 2 diabetes;	chr9:22028407	chr9:21512121~21512142:-
PRAD	cis	rs2910162	0.865	rs6878034	MIMAT0000449	hsa-miR-146a-5p	-3.62	0.000329	-0.13	-0.17	Allergic disease (asthma, hay fever or eczema);	chr5:160488114	chr5:160485372~160485393:+
PRAD	cis	rs12712135	0.709	rs10201184	MIMAT0019927	hsa-miR-4772-3p	-3.62	0.000329	-0.18	-0.17	Blood protein levels;	chr2:102472618	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.77	rs7897357	MIMAT0005878	hsa-miR-1287-5p	3.62	0.000329	0.18	0.17	Metabolite levels;	chr10:98403840	chr10:98395271~98395292:-
PRAD	cis	rs1409313	0.585	rs71471241	MIMAT0004766	hsa-miR-146b-3p	-3.62	0.000331	-0.22	-0.17	Autism spectrum disorder-related traits;	chr10:102297195	chr10:102436557~102436578:+
PRAD	cis	rs2823615	1	rs9984617	MIMAT0000064	hsa-let-7c-5p	-3.62	0.000332	-0.15	-0.17	Obesity-related traits;	chr21:16103927	chr21:16539838~16539859:+
PRAD	cis	rs79387448	0.638	rs116055209	MIMAT0019927	hsa-miR-4772-3p	-3.62	0.000332	-0.25	-0.17	Gut microbiota (bacterial taxa);	chr2:102415729	chr2:102432336~102432357:+
PRAD	cis	rs7503807	0.688	rs901060	MIMAT0015066	hsa-miR-3065-5p	3.62	0.000334	0.19	0.17	Obesity;	chr17:80621190	chr17:81125886~81125908:+
PRAD	cis	rs2280018	0.963	rs12928424	MIMAT0002819	hsa-miR-193b-3p	-3.62	0.000334	-0.12	-0.17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr16:15056916	chr16:14304017~14304038:+
PRAD	cis	rs9290936	0.572	rs3773992	MIMAT0004987	hsa-miR-944	3.61	0.000335	0.32	0.17	Waist circumference;	chr3:190535876	chr3:189829975~189829996:+
PRAD	cis	rs9290936	0.572	rs3773991	MIMAT0004987	hsa-miR-944	3.61	0.000335	0.32	0.17	Waist circumference;	chr3:190537206	chr3:189829975~189829996:+
PRAD	cis	rs3826656	0.848	rs1710403	MIMAT0000443	hsa-miR-125a-5p	3.61	0.000338	0.13	0.17	Alzheimer's disease;Cerebrospinal fluid biomarker levels;	chr19:51218889	chr19:51693268~51693291:+
PRAD	cis	rs7894407	0.522	rs116821290	MIMAT0005951	hsa-miR-1307-3p	3.61	0.000338	0.15	0.17	White matter hyperintensity burden;	chr10:103183633	chr10:103394301~103394322:-
PRAD	cis	rs7009110	0.967	rs6989309	MIMAT0022502	hsa-miR-5708	-3.61	0.000339	-0.21	-0.17	Asthma and hay fever;	chr8:80379973	chr8:80241398~80241417:+
PRAD	cis	rs2910162	0.865	rs4921142	MIMAT0000449	hsa-miR-146a-5p	-3.61	0.00034	-0.13	-0.17	Allergic disease (asthma, hay fever or eczema);	chr5:160490208	chr5:160485372~160485393:+
PRAD	cis	rs990171	0.538	rs7566063	MIMAT0019927	hsa-miR-4772-3p	-3.61	0.000345	-0.19	-0.17	Lymphocyte counts;	chr2:102496106	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.727	rs6584199	MIMAT0026738	hsa-miR-1287-3p	3.61	0.000345	0.13	0.17	Metabolite levels;	chr10:98410226	chr10:98395232~98395253:-
PRAD	cis	rs216303	1	rs216303	MIMAT0000617	hsa-miR-200c-3p	3.6	0.000347	0.19	0.17	Low vWF levels;	chr12:6049879	chr12:6963742~6963764:+
PRAD	cis	rs216303	1	rs216304	MIMAT0000617	hsa-miR-200c-3p	3.6	0.000347	0.19	0.17	Low vWF levels;	chr12:6050371	chr12:6963742~6963764:+
PRAD	cis	rs4927850	0.752	rs7624460	MIMAT0003235	hsa-miR-570-3p	3.6	0.00035	0.21	0.17	Pancreatic cancer;	chr3:196021659	chr3:195699460~195699481:+
PRAD	cis	rs944801	0.506	rs2106120	MIMAT0004504	hsa-miR-31-3p	-3.6	0.000353	-0.16	-0.17	Type 2 diabetes;	chr9:22017102	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.506	rs2106119	MIMAT0004504	hsa-miR-31-3p	-3.6	0.000353	-0.16	-0.17	Type 2 diabetes;	chr9:22017551	chr9:21512121~21512142:-
PRAD	cis	rs12765878	0.513	rs56093138	MIMAT0005951	hsa-miR-1307-3p	-3.6	0.000355	-0.14	-0.17	Coronary artery disease;	chr10:103858150	chr10:103394301~103394322:-
PRAD	cis	rs1018697	0.966	rs6584526	MIMAT0022727	hsa-miR-1307-5p	3.6	0.000357	0.13	0.17	Colorectal adenoma (advanced);	chr10:102806484	chr10:103394341~103394361:-
PRAD	cis	rs74233809	1	rs12413409	MIMAT0005951	hsa-miR-1307-3p	-3.6	0.000358	-0.24	-0.17	Birth weight;	chr10:102959339	chr10:103394301~103394322:-
PRAD	cis	rs3217992	0.563	rs10757264	MIMAT0004504	hsa-miR-31-3p	3.59	0.000362	0.16	0.17	Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);Psychosis proneness (hypomanic personality scale);	chr9:22019733	chr9:21512121~21512142:-
PRAD	cis	rs9641123	0.966	rs34588678	MIMAT0003328	hsa-miR-653-5p	-3.59	0.000363	-0.18	-0.17	BMI (adjusted for smoking behaviour);Lean body mass;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;BMI in non-smokers;	chr7:93561890	chr7:93482823~93482843:-
PRAD	cis	rs7072216	0.616	rs701801	MIMAT0026738	hsa-miR-1287-3p	3.59	0.000363	0.12	0.17	Metabolite levels;	chr10:98417112	chr10:98395232~98395253:-
PRAD	cis	rs523340	1	rs523340	MIMAT0004505	hsa-miR-32-3p	-3.59	0.000367	-0.29	-0.17	Information processing speed;	chr9:109091966	chr9:109046231~109046252:-
PRAD	cis	rs758129	0.501	rs2283430	MIMAT0000252	hsa-miR-7-5p	-3.59	0.000368	-0.2	-0.17	Schizophrenia;	chr15:89333005	chr15:88611856~88611879:+
PRAD	cis	rs758129	0.501	rs2283430	MIMAT0000252_1	hsa-miR-7-5p	-3.59	0.000368	-0.2	-0.17	Schizophrenia;	chr15:89333005	chr19:4770700~4770723:+
PRAD	cis	rs758129	0.501	rs2283430	MIMAT0000252_2	hsa-miR-7-5p	-3.59	0.000368	-0.2	-0.17	Schizophrenia;	chr15:89333005	chr9:83969811~83969834:-
PRAD	cis	rs6011674	0.731	rs74645182	MIMAT0016888	hsa-miR-4326	-3.59	0.000369	-0.32	-0.17	Response to cytadine analogues (cytosine arabinoside);	chr20:63169244	chr20:63286818~63286837:+
PRAD	cis	rs2277912	1	rs2277912	MIMAT0014995	hsa-miR-3130-5p	3.59	0.00037	0.25	0.17	Height;	chr2:206769512	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs2277912	MIMAT0014995_1	hsa-miR-3130-5p	3.59	0.00037	0.25	0.17	Height;	chr2:206769512	chr2:206783246~206783266:+
PRAD	cis	rs2277912	1	rs12620432	MIMAT0014995	hsa-miR-3130-5p	3.59	0.00037	0.25	0.17	Height;	chr2:206771794	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs12620432	MIMAT0014995_1	hsa-miR-3130-5p	3.59	0.00037	0.25	0.17	Height;	chr2:206771794	chr2:206783246~206783266:+
PRAD	cis	rs3826656	1	rs273635	MIMAT0000443	hsa-miR-125a-5p	3.59	0.00037	0.13	0.17	Alzheimer's disease;Cerebrospinal fluid biomarker levels;	chr19:51215611	chr19:51693268~51693291:+
PRAD	cis	rs990171	0.913	rs2272128	MIMAT0019927	hsa-miR-4772-3p	-3.59	0.000371	-0.21	-0.17	Lymphocyte counts;	chr2:102423469	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs1523201	MIMAT0019927	hsa-miR-4772-3p	-3.59	0.000374	-0.19	-0.17	Lymphocyte counts;	chr2:102490605	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.837	rs1568681	MIMAT0019927	hsa-miR-4772-3p	-3.58	0.000376	-0.21	-0.17	Lymphocyte counts;	chr2:102398236	chr2:102432336~102432357:+
PRAD	cis	rs7851726	0.966	rs4744378	MIMAT0019208	hsa-miR-3074-5p	-3.58	0.000379	-0.15	-0.17	Urinary albumin-to-creatinine ratio;	chr9:94816864	chr9:95086063~95086083:-
PRAD	cis	rs7072216	0.77	rs942810	MIMAT0005878	hsa-miR-1287-5p	3.58	0.00038	0.18	0.17	Metabolite levels;	chr10:98408103	chr10:98395271~98395292:-
PRAD	cis	rs1018697	1	rs7080587	MIMAT0022727	hsa-miR-1307-5p	3.58	0.000381	0.13	0.17	Colorectal adenoma (advanced);	chr10:102785517	chr10:103394341~103394361:-
PRAD	cis	rs944801	0.741	rs10811651	MIMAT0004504	hsa-miR-31-3p	-3.58	0.000383	-0.16	-0.17	Type 2 diabetes;	chr9:22067831	chr9:21512121~21512142:-
PRAD	cis	rs9290936	0.572	rs3821742	MIMAT0004987	hsa-miR-944	3.58	0.000385	0.3	0.17	Waist circumference;	chr3:190537626	chr3:189829975~189829996:+
PRAD	cis	rs74233809	1	rs11191560	MIMAT0022727	hsa-miR-1307-5p	-3.58	0.000386	-0.26	-0.17	Birth weight;	chr10:103109281	chr10:103394341~103394361:-
PRAD	cis	rs2277912	1	rs3762567	MIMAT0014995	hsa-miR-3130-5p	3.58	0.000386	0.25	0.17	Height;	chr2:206765614	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs3762567	MIMAT0014995_1	hsa-miR-3130-5p	3.58	0.000386	0.25	0.17	Height;	chr2:206765614	chr2:206783246~206783266:+
PRAD	cis	rs990171	0.874	rs6419573	MIMAT0019927	hsa-miR-4772-3p	-3.58	0.000387	-0.21	-0.17	Lymphocyte counts;	chr2:102410643	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.708	rs10811648	MIMAT0004504	hsa-miR-31-3p	-3.58	0.000387	-0.16	-0.17	Type 2 diabetes;	chr9:22067543	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.708	rs10811649	MIMAT0004504	hsa-miR-31-3p	-3.58	0.000387	-0.16	-0.17	Type 2 diabetes;	chr9:22067555	chr9:21512121~21512142:-
PRAD	cis	rs2257205	0.667	rs9909763	MIMAT0000433	hsa-miR-142-5p	3.58	0.000388	0.17	0.17	Pancreatic cancer;	chr17:58552279	chr17:58331283~58331303:-
PRAD	cis	rs7072216	0.922	rs942813	MIMAT0005878	hsa-miR-1287-5p	3.57	0.000388	0.18	0.17	Metabolite levels;	chr10:98393851	chr10:98395271~98395292:-
PRAD	cis	rs7851726	0.966	rs391784	MIMAT0019208	hsa-miR-3074-5p	-3.57	0.00039	-0.15	-0.17	Urinary albumin-to-creatinine ratio;	chr9:94813345	chr9:95086063~95086083:-
PRAD	cis	rs990171	0.687	rs13019784	MIMAT0019927	hsa-miR-4772-3p	3.57	0.00039	0.2	0.17	Lymphocyte counts;	chr2:102506842	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.77	rs7909131	MIMAT0005878	hsa-miR-1287-5p	3.57	0.000391	0.17	0.17	Metabolite levels;	chr10:98411714	chr10:98395271~98395292:-
PRAD	cis	rs2307449	0.929	rs28573320	MIMAT0000252	hsa-miR-7-5p	-3.57	0.000392	-0.2	-0.17	Menopause (age at onset);	chr15:89265108	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs28573320	MIMAT0000252_1	hsa-miR-7-5p	-3.57	0.000392	-0.2	-0.17	Menopause (age at onset);	chr15:89265108	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs28573320	MIMAT0000252_2	hsa-miR-7-5p	-3.57	0.000392	-0.2	-0.17	Menopause (age at onset);	chr15:89265108	chr9:83969811~83969834:-
PRAD	cis	rs12765878	0.627	rs1265166	MIMAT0005951	hsa-miR-1307-3p	-3.57	0.000394	-0.12	-0.17	Coronary artery disease;	chr10:103911490	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.901	rs11191425	MIMAT0022727	hsa-miR-1307-5p	-3.57	0.000395	-0.25	-0.17	Birth weight;	chr10:102866213	chr10:103394341~103394361:-
PRAD	cis	rs12712135	0.709	rs12469887	MIMAT0019927	hsa-miR-4772-3p	3.57	0.000395	0.18	0.17	Blood protein levels;	chr2:102470298	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.913	rs10190555	MIMAT0019927	hsa-miR-4772-3p	-3.57	0.000395	-0.21	-0.17	Lymphocyte counts;	chr2:102377596	chr2:102432336~102432357:+
PRAD	cis	rs28587833	1	rs28587833	MIMAT0015066	hsa-miR-3065-5p	-3.57	0.000397	-0.24	-0.17	Schizophrenia;	chr17:80537527	chr17:81125886~81125908:+
PRAD	cis	rs758129	0.501	rs2239286	MIMAT0000252	hsa-miR-7-5p	-3.57	0.000398	-0.2	-0.17	Schizophrenia;	chr15:89332812	chr15:88611856~88611879:+
PRAD	cis	rs758129	0.501	rs2239286	MIMAT0000252_1	hsa-miR-7-5p	-3.57	0.000398	-0.2	-0.17	Schizophrenia;	chr15:89332812	chr19:4770700~4770723:+
PRAD	cis	rs758129	0.501	rs2239286	MIMAT0000252_2	hsa-miR-7-5p	-3.57	0.000398	-0.2	-0.17	Schizophrenia;	chr15:89332812	chr9:83969811~83969834:-
PRAD	cis	rs7851726	1	rs356131	MIMAT0019208	hsa-miR-3074-5p	-3.57	0.000399	-0.15	-0.17	Urinary albumin-to-creatinine ratio;	chr9:94805045	chr9:95086063~95086083:-
PRAD	cis	rs990171	0.52	rs4851605	MIMAT0019927	hsa-miR-4772-3p	-3.57	0.000399	-0.18	-0.17	Lymphocyte counts;	chr2:102504409	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs4851606	MIMAT0019927	hsa-miR-4772-3p	-3.57	0.000399	-0.18	-0.17	Lymphocyte counts;	chr2:102504430	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs4851017	MIMAT0019927	hsa-miR-4772-3p	-3.57	4e-04	-0.18	-0.17	Lymphocyte counts;	chr2:102504310	chr2:102432336~102432357:+
PRAD	cis	rs6011674	0.731	rs113412477	MIMAT0016888	hsa-miR-4326	-3.57	0.000401	-0.31	-0.17	Response to cytadine analogues (cytosine arabinoside);	chr20:63182209	chr20:63286818~63286837:+
PRAD	cis	rs944801	0.776	rs1333039	MIMAT0004504	hsa-miR-31-3p	-3.57	0.000401	-0.16	-0.17	Type 2 diabetes;	chr9:22065658	chr9:21512121~21512142:-
PRAD	cis	rs990171	1	rs1420106	MIMAT0019927	hsa-miR-4772-3p	3.57	0.000402	0.21	0.17	Lymphocyte counts;	chr2:102418584	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.616	rs701801	MIMAT0005878	hsa-miR-1287-5p	3.56	0.000403	0.18	0.17	Metabolite levels;	chr10:98417112	chr10:98395271~98395292:-
PRAD	cis	rs944801	0.776	rs4977756	MIMAT0004504	hsa-miR-31-3p	-3.56	0.000409	-0.16	-0.17	Type 2 diabetes;	chr9:22068653	chr9:21512121~21512142:-
PRAD	cis	rs2823615	0.962	rs11088565	MIMAT0000064	hsa-let-7c-5p	-3.56	0.00041	-0.14	-0.16	Obesity-related traits;	chr21:16101911	chr21:16539838~16539859:+
PRAD	cis	rs990171	0.538	rs4851016	MIMAT0019927	hsa-miR-4772-3p	-3.56	0.000415	-0.18	-0.16	Lymphocyte counts;	chr2:102503941	chr2:102432336~102432357:+
PRAD	cis	rs7503807	0.688	rs7503203	MIMAT0015066	hsa-miR-3065-5p	3.55	0.00042	0.19	0.16	Obesity;	chr17:80616728	chr17:81125886~81125908:+
PRAD	cis	rs7121616	0.531	rs10892958	MIMAT0000423	hsa-miR-125b-5p	3.55	0.000421	0.12	0.16	Breast cancer;	chr11:123061415	chr11:122099809~122099830:-
PRAD	cis	rs7121616	0.531	rs10892958	MIMAT0000423_1	hsa-miR-125b-5p	3.55	0.000421	0.12	0.16	Breast cancer;	chr11:123061415	chr21:16590253~16590274:+
PRAD	cis	rs7503807	0.688	rs12942347	MIMAT0015066	hsa-miR-3065-5p	3.55	0.000421	0.19	0.16	Obesity;	chr17:80614142	chr17:81125886~81125908:+
PRAD	cis	rs990171	0.538	rs2075187	MIMAT0019927	hsa-miR-4772-3p	3.55	0.000426	0.19	0.16	Lymphocyte counts;	chr2:102503852	chr2:102432336~102432357:+
PRAD	cis	rs7851726	0.966	rs10993372	MIMAT0019208	hsa-miR-3074-5p	3.55	0.000428	0.15	0.16	Urinary albumin-to-creatinine ratio;	chr9:94856808	chr9:95086063~95086083:-
PRAD	cis	rs2823615	1	rs73175266	MIMAT0000064	hsa-let-7c-5p	-3.55	0.000428	-0.15	-0.16	Obesity-related traits;	chr21:16113914	chr21:16539838~16539859:+
PRAD	cis	rs6011674	0.731	rs77617940	MIMAT0016888	hsa-miR-4326	-3.55	0.000429	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63183616	chr20:63286818~63286837:+
PRAD	cis	rs990171	0.562	rs12469973	MIMAT0019927	hsa-miR-4772-3p	3.55	0.000432	0.21	0.16	Lymphocyte counts;	chr2:102565814	chr2:102432336~102432357:+
PRAD	cis	rs2823615	1	rs2823607	MIMAT0000064	hsa-let-7c-5p	-3.54	0.000434	-0.15	-0.16	Obesity-related traits;	chr21:16084293	chr21:16539838~16539859:+
PRAD	cis	rs944801	0.506	rs10811640	MIMAT0004504	hsa-miR-31-3p	-3.54	0.000437	-0.15	-0.16	Type 2 diabetes;	chr9:22013412	chr9:21512121~21512142:-
PRAD	cis	rs944801	0.506	rs10757263	MIMAT0004504	hsa-miR-31-3p	-3.54	0.000437	-0.15	-0.16	Type 2 diabetes;	chr9:22013806	chr9:21512121~21512142:-
PRAD	cis	rs758129	0.501	rs1054875	MIMAT0000252	hsa-miR-7-5p	-3.54	0.000439	-0.2	-0.16	Schizophrenia;	chr15:89335895	chr15:88611856~88611879:+
PRAD	cis	rs758129	0.501	rs1054875	MIMAT0000252_1	hsa-miR-7-5p	-3.54	0.000439	-0.2	-0.16	Schizophrenia;	chr15:89335895	chr19:4770700~4770723:+
PRAD	cis	rs758129	0.501	rs1054875	MIMAT0000252_2	hsa-miR-7-5p	-3.54	0.000439	-0.2	-0.16	Schizophrenia;	chr15:89335895	chr9:83969811~83969834:-
PRAD	cis	rs79600951	1	rs80261911	MIMAT0000430	hsa-miR-138-5p	3.54	0.00044	0.31	0.16	HDL cholesterol;	chr16:56821280	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs80261911	MIMAT0000430_1	hsa-miR-138-5p	3.54	0.00044	0.31	0.16	HDL cholesterol;	chr16:56821280	chr3:44114234~44114256:+
PRAD	cis	rs2307449	0.929	rs7167930	MIMAT0000252	hsa-miR-7-5p	-3.54	0.000445	-0.2	-0.16	Menopause (age at onset);	chr15:89267438	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs7167930	MIMAT0000252_1	hsa-miR-7-5p	-3.54	0.000445	-0.2	-0.16	Menopause (age at onset);	chr15:89267438	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs7167930	MIMAT0000252_2	hsa-miR-7-5p	-3.54	0.000445	-0.2	-0.16	Menopause (age at onset);	chr15:89267438	chr9:83969811~83969834:-
PRAD	cis	rs2277912	1	rs56243714	MIMAT0014995	hsa-miR-3130-5p	3.54	0.000446	0.25	0.16	Height;	chr2:206776345	chr2:206783276~206783296:-
PRAD	cis	rs2277912	1	rs56243714	MIMAT0014995_1	hsa-miR-3130-5p	3.54	0.000446	0.25	0.16	Height;	chr2:206776345	chr2:206783246~206783266:+
PRAD	cis	rs216303	0.554	rs216320	MIMAT0000617	hsa-miR-200c-3p	3.54	0.000447	0.19	0.16	Low vWF levels;	chr12:6034190	chr12:6963742~6963764:+
PRAD	cis	rs3858306	0.529	rs11017304	MIMAT0016847	hsa-miR-378c	3.54	0.000448	0.26	0.16	Peripheral arterial disease (traffic-related air pollution interaction);	chr10:130527121	chr10:130962634~130962658:-
PRAD	cis	rs11825709	0.661	rs4316471	MIMAT0022720	hsa-miR-1304-3p	-3.54	0.000448	-0.41	-0.16	Obesity-related traits;	chr11:93896866	chr11:93733691~93733712:-
PRAD	cis	rs421490	0.858	rs402660	MIMAT0004557	hsa-miR-34a-3p	3.54	0.000449	0.26	0.16	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr1:8216449	chr1:9151693~9151714:-
PRAD	cis	rs977145	0.721	rs11209773	MIMAT0000456	hsa-miR-186-5p	3.54	0.000449	0.13	0.16	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);	chr1:71358257	chr1:71067681~71067702:-
PRAD	cis	rs990171	0.511	rs2072509	MIMAT0019927	hsa-miR-4772-3p	-3.54	0.000449	-0.18	-0.16	Lymphocyte counts;	chr2:102501878	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs11690932	MIMAT0019927	hsa-miR-4772-3p	-3.54	0.000449	-0.18	-0.16	Lymphocyte counts;	chr2:102502570	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.806	rs9804285	MIMAT0026738	hsa-miR-1287-3p	3.53	0.00045	0.13	0.16	Metabolite levels;	chr10:98409715	chr10:98395232~98395253:-
PRAD	cis	rs7503807	0.664	rs9913181	MIMAT0015066	hsa-miR-3065-5p	3.53	0.000451	0.19	0.16	Obesity;	chr17:80600072	chr17:81125886~81125908:+
PRAD	cis	rs2307449	0.861	rs7496308	MIMAT0000252	hsa-miR-7-5p	-3.53	0.000451	-0.2	-0.16	Menopause (age at onset);	chr15:89268312	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.861	rs7496308	MIMAT0000252_1	hsa-miR-7-5p	-3.53	0.000451	-0.2	-0.16	Menopause (age at onset);	chr15:89268312	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.861	rs7496308	MIMAT0000252_2	hsa-miR-7-5p	-3.53	0.000451	-0.2	-0.16	Menopause (age at onset);	chr15:89268312	chr9:83969811~83969834:-
PRAD	cis	rs990171	0.538	rs6543155	MIMAT0019927	hsa-miR-4772-3p	-3.53	0.000454	-0.19	-0.16	Lymphocyte counts;	chr2:102498436	chr2:102432336~102432357:+
PRAD	cis	rs11678825	0.85	rs115289925	MIMAT0031175	hsa-miR-548ba	-3.53	0.000456	-0.31	-0.16	Reticulocyte fraction of red cells;	chr2:48440744	chr2:49059603~49059624:+
PRAD	cis	rs944801	0.966	rs7866783	MIMAT0004504	hsa-miR-31-3p	-3.53	0.000458	-0.16	-0.16	Type 2 diabetes;	chr9:22056360	chr9:21512121~21512142:-
PRAD	cis	rs2280018	0.963	rs11075255	MIMAT0002819	hsa-miR-193b-3p	-3.53	0.000459	-0.12	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr16:15072375	chr16:14304017~14304038:+
PRAD	cis	rs2823615	0.962	rs2823601	MIMAT0000064	hsa-let-7c-5p	-3.53	0.000459	-0.15	-0.16	Obesity-related traits;	chr21:16079315	chr21:16539838~16539859:+
PRAD	cis	rs79387448	0.638	rs11465698	MIMAT0019927	hsa-miR-4772-3p	-3.53	0.00046	-0.24	-0.16	Gut microbiota (bacterial taxa);	chr2:102438117	chr2:102432336~102432357:+
PRAD	cis	rs216303	0.642	rs216315	MIMAT0000617	hsa-miR-200c-3p	3.53	0.000462	0.19	0.16	Low vWF levels;	chr12:6027748	chr12:6963742~6963764:+
PRAD	cis	rs990171	0.538	rs2075188	MIMAT0019927	hsa-miR-4772-3p	-3.53	0.000465	-0.18	-0.16	Lymphocyte counts;	chr2:102503773	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs2075191	MIMAT0019927	hsa-miR-4772-3p	-3.53	0.000466	-0.18	-0.16	Lymphocyte counts;	chr2:102501840	chr2:102432336~102432357:+
PRAD	cis	rs4918072	0.874	rs3850670	MIMAT0005951	hsa-miR-1307-3p	3.53	0.000466	0.14	0.16	Coronary artery disease;	chr10:103899611	chr10:103394301~103394322:-
PRAD	cis	rs4918072	0.917	rs12571879	MIMAT0005951	hsa-miR-1307-3p	3.53	0.000466	0.14	0.16	Coronary artery disease;	chr10:103903588	chr10:103394301~103394322:-
PRAD	cis	rs7851726	1	rs1751434	MIMAT0019208	hsa-miR-3074-5p	-3.52	0.000467	-0.15	-0.16	Urinary albumin-to-creatinine ratio;	chr9:94775700	chr9:95086063~95086083:-
PRAD	cis	rs6011674	0.731	rs76137972	MIMAT0016888	hsa-miR-4326	-3.52	0.000467	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63175018	chr20:63286818~63286837:+
PRAD	cis	rs74233809	0.901	rs11191416	MIMAT0005951	hsa-miR-1307-3p	3.52	0.000467	0.22	0.16	Birth weight;	chr10:102845159	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.538	rs12712153	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102495302	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs11687071	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102495461	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs12987295	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102499379	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs4851599	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102499561	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.511	rs4851013	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102499676	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs12995030	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000468	-0.18	-0.16	Lymphocyte counts;	chr2:102500007	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs4851600	MIMAT0019927	hsa-miR-4772-3p	3.52	0.000468	0.18	0.16	Lymphocyte counts;	chr2:102499764	chr2:102432336~102432357:+
PRAD	cis	rs6011674	0.731	rs77857658	MIMAT0016888	hsa-miR-4326	-3.52	0.000468	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63182545	chr20:63286818~63286837:+
PRAD	cis	rs6011674	0.808	rs76956887	MIMAT0016888	hsa-miR-4326	-3.52	0.000468	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63182728	chr20:63286818~63286837:+
PRAD	cis	rs4918072	0.917	rs61861158	MIMAT0005951	hsa-miR-1307-3p	3.52	0.00047	0.14	0.16	Coronary artery disease;	chr10:103901928	chr10:103394301~103394322:-
PRAD	cis	rs74233809	0.551	rs3740393	MIMAT0005951	hsa-miR-1307-3p	-3.52	0.000471	-0.17	-0.16	Birth weight;	chr10:102876898	chr10:103394301~103394322:-
PRAD	cis	rs7121616	0.531	rs11218941	MIMAT0000423	hsa-miR-125b-5p	3.52	0.000473	0.12	0.16	Breast cancer;	chr11:123061701	chr11:122099809~122099830:-
PRAD	cis	rs7121616	0.531	rs11218941	MIMAT0000423_1	hsa-miR-125b-5p	3.52	0.000473	0.12	0.16	Breast cancer;	chr11:123061701	chr21:16590253~16590274:+
PRAD	cis	rs990171	0.566	rs10175045	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000477	-0.19	-0.16	Lymphocyte counts;	chr2:102486773	chr2:102432336~102432357:+
PRAD	cis	rs1409313	0.502	rs11595791	MIMAT0004766	hsa-miR-146b-3p	-3.52	0.000477	-0.2	-0.16	Autism spectrum disorder-related traits;	chr10:102288739	chr10:102436557~102436578:+
PRAD	cis	rs523340	1	rs1996608	MIMAT0004505	hsa-miR-32-3p	3.52	0.000477	0.29	0.16	Information processing speed;	chr9:109095111	chr9:109046231~109046252:-
PRAD	cis	rs3764400	0.506	rs72827851	MIMAT0000438	hsa-miR-152-3p	3.52	0.000478	0.18	0.16	Body mass index;	chr17:48375133	chr17:48037174~48037194:-
PRAD	cis	rs13405728	1	rs13405728	MIMAT0031175	hsa-miR-548ba	-3.52	0.000478	-0.32	-0.16	Polycystic ovary syndrome;	chr2:48751020	chr2:49059603~49059624:+
PRAD	cis	rs79387448	0.638	rs11465670	MIMAT0019927	hsa-miR-4772-3p	-3.52	0.000478	-0.24	-0.16	Gut microbiota (bacterial taxa);	chr2:102417980	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.526	rs7044859	MIMAT0004504	hsa-miR-31-3p	3.52	0.000483	0.15	0.16	Type 2 diabetes;	chr9:22018782	chr9:21512121~21512142:-
PRAD	cis	rs4792143	1	rs4792143	MIMAT0004945	hsa-miR-744-5p	3.52	0.000483	0.15	0.16	Ischemic stroke;	chr17:11482573	chr17:12081909~12081930:+
PRAD	cis	rs4792143	1	rs56049800	MIMAT0004945	hsa-miR-744-5p	3.51	0.000486	0.16	0.16	Ischemic stroke;	chr17:11485595	chr17:12081909~12081930:+
PRAD	cis	rs1409313	0.585	rs35000717	MIMAT0004766	hsa-miR-146b-3p	-3.51	0.000487	-0.21	-0.16	Autism spectrum disorder-related traits;	chr10:102340976	chr10:102436557~102436578:+
PRAD	cis	rs4918072	0.917	rs35041090	MIMAT0005951	hsa-miR-1307-3p	3.51	0.00049	0.14	0.16	Coronary artery disease;	chr10:103888928	chr10:103394301~103394322:-
PRAD	cis	rs7801581	0.58	rs12700794	MIMAT0001080	hsa-miR-196b-5p	3.51	0.000491	0.18	0.16	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;	chr7:27229229	chr7:27169528~27169549:-
PRAD	cis	rs523340	1	rs1533642	MIMAT0004505	hsa-miR-32-3p	3.51	0.000492	0.29	0.16	Information processing speed;	chr9:109141069	chr9:109046231~109046252:-
PRAD	cis	rs944801	0.776	rs10965224	MIMAT0004504	hsa-miR-31-3p	-3.51	0.000493	-0.16	-0.16	Type 2 diabetes;	chr9:22067277	chr9:21512121~21512142:-
PRAD	cis	rs2307449	0.894	rs7162632	MIMAT0000252	hsa-miR-7-5p	-3.51	0.000494	-0.19	-0.16	Menopause (age at onset);	chr15:89302885	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.894	rs7162632	MIMAT0000252_1	hsa-miR-7-5p	-3.51	0.000494	-0.19	-0.16	Menopause (age at onset);	chr15:89302885	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.894	rs7162632	MIMAT0000252_2	hsa-miR-7-5p	-3.51	0.000494	-0.19	-0.16	Menopause (age at onset);	chr15:89302885	chr9:83969811~83969834:-
PRAD	cis	rs2823615	1	rs2823611	MIMAT0000064	hsa-let-7c-5p	-3.51	0.000496	-0.14	-0.16	Obesity-related traits;	chr21:16103565	chr21:16539838~16539859:+
PRAD	cis	rs6011674	0.731	rs111567426	MIMAT0016888	hsa-miR-4326	-3.51	0.000499	-0.31	-0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63174863	chr20:63286818~63286837:+
PRAD	cis	rs990171	0.538	rs11682754	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102500636	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs6728288	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102500809	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs6741235	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102500824	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs7593935	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102501669	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs2075192	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102501769	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs2075190	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Lymphocyte counts;	chr2:102502100	chr2:102432336~102432357:+
PRAD	cis	rs6708413	0.501	rs2075189	MIMAT0019927	hsa-miR-4772-3p	-3.51	0.000499	-0.18	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102502230	chr2:102432336~102432357:+
PRAD	cis	rs4927850	1	rs7627706	MIMAT0003235	hsa-miR-570-3p	3.5	0.000505	0.2	0.16	Pancreatic cancer;	chr3:196026482	chr3:195699460~195699481:+
PRAD	cis	rs4927850	0.881	rs7630489	MIMAT0003235	hsa-miR-570-3p	3.5	0.000505	0.2	0.16	Pancreatic cancer;	chr3:196026530	chr3:195699460~195699481:+
PRAD	cis	rs4927850	1	rs7627868	MIMAT0003235	hsa-miR-570-3p	3.5	0.000505	0.2	0.16	Pancreatic cancer;	chr3:196026602	chr3:195699460~195699481:+
PRAD	cis	rs990171	0.538	rs2075193	MIMAT0019927	hsa-miR-4772-3p	3.5	0.000506	0.19	0.16	Lymphocyte counts;	chr2:102501568	chr2:102432336~102432357:+
PRAD	cis	rs17428041	0.843	rs11784721	MIMAT0000510	hsa-miR-320a-3p	-3.5	0.000508	-0.14	-0.16	Neuropathic pain in type 2 diabetes;	chr8:21864963	chr8:22244975~22244996:-
PRAD	cis	rs2302612	0.718	rs6742931	MIMAT0019927	hsa-miR-4772-3p	-3.5	0.00051	-0.19	-0.16	Serum protein levels (sST2);	chr2:102234783	chr2:102432336~102432357:+
PRAD	cis	rs7851726	1	rs7866848	MIMAT0019208	hsa-miR-3074-5p	-3.5	0.000513	-0.14	-0.16	Urinary albumin-to-creatinine ratio;	chr9:94743326	chr9:95086063~95086083:-
PRAD	cis	rs990171	0.538	rs2072508	MIMAT0019927	hsa-miR-4772-3p	-3.5	0.000513	-0.19	-0.16	Lymphocyte counts;	chr2:102501883	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.545	rs4977753	MIMAT0004504	hsa-miR-31-3p	-3.5	0.000516	-0.15	-0.16	Type 2 diabetes;	chr9:22030028	chr9:21512121~21512142:-
PRAD	cis	rs12765878	0.756	rs6584579	MIMAT0005951	hsa-miR-1307-3p	-3.5	0.000517	-0.11	-0.16	Coronary artery disease;	chr10:103885967	chr10:103394301~103394322:-
PRAD	cis	rs4918072	0.876	rs4918069	MIMAT0005951	hsa-miR-1307-3p	3.5	0.000519	0.14	0.16	Coronary artery disease;	chr10:103894633	chr10:103394301~103394322:-
PRAD	cis	rs2235649	0.798	rs4100646	MIMAT0025848	hsa-miR-6511b-3p	-3.5	0.00052	-0.2	-0.16	Blood metabolite levels;	chr16:1800445	chr16:2106679~2106701:-
PRAD	cis	rs2235649	0.798	rs4100646	MIMAT0025848_1	hsa-miR-6511b-3p	-3.5	0.00052	-0.2	-0.16	Blood metabolite levels;	chr16:1800445	chr16:15134076~15134098:-
PRAD	cis	rs9351814	0.961	rs9351817	MIMAT0000088	hsa-miR-30a-3p	-3.5	0.00052	-0.09	-0.16	Coronary artery disease or ischemic stroke;	chr6:71493302	chr6:71403554~71403575:-
PRAD	cis	rs2307449	0.892	rs8040654	MIMAT0000252	hsa-miR-7-5p	-3.49	0.000521	-0.19	-0.16	Menopause (age at onset);	chr15:89262401	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.892	rs8040654	MIMAT0000252_1	hsa-miR-7-5p	-3.49	0.000521	-0.19	-0.16	Menopause (age at onset);	chr15:89262401	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.892	rs8040654	MIMAT0000252_2	hsa-miR-7-5p	-3.49	0.000521	-0.19	-0.16	Menopause (age at onset);	chr15:89262401	chr9:83969811~83969834:-
PRAD	cis	rs7149242	0.662	rs4905998	MIMAT0001629	hsa-miR-329-3p	3.49	0.000524	0.21	0.16	Platelet count;	chr14:100715444	chr14:101026834~101026855:+
PRAD	cis	rs7149242	0.662	rs4905998	MIMAT0001629_1	hsa-miR-329-3p	3.49	0.000524	0.21	0.16	Platelet count;	chr14:100715444	chr14:101027151~101027172:+
PRAD	cis	rs6011674	1	rs1555337	MIMAT0016888	hsa-miR-4326	3.49	0.000525	0.32	0.16	Response to cytadine analogues (cytosine arabinoside);	chr20:63232289	chr20:63286818~63286837:+
PRAD	cis	rs990171	0.566	rs1523199	MIMAT0019927	hsa-miR-4772-3p	-3.49	0.000525	-0.19	-0.16	Lymphocyte counts;	chr2:102481732	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs6705272	MIMAT0019927	hsa-miR-4772-3p	-3.49	0.000528	-0.18	-0.16	Lymphocyte counts;	chr2:102490110	chr2:102432336~102432357:+
PRAD	cis	rs201798	0.553	rs149846	MIMAT0017990	hsa-miR-3613-5p	-3.49	0.000529	-0.15	-0.16	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;	chr13:50392777	chr13:49996465~49996486:-
PRAD	cis	rs74233809	0.901	rs11191425	MIMAT0005951	hsa-miR-1307-3p	-3.49	0.000531	-0.22	-0.16	Birth weight;	chr10:102866213	chr10:103394301~103394322:-
PRAD	cis	rs990171	0.513	rs6543152	MIMAT0019927	hsa-miR-4772-3p	-3.49	0.000533	-0.18	-0.16	Lymphocyte counts;	chr2:102497584	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.513	rs7573566	MIMAT0019927	hsa-miR-4772-3p	-3.49	0.000533	-0.18	-0.16	Lymphocyte counts;	chr2:102498746	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.538	rs4851014	MIMAT0019927	hsa-miR-4772-3p	-3.49	0.000534	-0.18	-0.16	Lymphocyte counts;	chr2:102499817	chr2:102432336~102432357:+
PRAD	cis	rs7851726	1	rs35487382	MIMAT0019208	hsa-miR-3074-5p	3.49	0.00054	0.14	0.16	Urinary albumin-to-creatinine ratio;	chr9:94823506	chr9:95086063~95086083:-
PRAD	cis	rs6708413	0.528	rs7567885	MIMAT0019927	hsa-miR-4772-3p	3.48	0.00054	0.18	0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102492393	chr2:102432336~102432357:+
PRAD	cis	rs79387448	0.655	rs3771167	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000544	-0.25	-0.16	Gut microbiota (bacterial taxa);	chr2:102369728	chr2:102432336~102432357:+
PRAD	cis	rs79387448	0.592	rs6728945	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000544	-0.25	-0.16	Gut microbiota (bacterial taxa);	chr2:102370011	chr2:102432336~102432357:+
PRAD	cis	rs523340	1	rs6477692	MIMAT0004505	hsa-miR-32-3p	3.48	0.000545	0.29	0.16	Information processing speed;	chr9:109142478	chr9:109046231~109046252:-
PRAD	cis	rs4792143	1	rs4792142	MIMAT0004945	hsa-miR-744-5p	3.48	0.000546	0.15	0.16	Ischemic stroke;	chr17:11474820	chr17:12081909~12081930:+
PRAD	cis	rs4792143	0.947	rs1588727	MIMAT0004945	hsa-miR-744-5p	3.48	0.000546	0.15	0.16	Ischemic stroke;	chr17:11479640	chr17:12081909~12081930:+
PRAD	cis	rs7072216	0.763	rs7923729	MIMAT0026738	hsa-miR-1287-3p	3.48	0.000547	0.12	0.16	Metabolite levels;	chr10:98409708	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs6584198	MIMAT0026738	hsa-miR-1287-3p	3.48	0.000547	0.12	0.16	Metabolite levels;	chr10:98410149	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs6584201	MIMAT0026738	hsa-miR-1287-3p	3.48	0.000547	0.12	0.16	Metabolite levels;	chr10:98410452	chr10:98395232~98395253:-
PRAD	cis	rs684232	0.666	rs2254134	MIMAT0004495	hsa-miR-22-5p	-3.48	0.000548	-0.14	-0.16	Prostate cancer;	chr17:725424	chr17:1713952~1713973:-
PRAD	cis	rs2823615	0.926	rs2823597	MIMAT0000064	hsa-let-7c-5p	-3.48	0.000551	-0.14	-0.16	Obesity-related traits;	chr21:16075052	chr21:16539838~16539859:+
PRAD	cis	rs990171	0.687	rs11685483	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000554	-0.2	-0.16	Lymphocyte counts;	chr2:102542634	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.649	rs6543159	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000554	-0.2	-0.16	Lymphocyte counts;	chr2:102543598	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.605	rs6739426	MIMAT0019927	hsa-miR-4772-3p	-3.48	0.000554	-0.2	-0.16	Lymphocyte counts;	chr2:102543984	chr2:102432336~102432357:+
PRAD	cis	rs2910162	0.865	rs4921291	MIMAT0000449	hsa-miR-146a-5p	-3.48	0.000556	-0.12	-0.16	Allergic disease (asthma, hay fever or eczema);	chr5:160493288	chr5:160485372~160485393:+
PRAD	cis	rs10506348	0.557	rs58801386	MIMAT0004805	hsa-miR-616-3p	-3.48	0.000557	-0.32	-0.16	Mosquito bite size;	chr12:56912440	chr12:57519183~57519204:-
PRAD	cis	rs523340	1	rs643632	MIMAT0004505	hsa-miR-32-3p	-3.47	0.00056	-0.29	-0.16	Information processing speed;	chr9:109077669	chr9:109046231~109046252:-
PRAD	cis	rs2307449	0.929	rs17804009	MIMAT0000252	hsa-miR-7-5p	-3.47	0.000562	-0.19	-0.16	Menopause (age at onset);	chr15:89280723	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs17804009	MIMAT0000252_1	hsa-miR-7-5p	-3.47	0.000562	-0.19	-0.16	Menopause (age at onset);	chr15:89280723	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs17804009	MIMAT0000252_2	hsa-miR-7-5p	-3.47	0.000562	-0.19	-0.16	Menopause (age at onset);	chr15:89280723	chr9:83969811~83969834:-
PRAD	cis	rs1436294	0.63	rs3113804	MIMAT0000275	hsa-miR-218-5p	-3.47	0.000563	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr4:20232788	chr4:20528299~20528319:+
PRAD	cis	rs1436294	0.63	rs3113804	MIMAT0000275_1	hsa-miR-218-5p	-3.47	0.000563	-0.14	-0.16	Colonoscopy-negative controls vs population controls;	chr4:20232788	chr5:168768211~168768231:-
PRAD	cis	rs944801	0.566	rs10965219	MIMAT0004504	hsa-miR-31-3p	3.47	0.000565	0.15	0.16	Type 2 diabetes;	chr9:22053688	chr9:21512121~21512142:-
PRAD	cis	rs11678825	0.789	rs78051501	MIMAT0031175	hsa-miR-548ba	-3.47	0.000567	-0.3	-0.16	Reticulocyte fraction of red cells;	chr2:48449807	chr2:49059603~49059624:+
PRAD	cis	rs3198697	0.617	rs11075253	MIMAT0002819	hsa-miR-193b-3p	-3.47	0.000568	-0.12	-0.16	Triglycerides;	chr16:15054789	chr16:14304017~14304038:+
PRAD	cis	rs2257205	0.667	rs1018051	MIMAT0000433	hsa-miR-142-5p	3.47	0.000569	0.17	0.16	Pancreatic cancer;	chr17:58832565	chr17:58331283~58331303:-
PRAD	cis	rs2307449	0.929	rs16942893	MIMAT0000252	hsa-miR-7-5p	3.47	0.00057	0.19	0.16	Menopause (age at onset);	chr15:89243190	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs16942893	MIMAT0000252_1	hsa-miR-7-5p	3.47	0.00057	0.19	0.16	Menopause (age at onset);	chr15:89243190	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs16942893	MIMAT0000252_2	hsa-miR-7-5p	3.47	0.00057	0.19	0.16	Menopause (age at onset);	chr15:89243190	chr9:83969811~83969834:-
PRAD	cis	rs7009110	1	rs2202750	MIMAT0022502	hsa-miR-5708	-3.47	0.000572	-0.2	-0.16	Asthma and hay fever;	chr8:80382269	chr8:80241398~80241417:+
PRAD	cis	rs7009110	0.967	rs2221641	MIMAT0022502	hsa-miR-5708	-3.47	0.000572	-0.2	-0.16	Asthma and hay fever;	chr8:80382467	chr8:80241398~80241417:+
PRAD	cis	rs79600951	1	rs79600951	MIMAT0000430	hsa-miR-138-5p	3.46	0.000581	0.3	0.16	HDL cholesterol;	chr16:56800342	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs79600951	MIMAT0000430_1	hsa-miR-138-5p	3.46	0.000581	0.3	0.16	HDL cholesterol;	chr16:56800342	chr3:44114234~44114256:+
PRAD	cis	rs7072216	0.763	rs10736129	MIMAT0026738	hsa-miR-1287-3p	-3.46	0.000586	-0.12	-0.16	Metabolite levels;	chr10:98411814	chr10:98395232~98395253:-
PRAD	cis	rs4722750	0.505	rs67479305	MIMAT0001080	hsa-miR-196b-5p	3.46	0.000587	0.23	0.16	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr7:27994095	chr7:27169528~27169549:-
PRAD	cis	rs6708413	0.521	rs6543153	MIMAT0019927	hsa-miR-4772-3p	-3.46	0.000592	-0.18	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102497744	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.763	rs12259939	MIMAT0026738	hsa-miR-1287-3p	3.46	0.000593	0.12	0.16	Metabolite levels;	chr10:98409264	chr10:98395232~98395253:-
PRAD	cis	rs2257205	0.667	rs9889494	MIMAT0000433	hsa-miR-142-5p	3.46	0.000596	0.16	0.16	Pancreatic cancer;	chr17:58552403	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs9889631	MIMAT0000433	hsa-miR-142-5p	3.46	0.000596	0.16	0.16	Pancreatic cancer;	chr17:58552998	chr17:58331283~58331303:-
PRAD	cis	rs7077446	0.733	rs4919606	MIMAT0002809	hsa-miR-146b-5p	-3.46	0.000598	-0.11	-0.16	Intelligence (multi-trait analysis);	chr10:101984095	chr10:102436520~102436542:+
PRAD	cis	rs7077446	0.733	rs6584467	MIMAT0002809	hsa-miR-146b-5p	-3.46	0.000598	-0.11	-0.16	Intelligence (multi-trait analysis);	chr10:101988576	chr10:102436520~102436542:+
PRAD	cis	rs79600951	1	rs79984435	MIMAT0000430	hsa-miR-138-5p	3.46	0.000599	0.29	0.16	HDL cholesterol;	chr16:56800322	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs79984435	MIMAT0000430_1	hsa-miR-138-5p	3.46	0.000599	0.29	0.16	HDL cholesterol;	chr16:56800322	chr3:44114234~44114256:+
PRAD	cis	rs79387448	0.638	rs7600961	MIMAT0019927	hsa-miR-4772-3p	-3.46	6e-04	-0.23	-0.16	Gut microbiota (bacterial taxa);	chr2:102418995	chr2:102432336~102432357:+
PRAD	cis	rs79600951	1	rs16962014	MIMAT0000430	hsa-miR-138-5p	-3.46	6e-04	-0.28	-0.16	HDL cholesterol;	chr16:56786007	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs16962014	MIMAT0000430_1	hsa-miR-138-5p	-3.46	6e-04	-0.28	-0.16	HDL cholesterol;	chr16:56786007	chr3:44114234~44114256:+
PRAD	cis	rs4918072	0.755	rs35168839	MIMAT0005951	hsa-miR-1307-3p	3.45	0.000603	0.13	0.16	Coronary artery disease;	chr10:103946501	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.763	rs3814140	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411005	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs3814142	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411347	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.691	rs3829853	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411417	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.727	rs10748728	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411441	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs10748729	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411614	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs10748730	MIMAT0026738	hsa-miR-1287-3p	3.45	0.000606	0.12	0.16	Metabolite levels;	chr10:98411683	chr10:98395232~98395253:-
PRAD	cis	rs990171	0.538	rs7591872	MIMAT0019927	hsa-miR-4772-3p	-3.45	0.000609	-0.19	-0.16	Lymphocyte counts;	chr2:102496182	chr2:102432336~102432357:+
PRAD	cis	rs9290936	0.572	rs9876152	MIMAT0004987	hsa-miR-944	-3.45	0.000613	-0.29	-0.16	Waist circumference;	chr3:190537403	chr3:189829975~189829996:+
PRAD	cis	rs4792143	1	rs1303977	MIMAT0004945	hsa-miR-744-5p	3.45	0.000614	0.15	0.16	Ischemic stroke;	chr17:11475402	chr17:12081909~12081930:+
PRAD	cis	rs4792143	1	rs2221937	MIMAT0004945	hsa-miR-744-5p	3.45	0.000614	0.15	0.16	Ischemic stroke;	chr17:11475565	chr17:12081909~12081930:+
PRAD	cis	rs4792143	1	rs56115958	MIMAT0004945	hsa-miR-744-5p	3.45	0.000614	0.15	0.16	Ischemic stroke;	chr17:11477423	chr17:12081909~12081930:+
PRAD	cis	rs11678825	0.538	rs76875602	MIMAT0031175	hsa-miR-548ba	-3.45	0.000616	-0.3	-0.16	Reticulocyte fraction of red cells;	chr2:48449683	chr2:49059603~49059624:+
PRAD	cis	rs2823615	1	rs9975788	MIMAT0000064	hsa-let-7c-5p	-3.45	0.000616	-0.14	-0.16	Obesity-related traits;	chr21:16092495	chr21:16539838~16539859:+
PRAD	cis	rs201798	0.509	rs201807	MIMAT0017990	hsa-miR-3613-5p	-3.45	0.000617	-0.15	-0.16	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;	chr13:50395555	chr13:49996465~49996486:-
PRAD	cis	rs4918072	0.798	rs2067831	MIMAT0005951	hsa-miR-1307-3p	3.45	0.000617	0.14	0.16	Coronary artery disease;	chr10:103883465	chr10:103394301~103394322:-
PRAD	cis	rs12765878	0.692	rs10883926	MIMAT0005951	hsa-miR-1307-3p	3.45	0.000619	0.11	0.16	Coronary artery disease;	chr10:103849080	chr10:103394301~103394322:-
PRAD	cis	rs684232	0.765	rs2456274	MIMAT0004495	hsa-miR-22-5p	3.45	0.000624	0.15	0.16	Prostate cancer;	chr17:715168	chr17:1713952~1713973:-
PRAD	cis	rs35000415	0.938	rs17338998	MIMAT0000259	hsa-miR-182-5p	-3.45	0.000624	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128978505	chr7:129770447~129770470:-
PRAD	cis	rs1409313	0.585	rs1628530	MIMAT0004766	hsa-miR-146b-3p	-3.44	0.000626	-0.21	-0.16	Autism spectrum disorder-related traits;	chr10:102269550	chr10:102436557~102436578:+
PRAD	cis	rs35000415	0.938	rs12536266	MIMAT0000259	hsa-miR-182-5p	-3.44	0.000626	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128970981	chr7:129770447~129770470:-
PRAD	cis	rs1018697	1	rs7088711	MIMAT0022727	hsa-miR-1307-5p	-3.44	0.000628	-0.12	-0.16	Colorectal adenoma (advanced);	chr10:102799509	chr10:103394341~103394361:-
PRAD	cis	rs12554020	0.681	rs77768484	MIMAT0000065	hsa-let-7d-5p	-3.44	0.000629	-0.18	-0.16	Schizophrenia;	chr9:93622011	chr9:94178841~94178862:+
PRAD	cis	rs12554020	0.681	rs79987346	MIMAT0000065	hsa-let-7d-5p	-3.44	0.000629	-0.18	-0.16	Schizophrenia;	chr9:93622467	chr9:94178841~94178862:+
PRAD	cis	rs10429558	0.619	rs78174934	MIMAT0000065	hsa-let-7d-5p	-3.44	0.000629	-0.18	-0.16	Neuroticism;	chr9:93627397	chr9:94178841~94178862:+
PRAD	cis	rs10429558	0.619	rs111522793	MIMAT0000065	hsa-let-7d-5p	-3.44	0.000629	-0.18	-0.16	Neuroticism;	chr9:93627518	chr9:94178841~94178862:+
PRAD	cis	rs990171	0.687	rs12712157	MIMAT0019927	hsa-miR-4772-3p	-3.44	0.000632	-0.19	-0.16	Lymphocyte counts;	chr2:102548670	chr2:102432336~102432357:+
PRAD	cis	rs4792143	1	rs113895472	MIMAT0004945	hsa-miR-744-5p	3.44	0.000632	0.15	0.16	Ischemic stroke;	chr17:11472528	chr17:12081909~12081930:+
PRAD	cis	rs7594645	1	rs7594645	MIMAT0016895	hsa-miR-2355-5p	3.44	0.000637	0.35	0.16	Episodic memory;	chr2:206781950	chr2:207110043~207110063:-
PRAD	cis	rs79600951	1	rs2895432	MIMAT0000430	hsa-miR-138-5p	3.44	0.000643	0.3	0.16	HDL cholesterol;	chr16:56823043	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs2895432	MIMAT0000430_1	hsa-miR-138-5p	3.44	0.000643	0.3	0.16	HDL cholesterol;	chr16:56823043	chr3:44114234~44114256:+
PRAD	cis	rs4908768	0.582	rs11121241	MIMAT0004557	hsa-miR-34a-3p	-3.44	0.000645	-0.23	-0.16	Subjective well-being (multi-trait analysis);Neuroticism (multi-trait analysis);	chr1:8835911	chr1:9151693~9151714:-
PRAD	cis	rs990171	0.649	rs6724322	MIMAT0019927	hsa-miR-4772-3p	-3.44	0.000646	-0.2	-0.16	Lymphocyte counts;	chr2:102508723	chr2:102432336~102432357:+
PRAD	cis	rs35000415	0.938	rs12706861	MIMAT0000259	hsa-miR-182-5p	-3.44	0.000647	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128976528	chr7:129770447~129770470:-
PRAD	cis	rs758129	0.501	rs2307449	MIMAT0000252	hsa-miR-7-5p	3.44	0.000647	0.19	0.16	Schizophrenia;	chr15:89320697	chr15:88611856~88611879:+
PRAD	cis	rs758129	0.501	rs2307449	MIMAT0000252_1	hsa-miR-7-5p	3.44	0.000647	0.19	0.16	Schizophrenia;	chr15:89320697	chr19:4770700~4770723:+
PRAD	cis	rs758129	0.501	rs2307449	MIMAT0000252_2	hsa-miR-7-5p	3.44	0.000647	0.19	0.16	Schizophrenia;	chr15:89320697	chr9:83969811~83969834:-
PRAD	cis	rs7072216	0.922	rs59667296	MIMAT0005878	hsa-miR-1287-5p	3.43	0.000648	0.17	0.16	Metabolite levels;	chr10:98386556	chr10:98395271~98395292:-
PRAD	cis	rs4927850	1	rs7630875	MIMAT0003235	hsa-miR-570-3p	3.43	0.00065	0.2	0.16	Pancreatic cancer;	chr3:196026895	chr3:195699460~195699481:+
PRAD	cis	rs9641123	0.9	rs10488554	MIMAT0003328	hsa-miR-653-5p	-3.43	0.000651	-0.17	-0.16	BMI (adjusted for smoking behaviour);Lean body mass;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;BMI in non-smokers;	chr7:93553003	chr7:93482823~93482843:-
PRAD	cis	rs990171	0.538	rs4851015	MIMAT0019927	hsa-miR-4772-3p	-3.43	0.000652	-0.18	-0.16	Lymphocyte counts;	chr2:102503897	chr2:102432336~102432357:+
PRAD	cis	rs10256972	0.684	rs2363279	MIMAT0004702	hsa-miR-339-3p	3.43	0.000653	0.16	0.16	Endometriosis;Longevity;	chr7:1056507	chr7:1022955~1022977:-
PRAD	cis	rs74233809	0.901	rs7098825	MIMAT0005951	hsa-miR-1307-3p	-3.43	0.000653	-0.22	-0.16	Birth weight;	chr10:102868477	chr10:103394301~103394322:-
PRAD	cis	rs2823615	1	rs2823616	MIMAT0000064	hsa-let-7c-5p	-3.43	0.000653	-0.14	-0.16	Obesity-related traits;	chr21:16111738	chr21:16539838~16539859:+
PRAD	cis	rs977145	0.721	rs12026468	MIMAT0000456	hsa-miR-186-5p	-3.43	0.000654	-0.12	-0.16	Venlafaxine response in generalised anxiety disorder (HAMA-A score reduction after 24 weeks);	chr1:71362349	chr1:71067681~71067702:-
PRAD	cis	rs2288884	0.79	rs7253849	MIMAT0000066	hsa-let-7e-5p	-3.43	0.00066	-0.18	-0.16	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52056992	chr19:51692793~51692814:+
PRAD	cis	rs2307449	0.929	rs11855314	MIMAT0000252	hsa-miR-7-5p	-3.43	0.000662	-0.19	-0.16	Menopause (age at onset);	chr15:89241450	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs11855314	MIMAT0000252_1	hsa-miR-7-5p	-3.43	0.000662	-0.19	-0.16	Menopause (age at onset);	chr15:89241450	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs11855314	MIMAT0000252_2	hsa-miR-7-5p	-3.43	0.000662	-0.19	-0.16	Menopause (age at onset);	chr15:89241450	chr9:83969811~83969834:-
PRAD	cis	rs4790312	0.846	rs2131704	MIMAT0000426	hsa-miR-132-3p	3.43	0.000668	0.15	0.16	Left atrial antero-posterior diameter;	chr17:2067604	chr17:2049929~2049950:-
PRAD	cis	rs6708413	0.52	rs6543151	MIMAT0019927	hsa-miR-4772-3p	-3.43	0.000669	-0.18	-0.16	Crohn's disease;Inflammatory bowel disease;	chr2:102497582	chr2:102432336~102432357:+
PRAD	cis	rs216303	0.642	rs216324	MIMAT0000617	hsa-miR-200c-3p	3.43	0.00067	0.19	0.16	Low vWF levels;	chr12:6036059	chr12:6963742~6963764:+
PRAD	cis	rs2307449	0.929	rs7497351	MIMAT0000252	hsa-miR-7-5p	-3.43	0.00067	-0.19	-0.16	Menopause (age at onset);	chr15:89268251	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs7497351	MIMAT0000252_1	hsa-miR-7-5p	-3.43	0.00067	-0.19	-0.16	Menopause (age at onset);	chr15:89268251	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs7497351	MIMAT0000252_2	hsa-miR-7-5p	-3.43	0.00067	-0.19	-0.16	Menopause (age at onset);	chr15:89268251	chr9:83969811~83969834:-
PRAD	cis	rs990171	1	rs3755267	MIMAT0019927	hsa-miR-4772-3p	3.43	0.00067	0.2	0.16	Lymphocyte counts;	chr2:102422127	chr2:102432336~102432357:+
PRAD	cis	rs7072216	0.763	rs6584205	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000671	0.12	0.16	Metabolite levels;	chr10:98414049	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.621	rs3750604	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000672	0.13	0.16	Metabolite levels;	chr10:98415824	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs10883091	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000675	0.12	0.16	Metabolite levels;	chr10:98407482	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs10883092	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000675	0.12	0.16	Metabolite levels;	chr10:98407519	chr10:98395232~98395253:-
PRAD	cis	rs684232	0.712	rs2955626	MIMAT0004495	hsa-miR-22-5p	3.42	0.000675	0.13	0.16	Prostate cancer;	chr17:714860	chr17:1713952~1713973:-
PRAD	cis	rs2823615	1	rs11909251	MIMAT0000064	hsa-let-7c-5p	-3.42	0.000684	-0.14	-0.16	Obesity-related traits;	chr21:16110067	chr21:16539838~16539859:+
PRAD	cis	rs7072216	0.763	rs6584202	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000686	0.12	0.16	Metabolite levels;	chr10:98410626	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs942803	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000687	0.12	0.16	Metabolite levels;	chr10:98408874	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.687	rs4551689	MIMAT0005878	hsa-miR-1287-5p	-3.42	0.000687	-0.17	-0.16	Metabolite levels;	chr10:98397836	chr10:98395271~98395292:-
PRAD	cis	rs7077446	0.76	rs4291608	MIMAT0002809	hsa-miR-146b-5p	-3.42	0.000694	-0.11	-0.16	Intelligence (multi-trait analysis);	chr10:101996993	chr10:102436520~102436542:+
PRAD	cis	rs7072216	0.763	rs6584200	MIMAT0026738	hsa-miR-1287-3p	3.42	0.000695	0.12	0.16	Metabolite levels;	chr10:98410280	chr10:98395232~98395253:-
PRAD	cis	rs990171	0.77	rs7562254	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000696	-0.2	-0.16	Lymphocyte counts;	chr2:102308487	chr2:102432336~102432357:+
PRAD	cis	rs4927850	0.958	rs1975582	MIMAT0003235	hsa-miR-570-3p	3.41	0.000698	0.2	0.16	Pancreatic cancer;	chr3:196024568	chr3:195699460~195699481:+
PRAD	cis	rs7851726	0.865	rs2584806	MIMAT0019208	hsa-miR-3074-5p	-3.41	0.000699	-0.14	-0.16	Urinary albumin-to-creatinine ratio;	chr9:94766996	chr9:95086063~95086083:-
PRAD	cis	rs944801	0.631	rs10757267	MIMAT0004504	hsa-miR-31-3p	-3.41	0.000702	-0.15	-0.16	Type 2 diabetes;	chr9:22052811	chr9:21512121~21512142:-
PRAD	cis	rs990171	1	rs6727306	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000704	-0.2	-0.16	Lymphocyte counts;	chr2:102365184	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs11465583	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000704	-0.2	-0.16	Lymphocyte counts;	chr2:102366006	chr2:102432336~102432357:+
PRAD	cis	rs990171	1	rs10197284	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000704	-0.2	-0.16	Lymphocyte counts;	chr2:102366243	chr2:102432336~102432357:+
PRAD	cis	rs990171	0.955	rs1573895	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000704	-0.2	-0.16	Lymphocyte counts;	chr2:102366416	chr2:102432336~102432357:+
PRAD	cis	rs10516173	1	rs10516173	MIMAT0018926	hsa-miR-378d	3.41	0.000706	0.17	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr4:5151418	chr4:5923279~5923298:-
PRAD	cis	rs10516173	1	rs10516173	MIMAT0018926_1	hsa-miR-378d	3.41	0.000706	0.17	0.16	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);	chr4:5151418	chr8:93916079~93916098:-
PRAD	cis	rs4927850	0.957	rs4927851	MIMAT0003235	hsa-miR-570-3p	3.41	0.000706	0.2	0.16	Pancreatic cancer;	chr3:196024982	chr3:195699460~195699481:+
PRAD	cis	rs4927850	0.918	rs4361313	MIMAT0003235	hsa-miR-570-3p	3.41	0.000706	0.2	0.16	Pancreatic cancer;	chr3:196025389	chr3:195699460~195699481:+
PRAD	cis	rs12712133	1	rs12712133	MIMAT0019927	hsa-miR-4772-3p	3.41	0.000707	0.17	0.16	Primary biliary cholangitis;	chr2:102249813	chr2:102432336~102432357:+
PRAD	cis	rs7536201	0.5	rs10903117	MIMAT0018191	hsa-miR-3917	-3.41	0.000707	-0.2	-0.16	Psoriasis vulgaris;	chr1:24957101	chr1:25906384~25906403:-
PRAD	cis	rs4792143	1	rs11650609	MIMAT0004945	hsa-miR-744-5p	3.41	0.000711	0.15	0.16	Ischemic stroke;	chr17:11471938	chr17:12081909~12081930:+
PRAD	cis	rs2823615	1	rs2823612	MIMAT0000064	hsa-let-7c-5p	-3.41	0.000713	-0.14	-0.16	Obesity-related traits;	chr21:16107233	chr21:16539838~16539859:+
PRAD	cis	rs2307449	0.929	rs17804034	MIMAT0000252	hsa-miR-7-5p	-3.41	0.000716	-0.19	-0.16	Menopause (age at onset);	chr15:89280830	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs17804034	MIMAT0000252_1	hsa-miR-7-5p	-3.41	0.000716	-0.19	-0.16	Menopause (age at onset);	chr15:89280830	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs17804034	MIMAT0000252_2	hsa-miR-7-5p	-3.41	0.000716	-0.19	-0.16	Menopause (age at onset);	chr15:89280830	chr9:83969811~83969834:-
PRAD	cis	rs990171	1	rs1465321	MIMAT0019927	hsa-miR-4772-3p	-3.41	0.000719	-0.2	-0.16	Lymphocyte counts;	chr2:102370158	chr2:102432336~102432357:+
PRAD	cis	rs12765878	0.513	rs10883922	MIMAT0005951	hsa-miR-1307-3p	-3.4	0.000721	-0.12	-0.16	Coronary artery disease;	chr10:103835672	chr10:103394301~103394322:-
PRAD	cis	rs944801	0.587	rs7049105	MIMAT0004504	hsa-miR-31-3p	3.4	0.000721	0.15	0.16	Type 2 diabetes;	chr9:22028802	chr9:21512121~21512142:-
PRAD	cis	rs35000415	0.938	rs10488631	MIMAT0000259	hsa-miR-182-5p	-3.4	0.000722	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128954129	chr7:129770447~129770470:-
PRAD	cis	rs35000415	0.873	rs12539741	MIMAT0000259	hsa-miR-182-5p	-3.4	0.000722	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128956751	chr7:129770447~129770470:-
PRAD	cis	rs4792143	1	rs1513742	MIMAT0004945	hsa-miR-744-5p	-3.4	0.000724	-0.15	-0.16	Ischemic stroke;	chr17:11470433	chr17:12081909~12081930:+
PRAD	cis	rs4790312	0.905	rs4790870	MIMAT0000426	hsa-miR-132-3p	3.4	0.000724	0.15	0.16	Left atrial antero-posterior diameter;	chr17:2066907	chr17:2049929~2049950:-
PRAD	cis	rs10811516	1	rs10811518	MIMAT0004504	hsa-miR-31-3p	-3.4	0.000725	-0.21	-0.16	Response to mepolizumab in severe asthma;	chr9:21256487	chr9:21512121~21512142:-
PRAD	cis	rs10811516	0.954	rs10964937	MIMAT0004504	hsa-miR-31-3p	-3.4	0.000725	-0.21	-0.16	Response to mepolizumab in severe asthma;	chr9:21257644	chr9:21512121~21512142:-
PRAD	cis	rs7072216	0.763	rs9787550	MIMAT0026738	hsa-miR-1287-3p	3.4	0.000726	0.12	0.16	Metabolite levels;	chr10:98409294	chr10:98395232~98395253:-
PRAD	cis	rs11174650	0.605	rs10506448	MIMAT0000415	hsa-let-7i-5p	-3.4	0.000727	-0.21	-0.16	Sense of smell;	chr12:62815843	chr12:62603691~62603712:+
PRAD	cis	rs11174650	0.605	rs10506449	MIMAT0000415	hsa-let-7i-5p	-3.4	0.000727	-0.21	-0.16	Sense of smell;	chr12:62816008	chr12:62603691~62603712:+
PRAD	cis	rs2307449	0.929	rs12915285	MIMAT0000252	hsa-miR-7-5p	-3.4	0.000729	-0.19	-0.16	Menopause (age at onset);	chr15:89262981	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs12915285	MIMAT0000252_1	hsa-miR-7-5p	-3.4	0.000729	-0.19	-0.16	Menopause (age at onset);	chr15:89262981	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs12915285	MIMAT0000252_2	hsa-miR-7-5p	-3.4	0.000729	-0.19	-0.16	Menopause (age at onset);	chr15:89262981	chr9:83969811~83969834:-
PRAD	cis	rs2257205	0.667	rs7209498	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58603281	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs16943134	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58604028	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs8077548	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58613487	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs8076021	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58617285	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs6503872	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58618647	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs8070007	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58631808	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs9904996	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58634346	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs79155614	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58645135	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs7217890	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58653904	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs11651859	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58654565	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs9916423	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58696473	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs8071942	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58700910	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs6503874	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58703098	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs73996262	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58707065	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs28363312	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58710932	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs16943186	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58724487	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.588	rs77430462	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58726724	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs78253932	MIMAT0000433	hsa-miR-142-5p	3.4	0.000732	0.16	0.16	Pancreatic cancer;	chr17:58726740	chr17:58331283~58331303:-
PRAD	cis	rs7149242	0.849	rs10146962	MIMAT0001629	hsa-miR-329-3p	-3.4	0.000733	-0.19	-0.16	Platelet count;	chr14:100704203	chr14:101026834~101026855:+
PRAD	cis	rs7149242	0.849	rs10146962	MIMAT0001629_1	hsa-miR-329-3p	-3.4	0.000733	-0.19	-0.16	Platelet count;	chr14:100704203	chr14:101027151~101027172:+
PRAD	cis	rs79600951	1	rs1803870	MIMAT0000430	hsa-miR-138-5p	3.4	0.000734	0.3	0.16	HDL cholesterol;	chr16:56805527	chr16:56858527~56858549:+
PRAD	cis	rs79600951	1	rs1803870	MIMAT0000430_1	hsa-miR-138-5p	3.4	0.000734	0.3	0.16	HDL cholesterol;	chr16:56805527	chr3:44114234~44114256:+
PRAD	cis	rs2295389	0.769	rs4900477	MIMAT0003329	hsa-miR-411-5p	-3.4	0.000737	-0.12	-0.16	Breast cancer;	chr14:100842045	chr14:101023340~101023360:+
PRAD	cis	rs4927850	0.881	rs7624638	MIMAT0003235	hsa-miR-570-3p	3.4	0.000737	0.2	0.16	Pancreatic cancer;	chr3:196021858	chr3:195699460~195699481:+
PRAD	cis	rs4927850	1	rs10881564	MIMAT0003235	hsa-miR-570-3p	3.4	0.000737	0.2	0.16	Pancreatic cancer;	chr3:196023455	chr3:195699460~195699481:+
PRAD	cis	rs4766566	0.704	rs10774617	MIMAT0027422	hsa-miR-6761-5p	3.4	0.000744	0.21	0.16	Gout;Atrial fibrillation;Renal overload gout;Renal underexcretion gout;	chr12:111317374	chr12:111799839~111799859:+
PRAD	cis	rs7009110	0.967	rs2370615	MIMAT0022502	hsa-miR-5708	3.39	0.00075	0.19	0.16	Asthma and hay fever;	chr8:80378152	chr8:80241398~80241417:+
PRAD	cis	rs74233809	1	rs11191548	MIMAT0005951	hsa-miR-1307-3p	3.39	0.000752	0.22	0.16	Birth weight;	chr10:103086421	chr10:103394301~103394322:-
PRAD	cis	rs7072216	0.763	rs7910014	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98412353	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs7910247	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98412495	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.727	rs7913541	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98412722	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs2274246	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98415303	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs2274245	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98415325	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs2274244	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000752	0.12	0.16	Metabolite levels;	chr10:98415461	chr10:98395232~98395253:-
PRAD	cis	rs9351814	0.961	rs12190423	MIMAT0000088	hsa-miR-30a-3p	-3.39	0.000753	-0.09	-0.16	Coronary artery disease or ischemic stroke;	chr6:71493008	chr6:71403554~71403575:-
PRAD	cis	rs7072216	0.621	rs11189595	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000755	0.13	0.16	Metabolite levels;	chr10:98407565	chr10:98395232~98395253:-
PRAD	cis	rs2257205	0.667	rs9893027	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58576087	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs8075108	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58579887	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs4340382	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58661558	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.588	rs7209327	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58664473	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs7220884	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58666587	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs9899893	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58677236	chr17:58331283~58331303:-
PRAD	cis	rs2257205	0.667	rs7221142	MIMAT0000433	hsa-miR-142-5p	3.39	0.000756	0.16	0.16	Pancreatic cancer;	chr17:58681425	chr17:58331283~58331303:-
PRAD	cis	rs11174650	0.605	rs73130086	MIMAT0000415	hsa-let-7i-5p	-3.39	0.000756	-0.21	-0.16	Sense of smell;	chr12:62815540	chr12:62603691~62603712:+
PRAD	cis	rs7536201	0.5	rs11580845	MIMAT0018191	hsa-miR-3917	3.39	0.000757	0.2	0.16	Psoriasis vulgaris;	chr1:24956865	chr1:25906384~25906403:-
PRAD	cis	rs7072216	0.763	rs733345	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000758	0.12	0.16	Metabolite levels;	chr10:98404458	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.763	rs733346	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000758	0.12	0.16	Metabolite levels;	chr10:98404568	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.726	rs4474372	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000758	0.12	0.16	Metabolite levels;	chr10:98404814	chr10:98395232~98395253:-
PRAD	cis	rs7851726	1	rs4385527	MIMAT0019208	hsa-miR-3074-5p	-3.39	0.000759	-0.14	-0.16	Urinary albumin-to-creatinine ratio;	chr9:94886305	chr9:95086063~95086083:-
PRAD	cis	rs7072216	0.69	rs113195335	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000761	0.12	0.16	Metabolite levels;	chr10:98415775	chr10:98395232~98395253:-
PRAD	cis	rs7072216	0.727	rs3750603	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000761	0.12	0.16	Metabolite levels;	chr10:98415779	chr10:98395232~98395253:-
PRAD	cis	rs3198697	0.663	rs12928099	MIMAT0002819	hsa-miR-193b-3p	-3.39	0.000765	-0.12	-0.16	Triglycerides;	chr16:15056648	chr16:14304017~14304038:+
PRAD	cis	rs35000415	0.872	rs2070197	MIMAT0000259	hsa-miR-182-5p	-3.39	0.000765	-0.17	-0.16	Systemic lupus erythematosus;	chr7:128948946	chr7:129770447~129770470:-
PRAD	cis	rs79387448	0.638	rs74731686	MIMAT0019927	hsa-miR-4772-3p	-3.39	0.000766	-0.23	-0.16	Gut microbiota (bacterial taxa);	chr2:102427521	chr2:102432336~102432357:+
PRAD	cis	rs944801	0.587	rs10965212	MIMAT0004504	hsa-miR-31-3p	3.39	0.000768	0.15	0.16	Type 2 diabetes;	chr9:22023796	chr9:21512121~21512142:-
PRAD	cis	rs2307449	0.929	rs17803620	MIMAT0000252	hsa-miR-7-5p	-3.39	0.000769	-0.19	-0.16	Menopause (age at onset);	chr15:89260812	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.929	rs17803620	MIMAT0000252_1	hsa-miR-7-5p	-3.39	0.000769	-0.19	-0.16	Menopause (age at onset);	chr15:89260812	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.929	rs17803620	MIMAT0000252_2	hsa-miR-7-5p	-3.39	0.000769	-0.19	-0.16	Menopause (age at onset);	chr15:89260812	chr9:83969811~83969834:-
PRAD	cis	rs9641123	0.931	rs1548457	MIMAT0003328	hsa-miR-653-5p	-3.39	0.00077	-0.17	-0.16	BMI (adjusted for smoking behaviour);Lean body mass;Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;BMI in non-smokers;	chr7:93563398	chr7:93482823~93482843:-
PRAD	cis	rs2307449	0.591	rs7497639	MIMAT0000252	hsa-miR-7-5p	-3.39	0.000772	-0.2	-0.16	Menopause (age at onset);	chr15:89230981	chr15:88611856~88611879:+
PRAD	cis	rs2307449	0.591	rs7497639	MIMAT0000252_1	hsa-miR-7-5p	-3.39	0.000772	-0.2	-0.16	Menopause (age at onset);	chr15:89230981	chr19:4770700~4770723:+
PRAD	cis	rs2307449	0.591	rs7497639	MIMAT0000252_2	hsa-miR-7-5p	-3.39	0.000772	-0.2	-0.16	Menopause (age at onset);	chr15:89230981	chr9:83969811~83969834:-
PRAD	cis	rs7072216	0.763	rs942805	MIMAT0026738	hsa-miR-1287-3p	3.39	0.000772	0.12	0.16	Metabolite levels;	chr10:98408615	chr10:98395232~98395253:-
PRAD	cis	rs7149242	0.696	rs7141210	MIMAT0001629	hsa-miR-329-3p	3.38	0.000779	0.2	0.16	Platelet count;	chr14:100716133	chr14:101026834~101026855:+
PRAD	cis	rs7149242	0.696	rs7141210	MIMAT0001629_1	hsa-miR-329-3p	3.38	0.000779	0.2	0.16	Platelet count;	chr14:100716133	chr14:101027151~101027172:+
PRAD	cis	rs990171	1	rs2058623	MIMAT0019927	hsa-miR-4772-3p	-3.38	0.000781	-0.2	-0.16	Lymphocyte counts;	chr2:102369710	chr2:102432336~102432357:+
PRAD	cis	rs2280018	1	rs2280018	MIMAT0002819	hsa-miR-193b-3p	-3.38	0.000782	-0.12	-0.16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr16:15056976	chr16:14304017~14304038:+
PRAD	trans	rs2967951	1	rs2648810	MIMAT0014995	hsa-miR-3130-5p	-6.06	2.88e-09	-0.39	-0.27	Body mass index;	chr5:10465961	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2648810	MIMAT0014995_1	hsa-miR-3130-5p	-6.06	2.88e-09	-0.39	-0.27	Body mass index;	chr5:10465961	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs1092913	MIMAT0014995	hsa-miR-3130-5p	-6	4.09e-09	-0.39	-0.27	Body mass index;	chr5:10467590	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs1092913	MIMAT0014995_1	hsa-miR-3130-5p	-6	4.09e-09	-0.39	-0.27	Body mass index;	chr5:10467590	chr2:206783246~206783266:+
PRAD	trans	rs2250644	0.51	rs2071509	MIMAT0004955	hsa-miR-374b-5p	5.97	4.86e-09	0.26	0.27	Fibrinogen levels;	chr10:89228493	chrX:74218587~74218608:-
PRAD	trans	rs991639	0.789	rs1516334	MIMAT0000461	hsa-miR-195-5p	-5.96	5.06e-09	-0.33	-0.27	Problematic alcohol use in trauma-exposed individuals;	chr3:64741	chr17:7017667~7017687:-
PRAD	trans	rs2967951	1	rs938453	MIMAT0014995	hsa-miR-3130-5p	-5.9	7e-09	-0.4	-0.27	Body mass index;	chr5:10460344	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs938453	MIMAT0014995_1	hsa-miR-3130-5p	-5.9	7e-09	-0.4	-0.27	Body mass index;	chr5:10460344	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs814597	MIMAT0014995	hsa-miR-3130-5p	-5.88	7.97e-09	-0.38	-0.27	Body mass index;	chr5:10468817	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs814597	MIMAT0014995_1	hsa-miR-3130-5p	-5.88	7.97e-09	-0.38	-0.27	Body mass index;	chr5:10468817	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2567573	MIMAT0014995	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463685	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2567573	MIMAT0014995_1	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463685	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2648812	MIMAT0014995	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463830	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2648812	MIMAT0014995_1	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463830	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2673894	MIMAT0014995	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463937	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2673894	MIMAT0014995_1	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463937	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2967951	MIMAT0014995	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463995	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2967951	MIMAT0014995_1	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10463995	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2245638	MIMAT0014995	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10465817	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2245638	MIMAT0014995_1	hsa-miR-3130-5p	-5.85	9.67e-09	-0.38	-0.26	Body mass index;	chr5:10465817	chr2:206783246~206783266:+
PRAD	trans	rs16864170	0.609	rs67726743	MIMAT0004513	hsa-miR-101-5p	5.81	1.15e-08	0.34	0.26	Chronic kidney disease;	chr2:5844840	chr1:65058477~65058498:-
PRAD	trans	rs16864170	0.609	rs16864391	MIMAT0004513	hsa-miR-101-5p	5.81	1.15e-08	0.34	0.26	Chronic kidney disease;	chr2:5845367	chr1:65058477~65058498:-
PRAD	trans	rs2967951	1	rs2673896	MIMAT0014995	hsa-miR-3130-5p	-5.78	1.41e-08	-0.38	-0.26	Body mass index;	chr5:10462020	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2673896	MIMAT0014995_1	hsa-miR-3130-5p	-5.78	1.41e-08	-0.38	-0.26	Body mass index;	chr5:10462020	chr2:206783246~206783266:+
PRAD	trans	rs991639	0.86	rs1516335	MIMAT0000461	hsa-miR-195-5p	-5.77	1.46e-08	-0.32	-0.26	Problematic alcohol use in trauma-exposed individuals;	chr3:68574	chr17:7017667~7017687:-
PRAD	trans	rs2967951	1	rs2648811	MIMAT0014995	hsa-miR-3130-5p	-5.75	1.63e-08	-0.38	-0.26	Body mass index;	chr5:10463831	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2648811	MIMAT0014995_1	hsa-miR-3130-5p	-5.75	1.63e-08	-0.38	-0.26	Body mass index;	chr5:10463831	chr2:206783246~206783266:+
PRAD	trans	rs2967951	1	rs2648809	MIMAT0014995	hsa-miR-3130-5p	-5.75	1.63e-08	-0.38	-0.26	Body mass index;	chr5:10466391	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs2648809	MIMAT0014995_1	hsa-miR-3130-5p	-5.75	1.63e-08	-0.38	-0.26	Body mass index;	chr5:10466391	chr2:206783246~206783266:+
PRAD	trans	rs6724465	1	rs72967942	MIMAT0004509	hsa-miR-93-3p	-5.74	1.78e-08	-0.27	-0.26	Height;	chr2:219052800	chr7:100093777~100093798:-
PRAD	trans	rs2967951	1	rs12520289	MIMAT0014995	hsa-miR-3130-5p	-5.61	3.48e-08	-0.36	-0.25	Body mass index;	chr5:10467145	chr2:206783276~206783296:-
PRAD	trans	rs2967951	1	rs12520289	MIMAT0014995_1	hsa-miR-3130-5p	-5.61	3.48e-08	-0.36	-0.25	Body mass index;	chr5:10467145	chr2:206783246~206783266:+
PRAD	trans	rs6451042	0.588	rs10073850	MIMAT0000266	hsa-miR-205-5p	5.61	3.57e-08	0.22	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:19187213	chr1:209432166~209432187:+
PRAD	trans	rs13067306	0.518	rs1552744	MIMAT0001341	hsa-miR-424-5p	-5.6	3.69e-08	-0.23	-0.25	Blood pressure measurement (high sodium intervention);	chr3:94343601	chrX:134546680~134546701:-
PRAD	trans	rs6451042	0.512	rs4409093	MIMAT0000266	hsa-miR-205-5p	5.6	3.79e-08	0.22	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:19186511	chr1:209432166~209432187:+
PRAD	trans	rs322662	0.59	rs1108138	MIMAT0016895	hsa-miR-2355-5p	-5.59	3.89e-08	-0.33	-0.25	Calcium levels;	chr3:25370993	chr2:207110043~207110063:-
PRAD	trans	rs991639	0.932	rs35089048	MIMAT0000461	hsa-miR-195-5p	-5.58	4.17e-08	-0.31	-0.25	Problematic alcohol use in trauma-exposed individuals;	chr3:45494	chr17:7017667~7017687:-
PRAD	trans	rs5167	0.677	rs73047643	MIMAT0000418	hsa-miR-23b-3p	-5.57	4.45e-08	-0.13	-0.25	Blood protein levels;	chr19:44954136	chr9:95085265~95085287:+
PRAD	trans	rs13067306	0.518	rs16841927	MIMAT0001341	hsa-miR-424-5p	-5.54	5.1e-08	-0.23	-0.25	Blood pressure measurement (high sodium intervention);	chr3:94354221	chrX:134546680~134546701:-
PRAD	trans	rs13067306	0.518	rs62267031	MIMAT0001341	hsa-miR-424-5p	-5.54	5.1e-08	-0.23	-0.25	Blood pressure measurement (high sodium intervention);	chr3:94356794	chrX:134546680~134546701:-
PRAD	trans	rs6724465	1	rs56345933	MIMAT0004509	hsa-miR-93-3p	-5.53	5.53e-08	-0.26	-0.25	Height;	chr2:219049013	chr7:100093777~100093798:-
PRAD	trans	rs6724465	1	rs56006038	MIMAT0004509	hsa-miR-93-3p	-5.53	5.53e-08	-0.26	-0.25	Height;	chr2:219049115	chr7:100093777~100093798:-
PRAD	trans	rs9561329	1	rs2762092	MIMAT0000423	hsa-miR-125b-5p	-5.52	5.71e-08	-0.24	-0.25	Neuroticism (age interaction);	chr13:93435212	chr11:122099809~122099830:-
PRAD	trans	rs9561329	1	rs2762092	MIMAT0000423_1	hsa-miR-125b-5p	-5.52	5.71e-08	-0.24	-0.25	Neuroticism (age interaction);	chr13:93435212	chr21:16590253~16590274:+
PRAD	trans	rs903027	0.887	rs1968990	MIMAT0005920	hsa-miR-1266-5p	5.52	5.81e-08	0.34	0.25	Whole-brain volume;	chr8:61491469	chr15:52277166~52277188:-
PRAD	trans	rs6451042	0.588	rs56127401	MIMAT0000266	hsa-miR-205-5p	5.52	5.84e-08	0.21	0.25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;	chr5:19175707	chr1:209432166~209432187:+